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INTRODUCTION 
On-line measurement of exhaled NO (anno 1995) 

CHAPTER 1 
General introduction and aims of the study 
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1.1 INTRODUCTION 
Airway inflanul1ation plays an important role in various respiratory disor-
ders of childhood including recurrent wheezing, asthma, cystic fibrosis (CF), 
bronchopulmonalY dysplasia (BPD), and respiratOlY distress syndrome (RDS) 
(1-4). In daily clinical practice, indirect indices of airway inflammation like 
symptoms and lung function l11easurCll1ents are routinely used for diagnosis and 
follow-up of inflammatOlY respiratory disorders. Especially in young children, 
these indirect indices of disease scvclity are less valuable than in adults; lung 
hlllction studies in children are often not possible because of lack of coopera-
tion. Furthermore, reporting of symptoms by others (parents) is much depen-
dent on perception of symptoms with the potential risk for both under and 
overperception. Therefore, there is a need for objective and early criteria to de-
tect and monitor airway inflanunation in order to prevent or minimize the irre-
versible changes which are described in various chromc respiratOlY disorders in-
cluding asthma, CF and BPD (5-9). The analysis of airway inflammato,y cells 
and mediators has traditionally been perfOlTIled by bronchoscopy on samples of 
bronchial mucosal biopsies or on bronchoalveolar lavage fluid (EALF) samples. 
Both methods are limited in their applicability because of the invasive procedu-
re of bronchoscopy. However, these invasive procedures have greatly enhanced 
the understanding of the role of airway inflanllnation in various respiratolY dis-
orders (10-13). Bronchoscopy has its own pitfalls in the study of airway inflam-
mation (14,15). All things considered, it is clear that in daily clinical practice, se-
riallneasurements of airway inflammation are not feasible with snch invasive 
1l1ethods. A noninvasive tnethod to assess the presence and activity of airway in-
flammation would be of great benefit for early diagnosis and monitoring of in-
flammatory airway diseases in children (16,17). 
Inflammatory markers can be measured in blood or in urine (18,19). The 
noninvasiveness of these Inethods is an advantage, but their indirect nature is a 
limitation. Measuretnent of certain inflanllllatolY tnarkers in blood and urine 
represents whole body production and does not necessarily reflect production of 
these inflauullatol), markers in the respiratOlY tract. It is reasonable to assmne that 
the composition of respiratory secretions might closer reflect ainvay inflatmna-
tion than substances in blood or urine (20). Sputum is one of the respiratory secre-
tions which can be used in the assessment of airway inflammation (21-23). 
Sputmll can be obtained noninv3sively, spontaneously or during chest physio-
therapy. Sputum examination has been limited by the difficulty in obtaining 
adequate samples. When sputum can not be produced spontaneously it can be 
induced by inhalation of an aerosol ofhypertollic saline (24). With this technique, 
sputum samples call be obtained in up to 75-100% of asthmatic and healthy adults 
(25). In children the success rate in obtaining adequate samples is definitely lower 
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(26). Other practical considerations of sputum induction include the inevitability 
of pretreatt11ent with short-acting Pragonists in order to prevent an obstructive 
airway response provoked by inhalation of hypertonic saline, and the 
titne-consuming procedure for inducing sputm11 and processing induced sputmn 
satnples. Furthennore, several studies have shown that repeated sputmn induc-
tion in itself induces changes in airway inf1anunation within 24-48 hours after 
spututn induction, which limits the usefulness of this tnethod for serial measure-
ments (27,28). Other secretions fi·om the respirat01Y tract include nasal and naso-
phatyngeal mucus. Nasal samples like nasal lavage fluid, mucosa brushing and 
-biopsies are easy to obtain and could represent a relatively noninvasive way of 
111onitoring airway inflammation. However, whether nasal secretions can be used 
as a model for the assessment oflower airway inflammation is doubtful (29,30). 
Exhaled air is a recently rediscovered vehicle of substances fi-mn the respirat01Y 
tract, in which several potential markers of airway inflammation can be detected. 
In contrast with the othersanlpling methods Inentioned above, exhaled air ofiers 
the advantage that it can be obtained completely noninvasively. Exhaled air may 
carry c01nponents £1'0111 the lower airways, and does not disturb the airways, in 
contrast to bronchial biopsies, BAL and induced sputum, and it can be obtained 
with Ininimal risk and inconvenience £1'onl both adults and children. 
1.2 HUMAN BREATH ANALYSIS 
The diagnosis of diseases through analysis of human breath has a long tra-
dition in tnedicine. In the past, diseases as diabetes l11ellitus, malfilnction of kid-
neys and hepatic failure were diagnosed by means of the olfactory sense of vola-
tile cOlnponents, such as acetone, anunonia and sulphur c01npounds (31). In the 
last decades, the development of sensitive analytic methods for the detection of 
volatile substances has led to new developments in exhaled air analysis. In the 
Ineantilne, approxiluately 200 difterent CO!11pOnents have been identified in hu-
l11an exhaled air, S01ne of which have been correlated to various diseases 
(31,32). Besides a potential diagnostic use for particular diseases, exhaled air ana-
lysis has been used in Inonitoring inhalation exposure to gaseous and volatile 
compounds (33). Furthermore, in daily life breath tests for the detection of et-
hanol in exhaled air are frequently used by the police for the sake of traffic safe-
ty. Diagnostic breath tests have been studied in intensive care (34), gastroente-
rology (35,36), infectiology (37), diabetes mellitus (38,39), uraemia (40) and 
oncology (41,42). Surprisingly the use of breath tests for the detection of disor-
ders of the respiratmy tract was until recently limited to lung cancer (43). Ho-
wever, in 1991 Gustafsson et al. (44) showed the possibility of measuring endo-
genous nitric oxide (NO) in the parts per billion (Ppb) range in exhaled air of 
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hmnans and experimental aninlals. This observation marked the onset of an ex-
citing recent developlllcnt of noninvasive monitoring of inflammation markers 
in exhaled air. Exhaled air analysis has the potential of becoming a rapid, nonin-
vasive diagnostic technique to assess airway in£lanunation. 
Apart from low-molecular weight volatile substances, exhaled air may also 
contain nonvolatile macromolecules (45). These nonvolatile substances can be 
transported oulyas aerosol particles in the exhaled air. In contrast to the nU111CrOUS 
studies on the cOlnposition and lung deposition of exogenous aerosols, the studies 
on the nature, cOlnposition and 31110unt of endogenous aerosols excreted in 
exhaled air are scanty. It is generally known that aerosol particles are generated in 
the respiratOlY tract during forced exhalation and coughing. Two studies 
confirmed the existence of aerosol particles in exhaled air during quiet tidal 
breathing (46,47). By cooling exhaled air, water vapour in the gaseous phase, 
including the aerosol particles, can be condensed to a liquid phase. Collection of 
exhaled air condensate is another noninvasive method for obtaining secretions of 
the respiratory tract. The volatile and nonvolatile substances in human breath can 
potentially be used for noninvasive asseSSlnent of airway inflamlnation based on 
the assumption that aerosol particles or vapour in exhaled air reflect the cOillposi-
tion of the lower airway fluids. By applying a cold trap setup, Scheideler et aJ. 
found proteins, carbohydrates and salts detectable in exhaled air condensate 
obtained during forceful breathing (45). Proteins in condensate were analysed by 
two-dimensional gel electrophoresis. Characterization is possible on the basis of 
their place in the electropherogram, or by molecular techniques. However, this 
study did not nlie out contam.inatioll with saliva, which is a rich source ofinflatll-
matory 111olecules. 
III stmtmary, exhaled air and breath condensate are noninvasive 111ethods 
to obtain samples from the lower respiratory tract. These methods are not dis-
turbing to airways in contrast to induced sputU111 and BAL, and can be used in 
the determination of acellular luarkers of inflallllnation in exhaled air like nitric 
oxide (NO) and hydrogen peroxide (H20 2). This may prove valuable in the 
early diagnosis of inflammatory airway diseases in children. 
1.3 EXHALED MARKERS OF INFLAMMATION 
The ideal marker of airway inflammation should fulfil the following cri-
teria: it should be a valid marker of in£lanunation which is sensitive enough to 
monitor early stages of airway inflammation and should preferably be specific 
for a particular respiratOlY disorder. It needs to be reproducible, simple and ra-
pid to perform, inexpensive and acceptable, with minimal discomfort to the 
subject. It should be noninvasive and feasible for adults as well as children. 
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In£lanullation markers should reflect the effect of anti-inflanmlatory treatment 
and be helpful in nlonitoring cOlnpliance with treattnent. 
1.3.1 NITRIC OXIDE 
The measurement of exhaled nitric oxide (eNO) as a simple noninvasive 
Ineans for the assessment of airway inflammation in the respiratory tract has ex-
cited considerable interest. NO is a reactive free radical gas which plays an im-
portant role in the regulation of many physiological and pathophysiological 
processes in various organ systems (48,49). In the past NO was regarded mainly 
as noxious air pollutant. In 1987, NO was characterized as the endothelium de-
rived relaxing (,ctor (EDRF), which acted through activation of guanylate cy-
clase and so increases cyclic GMP, resulting in relaxation of vascular s11100th 
muscle cells (50,51). NO is now also recognized as a mediator of host defense, 
ilnnUllle regulation, neural transmission, platelet inhibition and inflanunation 
(48,49). 
In the respiratory tract, endogenous NO nlay have various inlportant roles in 
physiologic regulation of airway functions but it is also involved in the 
pathophysiology of inflammatory diseases (52-54). NO is a potent vasodilator of 
the bronchial circulation and plays an important role in regulating blood flow in 
the pulmonary circulation (52). Furthermore, NO acts as an endogenous neural 
bronchodilator and appears to be an itnportant regulator of airway ciliary, illllllU-
nological and inflannnatOlY functions (53). 
NO is fanned fi-Dlll the semi-essential anlino acid L-arginine during oxidation to 
L-citmlline by the enzyme NO synthase (NOS). Two functional classes of NOS 
can be identified: the constitutive form (cNOS) continuously producing small 
amounts of NO, and the inducible form (iNOS) producing high amounts of NO 
(figure 1). The constitutive isoforlns are found in neuronal- (nNOS) and endo-
thelial cells (eNOS) and are activated by a rise in intracellular calcium, in response 
to receptor stimulation or to various physiological stimuli. The inducible 
isoforlns are induced in several cell types including endothelial cells, epithelial 
cells and macrophages by exposure to endotoxins and cytokines such as tutnor 
necrosis (,ctor-o:, interferon-y and interleukin-l~. Induction of iN OS is blocked 
by corticosteroids. All isoforlns have been detected in the human respiratOlY tract 
(55,56). The relatively low concentrations generated by cNOS can lead to airway 
and vascular slnooth 111uscle relaxation, whereas the relatively high concentra-
tions generated by iNOS have pro-inflammatOlY and immunomodulatory 
efrects. 
Endogenous NO is detectable in exhaled air of healthy subjects, and appears to be 
elevated in asthmatic subjects who are not taking inhaled steroids (44,57,58). 
Furthennore, corticosteroids reduce eNO in asdunatic patients but not in 
healthy subjects (59), which is presumably because iNOS is the major source of 
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FIGURE 1. Nitric oxide (NO) synthesis by the different nitric oxide synthase, (NOS) 
elevated eNO values, whereas eNO in healthy subjects depends on cNOS which 
is not suppressed by corticosteroids. Tllis suggests that eNO may be a useful 
11larker of airway inflammation and that its noninvasive lucasurCluent Inay be 
useful in 11lonitoring anti-inflamtnatory treatlllcnt. However, the production of 
NO in the respiratOlY tract is not only linlited to the lower airways. NO is also 
generated in the nose, paranasal sinuses and nasoplmynx (60,61). Nasal NO 
concentrations arc high in cOlnparison to the NO values detected in the lower 
respiratory tract. The high nasal NO values may have various physiologic roles, 
such as preserving sinus sterility and modulating cilialY motility (62,63). So, in the 
asseSSlllcnt of lower airway inflanunatioll by eN~, contamination of orally 
exhaled air with much higher NO concentrations from the upper airways should 
be avoided. 
The usual technique for lneasurenlent of NO in exhaled air is chenlilmnine-
scence which has long been used in 1110nitoring air pollution. The principle oftllis 
detection luethod is the reaction between NO in exhaled air and an excess of 
ozone (03), which leads to the fOlmation of an unstable reaction product 
(N0 2*). N02* spontaneously disintegrates to the ground state of N02 while 
enlitting a single photon. The photon is detected by a photomultiplier tube that 
proportionally converts the nUlnher of photons into an electrical signal fi"Oll1 
which the NO concentration can be calculated (64). There are three main 
approaches in sampling exhaled air for eNO measurement (65): 1) single breath 
constant flow method (on-line sampling); 2) single breath reselvoir method 
(off·line sampling); 3) tidal breathing method (on- or off-line sampling). With 
on-line sampling, exhaled air is directly sampled by the NO-analyser at a fixed 
flow limn a side port in the exhalation circuit. With off-line sampling, exhaled air 
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FIGURE 2. A) Exhaled NO measurement, obtained with the single breath 
constant flow method. B) Exhaled NO measurement obtained with the 
single breath balloon method. 
is collected in a NO-inert reservoir and later analysed for NO concentration. This 
has the advantage that it offers independence from the direct precence of an 
NO-analyser. 
Using the single breath constant flow method, subjects perform one slow exhala-
tion from total lung capacity (TLC) with a constant flow against an inline resistor. 
The resistor produces a positive pressure in the oropharyn;x which, by closing the 
soft palate, prevents contam..ination with llasal air. The initial part of the exhala-
tion shows a peak in eNO, which corresponds with NO accumulated in the dead 
space air vDImne, followed by a NO plateau when there is a constant exhalation 
flow (figure 2A). Mean end-expiratOlY plateau values of eNO are measured (66). 
With the single breath balloon method, exhaled air is collected by asking the 
subject to inhale orally to TLC and then immediately pe1form a slow vital 
capacity l11anoeuvre against an expiratory resistance into a NO-inert balloon. 
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The NO concentration in the balloon is analysed later (figure 2B). The tidal 
breathing method can be performed on- and off-line. NO is measured in mixed 
expired air during tidal breathing over a period afthne with or without a resistor 
in the expiration circuit. NO in exhaled air, recorded by a fast analyser, can be 
calculated as an average signal over several breaths. When recorded by a s10\v 
analyser, NO concentration is l11casured in a reservoir in which exhaled air during 
tidal breathing is collected. 
In recent years, the 111CaSUrClllcnt of NO in exhaled air has been studied for its 
potential as a noninvasive 11larker of airway inflauunation in both diagnosis and 
111onitoring of inflanllnation. Increased all10nnts of NO have been detected in 
exhaled air in hllluans with various inflauuuatory airway disorders such as stable 
and unstable astlllna, respiratoLY tract infections, bronchiectasis, fibrosing 
alveolitis, pulmonary sarcoidosis and lung allograft rejection (57,58,67-72). On 
the other hand low NO values have been detected in respiratory disorders such as 
cystic fibrosis, immotile cilia syndromes, adult respiratory distress syndrome and 
smokers (73-76). Corticosteroids reduce eNO values in asthmatics but not in 
healthy subjects and tlus is because of an inhibitory eflect on iNOS (77). Inhaled 
steroids will reduce eNG to nonnallevels even before an effect on synlptOllls is 
apparent (78). Furthermore, eNO increases during reduction of inhaled 
corticosteroids in asthmatic subjects. In asthmatic children, exhaled NO is 
reduced by leukotriene receptor antagonists ,vhich reduce airway eosinophilia 
(79,80). Anotherinterestingfinding is the positive correlation between eNO and 
eosinophils in induced sputtllll in asthmatic subjects, with eosinophil cationic 
protein (ECP) in induced sputum, and with eosinophil peroxidase (EPO) in 
BALF (81-83). Tlus suggests that eNO may reflect eosinophilic airway in flam-
tnation. However, there was no correlation between eNG and direct indices of 
inflammation in airway biopsies (78). Anyhow, different research groups have 
reported widely varying levels of eNO values in similar patient groups and even in 
healthy subjects, probably due to diflerences in methodology. 
1.3.2 HYDROGEN PEROXIDE 
Oxygen derived free radicals are important mediator~ of cell and tissue 
injury during inflammation and are produced by several types of inflammatory 
cells and by airway epithelial cells (84,85). A free radical is a molecule or an atom 
with an unpaired electron in its outer orbit. The unpaired electron alters the 
chemical reactivity of a lllolecule or atolll, usually making it lnore reactive than 
the corresponding non-radical (86). Free radicals react with a wide range ofbio-
logical molecules. The partial reduction of O 2 by sequential single electron steps 
produces three intermediates: superoxide aruon (02'), hydro",,1 radical (OH'). 
and hydrogen peroxide (H202). each more reactive than O 2 itself (figure 3). 
These three intermediates together with hypochlorus acid (HOCL) are called 
~ 
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FIGURE 3. Reactive oxygen species, antioxidants and oxidative 
damage. SOD: superoxide dismutase; CAT: catalase; GPX: glutathione 
peroxidase; DNA: deoxyribonucleic acid. 
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reactive oxygen species (ROS). Antioxidant enzymetic systems are present for 
disposal ofROS. Superoxide dismutase, catalyzes the breakdown of O 2'' to O2 
and H 20 2 , catalase converts H 20 2 to H20 and O 2, and glutathione peroxidase 
removes both H 20 2 and lipid hydroperoxides. An excess of ROS, oxidative 
stress, has been implicated in the pathophysiology of a number of respiratory 
disorders such as chronic obstmctive puhllona1Y disease (COPD), CF, and 
asthma (87-90). Activation of inflammatory cells such as eosinophils, neutrop-
hils, and Inacrophages induces a respiratory burst resulting in the production of 
ROS. ROS l11ay dal11age airway stnlCtural and functional cOlnponents inclu-
ding lipids, enzymes and DNA (figure 3). H 20 2 is a central precursor to OH' 
and HOCL, which are both extremely potent oxidants (87). Bronchial and 
tracheal epithelial cells release H 20 2 in response to inflammatOlY stimuli (85). In 
1986 Baldwin et al. showed that H 20 2 can be detected in exhaled air condensa-
te of human subjects with respiratory distress syndrome (91). Increased levels of 
exhaled peroxide have been found in various respiratory disorders such as 
asthma, COPD, ARDS, sl11okers, and in bronchiectasis, lnainly in adults 
(92-95). Therefore, exhaled H 20 2 is a promising noninvasive marker of airway 
inflanll11ation and, more specifically, oxidative stress. 
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1.3.3 OTHER EXHALED INfLAMMATORY MARKERS 
NO is not the only inflanullation Inarker that can be Ineasl1red in exhaled 
air. However, data of those other exhaled inflatnmatory markers remains scanty. 
especially in children. Carbon monoxide (CO), a product of heme degradation 
by heme OA),genase I (OH-I) which is induced by inflanunatOlY cytokines and 
oxidants, has been put forward as a potentialll1arker of airway inflaullnation and 
oxidative stress. Increased levels of exhaled CO have recently been demonstra-
ted in adult asthmatics as well as in asthmatic children (96,97). The value of ex-
haled CO in the asseSSluent of astlunatic airway inflammation has not yet been 
established. A recent study showed no difterence in exhaled CO in asthmatics 
and healthy controls (98). Elevated exhaled CO values are not specific for 
asthma because they arc also found in association with various respiratory disor-
ders such as CF, bronchiectasis, sll10king and viral upper respiratolY tract infec-
tions (99-102). A limited number of studies have evaluated exhaled volatile al-
kanes like pentane and ethane, products of lipid peroxidation, as markers of 
oxidative stress and airway inflanunation, by l11eans of gas chromatography 
(103). In adults, elevated levels of exhaled alkanes were found in smokers, 
asthmatics and patients with obstmctive sleep apnea (104-106). In preterm in-
fants pentane exhalation was related to the course of neonatal disease in a very li-
mited number of infants (107). 
Besides H 20 2 other potential Inarkers of airway inflaull11ation can also be 
detected in breath condensate of adults and children, including oxidation metab-
olites of NO , nitrite and nitrate. Elevated levels have been shown in CF patients, 
even if eNO is not elevated in the gas phase, and in asthmatic patients (108,109). 
Exhaled air analysis of 8-isoprostane, is a new noninvasive approach to study 
oxidative stress in airway in£lanlll1atolY diseases. Isoprostanes are fi·ee radi-
cal-catalyzed products of arachidonic acid oxidation that may reflect oxidative 
stress in the respiratory tract. Recently, isoprostane has been found to be 
increased in exhaled condensate in astlul1atic subjects, CF and in adult respiratory 
distress syndrome (110-112). Exhaled isoprostanes have not yet been studied in 
pediatric respiratolY disease. There are also a few reports of Ineasnrements of 
leukotrienes (LTs) (the chemotactic LTB4 and the cysteinyl LTs, LTC4, D4 and 
E4) and cytokines (TNF-a) in exhaled air condensate of adults (45,113). There is 
a lack of data relating to children, and further information is needed on normal 
values, reproducibility and validation of these potential markers. 
1.4 AIMS OF THE STUDIES AND OUTlINE Of THIS THESIS 
At the 11l0lnent, there is no specific, noninvasive and objective tuethod 
for the assesstl1ent of airway in£lanllllation in children. The aill1 of the studies 
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,vas to develop noninvasive 111ethods to assess airway inflammation in children. 
For this purpose, two approaches have been followed: 
1. Detection of NO in exhaled air of children. 
2. Detection ofHzOz in breath condensate of children. 
In the studies in tllis thesis, eNO and H 20 2 in breath condensate were 111easured, 
by Ineans of chemilunlinescence and fluorilnetlY, respectively, in children with 
astllllla, cystic fibrosis and in healthy controls with and without upper respiratolY 
tract infections. We hypothesized that those markers could be measured 
reproducibly and are sensitive enough to discriminate healthy children from 
those with airway inflanullation and reflect the severity of the inflanllnatory 
process. This could be valuable in the early diagnosis and n10nitoring of airway 
inflammation in children, and could potentially be applied to guide anti-
inflanul1atory drug treatment. 
Values of exhaled NO as initially reported by various investigators diflered greatly 
in similar patient groups and even in healthy subjects. This can be explained by 
ditferences in measurelnent techniques. Therefore, we first compared difl:erent 
methodological aspects of NO measurement in stable asthmatic and healthy cllll-
dren, and assessed the reproducibility of NO measurements (chapter 2). 
Since NO continuously diffuses into the airway Imnen, high concentrations ,vill 
result when exhalation is slo,v, and lo,v concentrations when exhalation is £1St. It 
is unknown to what extent disease aflects the flow-dependency of NO in exhaled 
air. Therefore, we examined the eflect of varying the exhalation flow on the NO 
concentration in exhaled air of children, and exanlined the concentration of NO 
and the NO/flow relationship in healthy children, asthmatic children and cllll-
dren with CF (chapter 3). 
In an attelnpt to standardize eNO lueasurelncnts a European RespiratolY Society 
(ERS) task force group recommended on-line eNO measurement. However, 
this method is, in contrast to off-line eNO 111easurelnent, rather difficult to 
perform on clllldren. In chapter 4 we established a reference range of eNO, 
obtained with the clllld friendly ofl:'line sampling balloon method, in a large 
group of healthy school clllldren and examined the influence of ambient NO, 
nose clip and breathholding on eNO. 
The objective of the study in chapter 5 was to validate an alternative ofl:'line 
single breath, low flow eNO sampling method against on-line sampling 
according to ERS guidelines, in children old enough to perform both sampling 
methods and to establish a reference range oflow flow ofl:'line eNO measure-
ment in healthy children. 
In chapter 6 reference values ofHzOz in exhaled air condensate in a large group 
of healthy school-aged children were established as well as the reproducibility of 
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repeated measurements and the stability of peroxide in the frozen condensate 
over a period of titne. 
In chapter 7 we compared the H20 2 concentration in exhaled air condensate of 
stable asthmatic children versus healthy controls and determined the influence of 
inhaled steroids on exhaled H 20 2 in the asthmatic study population. 
As CF-patients characteristically have severe chronic airway inflamn1ation due to 
bacterial infection, noninvasive luarkers of airway inflauuuation could be useful 
to guide anti-inflammatmy treatment in CF-subjects. The objective of the study 
described in chapter 8 was to assess whether serial lueasnrement of exhaled 
H 20 2 and NO can serve to Jnanitar the anti~inflammatory effect of treattnent 
with antibiotics in CF-children with acute infective puhnonalY exacerbations. 
Exhaled H202 is elevated in various inflammatory disorders of the lower respira-
tmy tract. However, exhaled H 20 2 can potentially be confounded by inflamma-
tion of the upper airways. In chapter 9 we studied whether upper respiratmy 
tract infections influenced the concentration ofH20 2 in exhaled air condensate 
of healthy subjects. 
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EXHALED NITRIC OXIDE 
Off-line collection of exhaled NO (balloon method) 

CHAPTER 2 
Sampling of exhaled nitric oxide in children: 
end-expiratory plateau, balloon and tidal 
breathing methods compared 
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ABSTRACT 
The aim of this study was to compare exhaled nitric oxide (NO) concentrations 
obtained during controlled slow exhalation, presently considered as the 
method of choice, with two sampling methods that are easily performed by 
children: blowing air into a balloon and tidal breathing through a mouthpiece. 
One hundred and one well controlled, stable allergic asthmatic children (me-
dian age 11.7 yrs) performed the following tasks in duplicate: 1) exhalation 
from total lung capacity (TLC) through a mouthpiece against a resistor with a 
standardized flow rate of 20% of the subject's vital capacity per second, using 
a biofeedback system; 2) a single deep exhalation into an NO-impermeable My-
lar balloon; and 3) tidal breathing through a low resistance mouthpiece over 2 
minutes. NO was measured using a chemiluminescence analyser. Twentywnine 
children (29%) were not able to perform a constant-flow exhalation of at least 
3 sec. All children performed the balloon and tidal breathing methods without 
difficulty. NO concentrations (means±SEM) were 5.3±0.2 parts per billion (ppb) 
at the end-expiratory plateau, 5.2±0.3 ppb in balloons (intraclass correlation 
coefficient (ri)-0.73) and 8.0±0.4 ppb during tidal breathing (p<0.001, ri-
0,53 compared to plateau values). Mean values of NO during tidal breathing in-
creased significantly with time, suggesting increasing contamination with naw 
sal air. It was conduded that, in asthmatic children, the end-expiratory 
plateau concentration of NO during exhalation at 20% of the vital capacity per 
second is similar to values obtained with the balloon method, with satisfactory 
agreement, but differs from values obtained during tidal breathing. The bal-
loon method is cheap, simple and offers the interesting possibility to study eX' 
haled NO in young children independently of the presence of an NO-analyser. 
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INTROOUCTION 
Invasive procedures such as bronchoscopy and bronchoalveolar lavage 
(BAL) have greatly enhanced the understanding of the role of inflammation in 
asthma (1-3). In young children, BAL is generally not acceptable for research, 
diagnosis and 1110lutoring purposes. A noninvasive nlethod to assess the presen-
ce and severity of airway inflammation is important for tlus group (4). GustafS-
son et aJ. demonstrated that lutric oxide (NO) can be detected in exhaled air of 
animals and humans (5). NO is produced by various cells witlun the respiratory 
tract, and plays an illlportant role in the pathophysiology of inflammatory air-
way disease (6,7). In recent years, the measurement of NO in exhaled air has 
been studied for its potential as a Inarker of airway inflanllnation in both diagno-
sis and 111anageluent. Increased al110unts of NO have been detected in the exha-
led air in hmnans with various inflamlnatory airway disorders (8-12). There is 
persuasive evidence that levels of NO are decreased by anti-inflanllnatolY thera-
py (13-16). However, difierent groups have reported widely varying levels of 
exhaled NO in similar patient groups and in healthy subjects, probably owing to 
differences in methodology (17,18). In an attempt to standardize NO measure-
ment in exhaled air a European RespiratOlY Society (ERS) task force report was 
recently published (18). In adults and children (from the age of6 yrs), a slow ex-
halation from total lung capacity (TLC) through a mouthpiece with a constant 
flow against a resistance was reconlluended for the lueasurelnent of NO in ex-
haled air. It appears, however, that children may have difficulty maintaining a 
fL"ed flow. As recommended in the ERS task force report, a balloon method, a 
simple tecluuque which is easily performed by children, was used in this study 
to measure exhaled NO. Others have proposed a tidal breathing method with 
Ineasurenlent of NO in the mixed expired air during resting ventilation, with or 
without a fixed resistor in the expiration circuit (8,19,20). Comparison between 
these difierent sampling methods in subjects is needed. The aim of this study 
was to cOlllpare in subjects: 1) single exhalation £i·onl TLC with a constant flow 
against a resistance; 2) single uncontrolled deep expiration into a balloon; and 3) 
continous sampling of exhaled air during tidal breatlung without expiratOlY re-
sistor. Furthennore, the short tenn reproducibility of NO Ineasurenlents in ex-
haled air with the different sampling luethods was assessed. 
PATIENTS AND METHODS 
STUDY POPULATION 
One hunderd and one stable asthmatic children (67 males and 34 females) 
attending the outpatient clituc for pediatric respiratOlY medicine at Sophia Chil-
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dren's Hospital were included. Their median age was 11.7 years (range 
7.0-17.6). Asthma was diagnosed on clinical grounds and according to interna-
tional guidelines (21). All had bronchial hyperresponsiveness (a provocative 
dose of inhaled methacholine that produced a 20% fall in forced expiratOlY vo-
lume in one second (PD20) of < 150 J.lg) documented in the past, and had aller-
gy as documented by a radio allergosorbent test (RAST) class 2 or higher for at 
least one common airborne allergen. Appropriate therapy was prescribed by the 
patient's own physician, and had not been changed during the 3 tnonths prece-
ding the study. All subjects used an inhaled bronchodilator on demand, 90 
(89%, 60 males and 30 females) used an inhaled corticosteroid (mean daily dose 
400 J.lg budesonide or beclomethasone, range 100-1500 J.lg), and 23 used 
long-acting beta-agonists. All were lifelong nonsmokers and were clinically sta-
ble. None of the subjects reported symptoms of acute respiratOlY infection wit-
hin the month before NO was measured. The study was approved by the medi-
cal ethics committee of the university hospital. 
LUNG FUNCTION 
All subjects underwent flow-volmne IneasurClnents inuuediatcly before 
NO \vas Ineasured. Flow-volmue curves were obtained in triplicate, using a Lil-
ly-type pneumotachograph (Masterlab Jaeger, Wiirzberg, Germany). Results of 
forced expiratory volume in 1 second (FEV V and forced expiratOlY vital capaci-
ty (FVC) were expressed as percentage predicted (22). 
EXHALED AIR SAMPLING AND NITRIC OXIDE MEASUREMENT 
All subjects performed 3 difierent expiratory luanoellvres in duplicate, al-
ways in the s;lInc order. 
A sillgle 510'" ex/lalatioll: children were instructed to perform a slow exhalation 
fi0111 TLC through a 1110uthpiece and a two way non-rebreathing valve 
(Rudolph Inc., Kansas City, MO, USA) into a wide bore teflon tube against an 
inline resistor (20 cm H 20/L/sec, Rudolph Inc.) with an individually standard-
ized flow rate of20% of the subject's vital capacity (VC) per second. A biofeed-
back exhalation flow display provided visual guidance to help the subject 
maintain their exhalation flow at the desired level. The mean end-expiratOlY NO 
level was measured in duplicate from air sampled from exhalation at 200 mL/min. 
via teflon tubing during an end-expiratOlY flow plateau of at least 3 sec. 
Olle sillgle deep expiratioll illto a ballooll: subjects were asked to take a deep breath, 
not necessarily to TLC, and to perform one single deep exhalation via a plastic 
tube (length 5 cm, internal diameter 3.7 mm) into an NO-impermeable Mylar 
balloon (Inaxiuuull capacity 1750 mL). Flow and pressure were not 11lonitored, 
but with balloon filling in 3-5 sec, to a volume of 1250-1750 mL, flow rates 
would range 250 and 600 mLlsec. Preliminary measurements showed that, 
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during balloon blowing, oral positive pressure was always >6 Cll1 H 20, sufficient 
to close the velUln and prevent nasal contamination of exhaled air. Gas \vas 
sampled from the balloon within 15 min after filling. The mean NO concentra-
tion was measured during 30 sec of sampling fi'om the balloon (at 200 mL/min). 
This Inanoeuvre was performed in duplicate. 
Tidal breathillg: subjects performed two minutes of quiet tidal breathing through a 
1110uthpiece connected to a two way non-rebreathing valve into a wide bore low 
resistance teflon tube, where gas was continuously saillpled via a side port at 200 
mL/nun. The mean NO value of the first minute and of the second minute were 
calculated by computer. 
All measurements were performed with the children seated. All children were 
allowed 2 min rest between the different expiratoty Inanoeuvres to restore resting 
conditions of ventilation. They did not wear a noseclip. To exclude the efrect of 
high ambient NO levels to the level of exhaled NO, all tests were performed with 
ambient NO concentrations < 1 0 parts per billion (ppb). Preliminary experiments 
demonstrated that NO concentrations in Mylar balloons relnain stable for at least 
6 h. NO was measured witha chemiluminescence analyser (Sievers 280, Boulder, 
CO, USA) with a sampling flow rate of200 mL/min and a response time of200 
milliseconds. The analyser was regulaty calibrated according to the l11anufac-
turer's guidelines, using certified NO gases (100 ppb and 9 ppm) and certified 
NO-free gas (HoekLoos, Barendrecht, The Netherlands). 
DATA ANALYSIS 
Data of NO concentration and flo\v rates were entered into a c0111puter 
at a sampling rate of20 Hz. Mean values of NO concentrations at selected titne 
intervals were calculated afterwards by Ineans of a custom data processing pro-
gram. Data are presented as mean ± standard error (SEM). End-expiratOlY NO 
during exhalation fi0111 TLC with continuous flow was taken as the gold stand-
ard. The agreement of the balloon method and the tidal breathing method with 
end-expiratOlY levels was assessed according to Bland and Altman (23). As these 
plots indicated that the outcome variability increased with increasing NO le-
vels, further analysis was carried out using logarithmically transfonned data to 
stabilize variances. Mean data froln the difierent ll1ethods were cOInpared using 
the Student t-test for paired satllples. To characterize the agreetnent between 
methods, intmelass correlation coemcients (ri) were calculated (24). The same 
methods were used to analyse within-subject reproducibilities. A two tailed 
p-value <0.05 was considered significant. 
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RESULTS 
Lung fimctioll 111casnrctllents showed near-normallnean values (lucan ± 
SEM): FVC 103 ± 2% predicted, FEV I 94 ± 2% pred. Twenty-nine children 
(29%) (mean age 11.0 yrs, range 7.3-16.3 yrs) were not able to sustain a stable 
end expiratory flow plateau of at least 3 sec. In contrast, all children performed 
the balloon method and the tidal breathing method without any difficulty. In 
the 72 stable asthmatic children (mean age 12.1 yrs, range 7-17.6 yrs) who per-
farIned the three different procedures sllccessfitlly, NO concentrations {tnedian 
(range)) were 5.0 (2.3-12.8) ppb at the end expirat01Y plateau; 4.8 (2.2-17.2) 
ppb li-01n balloons; and 7.8 (2.7-20.0) ppb during tidal breathing (p=0.43 and 
p<O.OOI, respectively, compared to plateau values). The within-method 
short-term reproducibility of duplicate NO values obtained at the 
end-expiratory plateau and li-01n balloons was excellent (ri = 0.90 and 0.91, res-
pectively). The reproducibility of the tidal breathing method was less (ri=0.85). 
With tidal breathing, consistently higher mean NO concentrations were found 
during the second minute than during the first minute (8.5 ppb versus 7.5 ppb), 
the diflerence being dependent on lllcan NO concentration. The lncan of all 
individual coefficients of variation of all NO values was 7% for the 
end-expirat01Y plateau, 7% for the balloon method, and 22% for the tidal breat-
hing tnethod. Ninety percent of all within-subject coefficients of variation were 
<15% for the end-expirat01Y plateau, <12 % for the balloon method, and <81% 
for tidal breathing. Comparison of the average NO (duplicate measurements) 
obtained at end-expirat01Y plateau and li-01n balloons showed a statisf.oct01Y ag-
reement between the two sampling methods (ri = 0.73) (figure 1), and this was 
similar if the first NO measurements only were considered (ri=O.72). The geo-
metric mean ratio of the NO values obtained at the end-expirat01Y plateaus and 
with balloons was 1.05 ppb with 2.5 and 97.5 percentiles of 0.60 and 1.60 ppb, 
respectively (figure 2), indicating no systematic error and good agreement. In 
contrast, a poor agreclnent was found between the NO values obtained with 
the tidal breathing method and at the end expirat01Y plateau, with r;=0.52 for 
duplicate lueasnrClnents, and fi=O.S3 for single IneasnrClllcnts (figure 3). 
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FIGURE 1. Comparison of exhaled NO concentrations obtained during a 
single exhalation at a fixed flow of 20% of vital capacity per sec (x-axis) 
and values measured in Mylar balloons filled in a single deep exhalation 
(y-axis). Data are from 72 out of 101 children who were capable of 
performing both methods. There is good agreement with an rj of 0,73. 
The line represents line of identity. Note the logarithmic scale. 
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FIGURE 2. Ratios of exhaled NO concentrations obtained from Mylar 
balloons and at an end-expiratory plateau during exhalation with 
constant flow of 20% of vital capacity per sec (logarithmic scale), 
plotted against their means (x-axis). The average ratio is 1.05; hori-
zontallines indicate the 2.5 - 97.5 percentile range. A good agree-
ment was noted with no systematic error. ppb: parts per billion. 
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FIGURE 3. Comparison of exhaled NO concentrations obtained at the 
end-expiratory plateau during a single exhalation at a fixed flow of 
20% of vital capacity per sec (x-axis) and the mean concentration of 
exhaled NO during 2 min of quiet tidal breathing (y-axis). Data are 
from 72 out of 101 children who could perform both methods satisfac-
torily. There is poor agreement with an rj of 0.52; NO values during 
tidal breathing showed an increase over time. Note the logarithmic 
scale. ppb: parts per billion. 
DISCUSSION 
This is the first study in children that has compared different sampling 
methods for exhaled NO. Thirty percent of the children studied were not able 
to perfonn the recollllllcnded sampling procedure of single slow exhalation 
with a constant flow against a resistance. Tllis underlines the importance of de-
veloping alternative Inethods for use in children. Until recently, Ineasurelnent 
techniques for expired NO were not standardized. Values have been obtained 
for peak expired NO, end-expiratOlY plateau levels, mixed expired levels du-
ring tidal breatlling and NO production over tilne. TIllS study compared three 
difterent NO Ineasureluent nlethods in stable asthmatic children, using control-
led exhalation with constant flow as a gold standard. SatisfactOlY agreement and 
no significant differences were found between the end-expiratory plateau value 
of NO during exhalation at 20% ofVC/sec and NO values obtained from a bal-
loon. However, there was a highly significant, tinle and concentration-depen-
dent difrerence between NO values during tidal breathing and at the end-
expiratOlY plateau, suggesting that sampling during tidal breathing without ex-
piratory resistance has limited value in children. 
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Relatively low NO values were found in well controlled asthmatic children, 
nlost of whom used inhaled steroids. This is in agreement with a number of other 
studies showing that inhaled steroids nonnalize exhaled NO in asthmatics 
(11,13,15). 
Regarding the feasibility of slow exhalation with constant flow, the present 
results are dift"rent /i'om those ofBalfotlr-Lynn et al. (25), who reported single 
slow exhalations against a resistance by 63 children with cystic fibrosis and 57 
normal children aged 6-17 yrs. However, they did not control for the exhalation 
flow rate or presstlre. As the concentration of NO depends on air flow (26,27), 
111aintaining a constant expiratolY flow is now considered important (18). 
Other studies have Ineasured NO in mixed exhaled air, collected in a reservoir 
during tidal breathing (19,20). In the present study, mean exhaled NO values 
obtained with the tidal breathing method were significantly higher than those 
obtained with the other two methods and increrased with time. This could well 
be due to contamination from nasal NO. DUling tidal breathing, NO may diffuse 
fr01n the upper airways and contaminate orally exhaled air, as the soft palate opens 
dming inspiration (26,28). Although contamination of orally exhaled NO by 
nasal NO can be prevented by single exhalations against a resistance (26,29), an 
expiratOlY resistor was not used dtlring tidal breathing. The palate will open 
during tidal inspiration regardless, thereby allowing for contamination with nasal 
NO. 
No significant diflerences, and a good agreement were found between [NO] in 
balloons and [NO] dming controlled single exhalations. Balloon filling through 
the resistor tube produced at least 6 cm of H 20 positive presstlre in the mouth, 
which will close the soft palate. This has been previously demonstrated in studies 
using Argon gas, a tracer appJied to the nose that was not retrieved in either the 
exhaled air or in balloons (30,31). 
The balloon method collects air not only from the alveolar compartment, but also 
/i'om the dead space. The potential efiect of the dead space on the NO concentra-
tion in the balloon is a point of concern, as the concentration of NO in the dead 
space may be relatively high, causing an initial NO peak during slow exhalations. 
However, no systell1atic difierence was fonnd between the balloon Inethod and 
single exhalations with constant flow. This may partly be explained by the £1ct 
that children have a smaller dead space than adults which, with a similar balloon 
voltune, will have a Sll1aller efiect on mixed NO values. To prevent accumulation 
of NO in the airways and nasal NO entering the dead space comparttnent, care 
was ~1ken that the NO in the ambient air was kept <10 ppb, that children inhaled 
through the mouth, and exhaled immediately without breath holding. Another 
point of concern in the balloon method is the lack of flow standardization. 
However, the short-tell11 reproducibility of NO data obtained with the balloon 
method appeared excellent, and corresponded well with end-expiratory plateau 
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NO levels during exhalation at a constant flow. This may be explained by the 
relatively high flow rate used in both methods; it is evident that flow dependency 
is most important with very low flow rates of approximately 5200 mL/min (26), 
whereas dependency is much less at higher flow rates such as that employed in the 
present study. It may be advantageous to adapt the balloon method for lower, 
controlled flow rates, although this would require a more cOll1plicated systctll and 
better cooperation and skills from the children (31,32). 
Recently, Deykin ct 31. demonstrated that repeated spirOlnetlY may induce a slow 
onset, prolonged fall in exhaled NO (33). In the present study spirometry was 
performed immediately before NO sampling and may have introduced a bias. 
However, all 111easnrClnents were ahvays perfonncd in the saine order, nlOstly 
within 15 min, whereas the maximal fall in NO after spiromctty reported by 
Deykin et a!. (33) occurred after 30 min; furthermore, an excellent 
within-method short-term reproducibility of single exhalations and balloons, 
without a downward trend, was found in the present study. Therefore, it is 
believed that the possible systematic error induced by the spirometry does not 
invalidate the results fimn this study. 
III colle/tlsioll, a simple and reproducible method of measuring exhaled 
NO in balloons was described, producing results that are similar to the values 
obtained at an end-expiratmy plateau. The balloon method is feasible in young 
children and has the additional advantage that it can be carried out independent 
of the presence of an NO analyser. 
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ABSTRACT 
The concentration of nitre oxide (NO) in exhaled air, a marker of airway inflam~ 
mation, depends critically on the flow of exhalation. Therefore, the aim ofthis 
study was to determine the effect of varying the flow on end-expiratory NO 
concentration and NO output in children with asthma or cystic fibrosis (CF) and 
in healthy children. Nineteen children with stable asthma, 10 with CF, and 20 
healthy children exhaled from TLC while controlling expiratory flow by means 
of a biofeedback signal at approximately 2, 5, 10 and 20% of their vital capac-
ity per second. NO was measured in exhaled air with a chemiluminescence 
analyser. Comparisons between the three groups were made by analysing the 
NO concentration at the endexpiratory plateau and by calcu[ating NO output at 
different flows. Exhaled NO decreased with increasing flow in all children. 
Children with asthma had significantly higher NO concentrations than healthy 
children, but only at the lowest flows. Asthmatics using inhaled steroids 
(n=13) tended to have lower median exhaled NO than those without steroids. 
The slope of linearized ([og-Iog transformed) NO/flow plots was significantly 
steeper in asthmatics than in healthy controls. CF patients had a significantly 
[ower NO concentration and output over the entire flow range studied, com· 
pared to asthmatics and control subjects, with a similar NO/flow slope as con-
trol subjects. In conclusion, the NO concentration in exhaled air is highly 
flow· dependent, and the NO-flow relationship differs between asthmatics ver-
sus CF patients and control subjects. Assessment of the NO/flow relationship 
may help in separating asthmatics from normal children. 
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INTRODUCTION 
Nitric oxide (NO) has an important regulat01Y role in the lung and has 
been implicated in the pathophysiology of airway diseases (1). During the past 
few years, NO in exhaled air has been exanuned as a lnarker of airway inflaln-
mation. NO can be measured directly in exhaled air (2); increased levels have 
been docllInented in several inflanllnatOlY airway disorders, including astlulla. 
However, patients with cystic fibrosis (CF) \vere found to have siIniiar or lower 
levels compared to normal subjects, either in nasal or in oral air (3,4). Both an 
increase and a decrease in the level of NO in exhaled air may therefore be taken 
as potential markers of disease and exhaled NO may be clinically useftll in diag-
nosing and nl0nitoring airway diseases. Values of exhaled NO reported by vari-
ous investigators difier greatly (5). This can be explained by difierences in the 
methods of measurement. NO in exhaled air depends on airflow (6). Since NO 
is continuously released into the airway lUlu en, high concentrations will result 
when exhalation is slow, and low concentrations when exhalation is £1St. It is 
unknown to what extent disease afrects the flow-dependency of NO in exhaled 
air. Recently, a European Respiratory Society task force published guidelines 
on 111eaSurelnent of exhaled NO, elnphasizing that nonnalizatioll for flow is vi-
tal (7). Until now, studies on exhaled NO in children did not take flow-
dependency into account. Therefore, the aitn of this study was to determine the 
effect of vatying the flow of exhalation on the NO concentration in exhaled air, 
and to examine the concentration of NO and the NO/flow relationship in nor-
mal subjects, asthmatic children and children with CF. 
PATIENTS AND METHODS 
STUDY POPULATION 
Patients were recruited fi-om the outpatient clinic for pediatric respirato-
ry medicine of Sophia Children's Hospital, and healthy control subjects were 
selected from a school population according to the following criteria. Asthma 
was diagnosed according to international guidelines, based on a typical clinical 
history (8). In addition, all asthmatic children had bronchial hyperresponsive-
ness (provocative dose ofinhaled methacholine that produced a 20% fall in for-
ced expiratory volume in 1 sec of <150 fig) and allergy, as previously documen-
ted by radio allergosorbent test class ;;:::2 for at least one C0l1Ull0n airborne 
allergen. All asthmatics were clinically stable for at least 2 weeks before the mea-
surelnent, and all were lifelong nonslnokers. Thirteen used inhaled corticoste-
roids (median daily dose 400 fig, range 100-1 000 ~lg/ day), all used bronchodila-
tors on demand. CF was diagnosed on the basis of typical clinical symptoms, 
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abnormal sweat test and the identification of 2 CF mutations. All CF patients 
had been clinically stable for at least 2 weeks prior to the measurements. One 
CF patient used inhaled corticosteroids. Healthy children were selected on the 
basis of no history of allergic respirat01Y disease and eczema, as defined by nega-
tive answers to the International Study on Allergies and Asthma in Children 
(ISAAC) core questionnaires, no symptoms of respiratOlY infection during the 
past 2 weeks, never smoked and had no other chronic disease. All had a normal 
lung function. None used 111cdication. All subjects underwent flow volmne 
curve IneasllrClucnts, using a heated Lilly-type pneumotachograph Gaeger, 
Wiirzburg, Germany); results were expressed as per cent predicted (9). The stu-
dy was approved by the hospital ethics committee and informed consent was 
obtained from all subjects. 
NITRIC OXIDE MEASUREMENT 
NO was tneasured in exhaled air with a Sievers 280 chenuluminescence 
analyser (Sievers, Boulder, CO, USA) with a sensitivity of < 0.1 parts per billion 
(Ppb) and a detection range of <0.1-500,000 ppb. The sampling flow was 0.2 
L/min, the response time was 0.2 sec and data were displayed with a lag time of 
approximately 2 sec. The analyser was calibrated regularly according to the ma-
nufacturer's guidelines, employing certified calibration gases containing 0 ppb, 
100 ppb and 9 parts per million (ppm) NO (HoekLoos, Barendrecht, the Ne-
therlands). The l11caSllrClnent circuit consisted of a 1110uthpiece connected to a 
two-way non rebreathing valve (Rudolph Inc.,MO,USA) through which the 
subjects inhaled ambient air willie seated and without wearing a lloseclip. After 
inserting the mouthpiece the subjects inhaled to total lung capacity (TLC) and 
immediately exhaled for as long as possible into a wide bore tube, with an 
in-line flow resistance (model #7100 R-20, 20 cm H 20/Llsec, Rudolph Inc.). 
TIllS was performed at flows corresponding to 2, 5,10 and 20% of the subject's 
vital capacity (VC) per second. A fine bore teflon tube continuously sampled 
the exhaled air from a side-port directly after the mouthpiece at 0.20 L/nlln for 
the measurement of NO. Airflow was measured by a heated Lilly-type pneu-
motachograph (Jaeger), mounted after the resistance. Flow was displayed on a 
video screen as a moving block that could be seen by the subject and should be 
kept between two arrows. TIllS biofeedback system made it possible to standar-
dize ex11aled flow to an individually set value. An end-expiratOlY flow-plateau 
of at least 3 s for the different flows (2 s for the highest flow) was the end-point 
of the Ineasurenlcnt. A plateau was defined as a flow tracing which varies less 
than ±1O% around the target flow. The test was performed in triplicate for eve-
ry flow and average NO values at the flow plateau were calculated. Between the 
different lnanoevres, a resting period of2-3 lnin was lnaintained for eqllilibrati-
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on of resting ventilatory conditions. All tests were perfonned with ambient NO 
concentrations <5 ppb. 
DATA ANALYSIS 
Both the NO signal and the flow signal were fed into a computer at a 
sampling rate of20 Hz. Values of NO and flow were obtained at each attempt 
by calculating the mean value in defined time intervals of 3 or 2 seconds, using 
custOIn-Inade software, and individual Ineal1S were calculated frotn triplicate 
NO and flow (L/sec) values. NO output, defined as the product of mean NO 
and flow (L/sec) , was calculated for each target flow, and expressed in nL/min. 
NO concentrations and NO output values were lognormally distributed and 
compared for each off our target flows between patient groups and healthy con-
trol subjects by means of the Mann-Whitney test. Plots of NO versus flow in 
Llsec were linearized by log-log transfoflnation, and regression analysis for re-
peated measurements was used to compare NO/flow slopes for the 3 groups 
(10). The efiect of normalizing flow for VC was evaluated by plotting individual 
NO values versus flow, either expressed as %VC/sec or as mL/sec, in log-log 
normalized plots. Standard deviations of the intercepts of individual regression 
lines in both types ofNOlflow plots at an arbitrary flow oflog(7%VC/sec) and 
log (300 mL/sec) were compared. The level of significance was set at p= 0.05 
(two sided). 
RESULTS 
Patient characteristics are given in Table 1. The lueasurelnents were ,vell 
tolerated. Two or three reproducible NO values for each flow rate were always 
obtained within five attempts. The NO level at the end-expiratory plateau de-
creased with increasing flows in all children. Median values of NO concentra-
tion and NO output, as well as the median absolute flows at which these were 
obtained, are given in table 2. Individual NO-flow relationships for the three 
groups are shown in figure 1. Astlunatics had higher tnedian NO concentrations 
than control subjects, but a significant difrerence was only present at the lo,vest 
end of the flow spectnlln. Likewise, tuedian NO output was higher in astlul1a-
tics than in control subjects at the lower end of the flow range, but the difieren-
ces were not significant. Strikingly, the variation in exhaled NO was luuch lar-
ger in asthmatics than in healthy children. Median NO values were higher in 
asthmatics without corticosteroids than in those with steroids (12.1, 6.1,4.2 and 
2.7 ppb versus 16.7, 17.1, 1l.1, and 6.8 ppb at a flows of2, 5, 10 and 20% of 
VC, respectively), but none of the differences reached statistical significance. 
CF patients had a significantly lower median NO concentration and output 
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TABLE 1. Patient characteristics 
Healthy controls Asthmatic children CF patients 
Number 20 19 10 
Sex (m/I) 12/8 9/10 5/5 
Age (months) 165 ± 10 (149-180) 154 ± 22 (116-198) 143 ± 22 (114-183) 
FVCOfo 101 ± 12 (82-122) 101 ±12 (76-121) 94 ± 13 (78-126) 
FEV1 % 103 ± 12 (85-126) 88 ± 16 (54-116) 84 ± 17 (52-110) 
Data are mean ± standard deviation (ranges). CF: cystic fibrosis; m: male; f: female. 
TABLE 2. Exhaled NO in children with and without asthma or cystic fibrosis 
Healthy controls Asthmatic children CF patients 
(n~20) (n~19) (n~10) 
Exhaled NO (ppb) 
at 2 %NC/sec 8.8 (5.4-23.6) 12.1 (1.7-75.1)' 3.5 (0.4-9.9)" 
at 5 OfoVC/sec 5.9 (3.6-13.9) 6.4 (1.0-36.8) 1.9 (0.6-4.3)" 
at 10 o/OVC/sec 4.8 (2.6-10.0) 4.6 (1.1-21.3) 1.5 (0.2-3.6)" 
at 20 OfoVC/sec 4.4 (3.2-6.6) 3.2 (0.9-18.5) 1.4 (0.4-2.6)" 
NO output (nl/min) 
at 2 OfoVC/sec 39 (17-107) 64 (6-271) 11 (1-35)" 
at 5 OfoVC/sec 65 (35-195) 72 (7-320) 15 {3-40)'" 
at 10 %VC/sec 102 (60-241) 109 (15-357) 27 {5-45)'" 
at 20 c/OVC/sec 190 (113-368) 151 (24-650) 43 {16-83)'" 
Actual flows (ml/sec) 
at 2 OfoVC/sec 70 (40-120) 60 (30-300) 52 (30-200) 
at 5 OfoVC/sec 170 (100-300) 150 (l0-270) 123 (90-21O) 
at 10 OfoVC/sec 341 (200-610) 283 (160-540) 272 (160-410) 
at 20 %VC/sec 716 (420-121O) 570 (340-1070) 556 (360-740) 
All data are median (range). *: p<O.05; **: p<O.001, ***; p<O.0001 compared to control subjects 
and asthmatics. 
than healthy control subjects and asthmatics over the entire flow range tested. 
Double logarithmic transformation of flow and NO resulted in a linear 
NO/flow relationship for each individual in all three groups within the flow 
range studied (figure 1). Using regression analysis oflog NO versus log flow, 
with flow expressed as mL/sec, it appeared that the average decrease of NO per 
doubling offlow in asthmatics was 33% (95% confidence interval (CI) 29-37%). 
For healthy children and CF patients, these figures were 21 % (95% CI 18-24%), 
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FIGURE lA, B, C. Exhaled NO versus flow end-expiratory plateaus in A) healthy children (n.20), B) 
children with asthma (n.19) and C) children with cystic fibrosis (n.l0). Each line represents one 
child. Both exhaled NO and end-expiratory flow were measured on a logarithmic scale. ppb:parts per 
billion. 
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FIGURE 2. log-log transformed plots of exhaled NO of 20 healthy 
children versus flow normaLized as a percentage of the patients' 
vital capacity (Ve) per sec (X-axis). Comparison with fig. lA 
shows that normalization of flow for lung size did not result in a 
reduced variation, confirmed by statistical analysis, showing a 
similar standard deviation of the intercepts of individual regres-
sion lines at arbitrary flows of 7% of VC and 300 ml/sec (see 
Results section). 
and 24% (95% Cll0-36%), respectively. The slope of NO versus flow was sig-
nificantly steeper for the asthmatic patients than for the control subjects 
(p=O.003). These results were the same, irrespective of whether flow was ex-
pressed as mL/sec or as %VC/sec. 
For each group, whether baseline lung function influenced the olltCOll1es was 
investigated. ltappeared that the NO concentration, -output and slopes were not 
significantly atTected by either forced expiratory volume in one second (FEV [) or 
forced vital capacit), (FVC). The asthmatic patients who used steroids (n=13) had 
NO levels that were slightly lower, but not significantly ditTerent fi'om those 
without steroids. Within groups, age did not correlate with exhaled NO values. 
Normalizing flow for lung and airway size by expressing it as a percentage of 
VC/sec instead ofmL/sec did not reduce the standard deviation of the intercepts 
of the individual regression lines at an arbitrary flow of7%VC/sec or 300 mL/sec 
within groups (fig. 2). 
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DISCUSSION 
The present study confirms that the NO concentration in exhaled air ri-
ses with decreasing flow, and shows that the NO/flow relationship differs be-
tween children with asthma on the one hand, and CF patients and healthy chil-
dren on the other hand. The clinical implication of these results is that the 
measurement of NO clearly distinguished between the different disease states at 
low flow rates, and that not only NO concentration at a fL'(ed flow rate, but also 
the slope of the NO/flow relationship discriminates between asthmatics and 
healthy subjects or CF patients. 
Tins study is the first to quantifY the effect of varying the flow rate on the NO 
concentration in exhaled air in children and to establish the effect of difIerent 
disease states on the NO/flow relationslnp. SilkofIet al.(6) recruited a group of 
healthy adult volunteers (age 16-50 yrs) for their study of the flow-dependency of 
end-expiratory NO in exhaled air. Sato et al. (11) studied the effect of the duration 
of exhalation on the NO levels in exhaled air in healthy and asthmatic adults. 
Exhaled air was collected in a reservoir and the subjects wore a noseclip. Hence, 
not only the plateau level of NO, but also the initial peak level, and probably 
contamination with nasal air contributed to the results of this study. Byrnes et a1. 
(12) studied the mean peak concentration of NO at different flow rates in adults. 
However, peakNO concentrations reflect the NO concentration in the anatOlll-
ical dead space, contaminated by nasal NO; noseclips may have enhanced nasal 
contamination. The increase of NO in exhaled air with decreasing £lo,v observed 
in the current study matches the results by SilkofIet al. (6) and Byrnes et al. (12), 
and confirms that the NO levels in exhaled air in well-controlled asthmatics are 
only slightly higher than in healthy subjects. 
The results of the present study might have been biased by methodological 
aspects. Firstly, it could be argued that the flow resistance used was not high 
enough to close the soft palate, leading to nasal contamination. In a study in 
adults, no contamination of NO frOln the nasal cavity was observed with a flow 
resistance of at least 3 cm H 20/L/ sec (13). No similar studies have been published 
for clrildren. The flow resistance used in the current study was 20 cm H20/L/ sec, 
and it is therefore likely that nasal contamination of the NO concentration in 
exhaled air was effectively prevented at least at flow rates >150 mL/sec, corre-
sponding to oral pressures >3 Clll H 20/L/sec. However, the mean £lows at 2%, 
and sOlnetimes at 5% ofVe/sec were belo,v tills value, and therefore sonle nasal 
contamination at the lowest flows cannot be excluded. TIllS has not necessarily 
introduced a bias, as it would affect results in astlllnatic and control subjects sirni-
larly. 
Secondly, the study assessed whether nOl1l1alizing expiration flow as a percentage 
of the patient's VC has advantages above comparing fixed flows, winch do not 
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take diflerences in lung and airway size into account. The results showed that 
normalization of expiration flow for the VC is not velY important when 
comparing exhaled NO in children of different sizes. It may still be that in larger 
groups within-group variation is smaller with IneasurClnent at a lung 
size-dependent flow, but tIus rcrnains to be shown. Alternatively, standardizing 
for the lung volume at which NO is measured may increase the accuracy of NO 
measurements. However, the present study did not explicitly define the lung 
volmue at which results ,vere obtained. 
A final source of error may be the repeated perfonnance of expiratolY manoevres. 
All children performed a number of deep inspirations and expirations and, since 
tills study, it has been shown that forced manoevres cause a decreased NO output 
(14). The NO levels may therefore have been underestimated. It is thought that 
such an effect may have been sillall, as no decreasing trend was obvious for the 
repeated IneasurCluents at a given target flow. 
The group of children with asthma had a higher median level of NO in exhaled 
air, which lllay be due to residual chronic airway iu£1anunation despite steroid 
treatment, and to the fact that a number of children did not use steroids and, 
indeed, tended to have higher NO values than those who did. 
CF patients have lower exhaled NO than healthy subjects. As irtflarmnation is 
invariably present in CF airways (15), it has been speculated that the increased 
3Illount of thick broncrualtuucus in patients with CF may favour retention and 
metabolism of NO in airway liquids (4). That increased NO production takes 
place in CF airways is supported by data demonstrating increased nitrite levels in 
breath condensate, despite normal NO in exhaled air, in a group of older CF 
patients (16). The results of the present study confirm that increased NO levels in 
inflamed CF airways are not reflected by an increase in exhaled NO (3,4,16). In 
contrast to earlier reports, sigrllficantly lower orally exhaled NO values in CF 
than in control subjects were found. TIllS may partly be due to important differ-
ences in methodology: no expiratory resistance (4), tidal breatlllng versus single 
controlled expiration (3) and older, more severe patients (16) in previous studies. 
III COllelIlS;OIl, this study shows that differences in exhaled NO between 
asthmatics, CF patients and healthy children are greatest at low flows; the linea-
rized NO/flow relationship is steepest in asthmatics. These results indicate that 
accurate standardization oflow flow rates is necessary; a convenient target flow 
could be 100 mL/sec. For firm reconunendations, larger groups should be stu-
died and a cutofl'level determined for a given purpose, e.g. detection of disease. 
For diagnostic purposes in children, NO l11easnrements in exhaled air at diffe-
rent flow rates may prove an additional new tool for the diflerential diagnosis of 
airway diseases, especially asthma and cystic fibrosis. 
Nitric oxide IS3 
REFERENCES 
1. Lundberg JON, \Veitzberg E, LundbergJM, Alving K. Nitric oxide in exhaled air. 
Eur Respir] 1996; 9: 2671-2680. 
2. Gustafsson LE, Leone AM, Persson MG, \Viklund NP, Moncada S. Endogenous 
nitric oxide is present in the exhaled air of rabbits, guinea-pigs and humall5. Biochem 
Biophys Res C01l111lun 1991; 181: 852-857. 
3. LundbergJON, Nordvall SL, \Veitzberg E, Kollberg H, Alving K. Exhaled nitric 
oxide in pediatric asthma and cystic fibrosis. Arch Dis Child 1996; 75: 323-326. 
4. Balfour-Lynn 1M, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in 
cystic fibrosis. Arch Dis Child 1996; 75: 319-322. 
5. Kharitonov SA, Barnes PJ. Eflect ofpressm'e and flow on measurement of exh.tledand 
nasal nitric oxide. AmJ Respir Crit Care Med 1997; 155; 4: A825. 
6. SilkoffPE, McClean PA, Slutsky AS, Furlott HG, HoffiteinE, Wakiti S, Chapman KR, 
Szalai JP, Zamel N. Marked flow-dependence of exhaled nitric oxide using a new tech-
nique to exclude nasal nitric oxide. Am J Respir Crit Care Med 1997; 155: 260-267. 
7. Kharitonov SA, Alving K, Barnes Pl. E.R.S. task force: Exhaled and nasal nitric oxide 
measurement: recommendations. Eur Respir] 1997; 10: 1683-1693. 
8. WarnerJO, Gotz M, Landau LI, et al. Management of asthma: a consensus statement. 
Arch Dis Child 1989; 64: 1065-1079. 
9. Zapletal A, Samanek M, Paul T. Lung function in children and adolescents: Methods, 
reference-values. Basel; Karger Verlag, 1987; 191-197. 
10. BIvIDP Statistical Software manual. Unbalanced repeated measures models with stnlC-
tured covariance matkes. University of California Press, Berkeley, 1992: 1330-1335. 
11. Sato K, Sakamaki T, Sumino H, Sakamoto H, Hoshino J, Masuda H, Sawada Y, 
Mochida M, Ohyama Y, Kurashina T, Nakamura T, Ono Z. Rate of nitric oxide 
release in the lung and factors influencing the concentration of exhaled nittic oxide. 
Am] Physiol1996; 270: L914-L920. 
12. Byrnes CA, Dinarevic S, Busst CA, Shinebourne EA, Bush A. Effect of measurement 
conditions on measured levels of peak exhaled nitric oxide. Thorax 1997; 52: 
697-701. 
13. Kharitonov SA, Barnes PJ- Nasal contribution to exhaled nittic oxide during exhala--
tion against a resistance or during breath-holding. Thorax 1997; 52: 540-544. 
14. Deykin A, Halpern 0, Massaro AF, Drazen]M, Israel E. Expired nitric oxide after 
bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir 
Crit Care Mcd 1998;157:769-775. 
15. Konstan M\V, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings 
in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoinginfec--
tion and intlanunation. Am] Respir Cdt Care Med 1994; 150: 448-454. 
16. Ho LP, Innes JA, Greening AP. Nitrite levels in breath condensate of patients with 
cuystic fibrosis is elevated in contrast to exhaled nitric oxide. Thorax 1998; 53: 
680-684. 

CHAPTER 4 
Off-line sampling of exhaled air for nitric 
oxide measurement in children: 
methodological aspects 
Q. Jiibsis'·3, S.l. Schellekens', A. Kroesbergen 1 W.c.J. Hop' and J.e. de Jongste' 
1 Department of Paediatrics, division Paediatric Respiratory Medicine, and 
2 Department of Epidemiology and Biostatistics, Erasmus University and University 
HospitaljSophia Children's Hospital, Rotterdam and 3 Oept. of Paediatrics, University 
Hospital Maastricht, The Netherlands 
Eur Respir J 2000; in press 
155 
56 
ABSTRACT 
Measurement of nitric oxide (NO) in exhaled air is a non·invasive method to as-
sess airway inflammation in asthma. This study was undertaken to establish the 
reference range of exhaled NO in healthy school-aged children and to deter-
mine the influence of ambient NO, noseclip and breathho[ding on exhaled NO 
using an off-line balloon sampling method. A[[ children attending a primary 
school (age range 8-13 years) underwent NO measurements on two occasions 
with high and [ow ambient NO. Each time, the children performed 4 expiratory 
manoeuvres into NO-impermeable baUoons, with and without 10 sees of 
breathho[ding and with and without noseclip. Exha[ation flow and pressure 
were not controUed. NO was measured within 4 h after collection, by means of 
chemiluminescence. AU children completed a questionnaire on respiratory and 
allergic disorders, and performed flow-volume curves. With [ow ambient NO, 
the mean exhaled NO value of 72 healthy children with negative questionnaires 
and normal lung function was 5.1±O.2 ppb, versus a mean of 6.8±O.3 ppb in the 
remaining 49 children with positive questionnaires for asthma and allergy, 
and/or recent symptoms of cold (p=O.OOl). Exha[ed and ambient NO were sig· 
nificantly related, especially with ambient NO > 10 ppb (r=0.86, p=O.OOOl ver-
sus r=0.34, p=0.004 for ambient values < 10 ppb). The use of a noseclip, with 
[ow ambient NO and without breathholding, caused a small decrease in exhaled 
NO values (p=O.OOl). The effect of breathho[ding on exhaled NO depended on 
ambient NO. With ambient NO > 10 ppb exhaled NO decreased, whereas with 
ambient NO < 10 ppb, exhaled NO increased after 10 sec breathhold. We con-
clude that off-line sampling in balloons is a simple and, hence, attractive 
method for exhaled NO measurements in children, which differentiates be-
tween groups with and without self-reported asthma, allergy and colds, when 
ambient NO is < 10 ppb. Wearing a noseclip and breathho[ding affect measured 
values and should therefore be standardized or, preferably, avoided. 
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INTRODUCTION 
Nitric oxide is a reactive free radical gas, produced by various cells within 
the respiratory tract. It plays an important role in the pathophysiology of in flam-
matOlY airway disease and can be detected in exhaled air (1-4). There is now 
convincing evidence that NO in exhaled air (eNO) is a non-invasive marker of 
airway inflaU1mation in various airway disorders (1,5,6). Recently, sio\v exhala-
tion ti-Ol11 TLC with a constant flow against a resistance \vas recollllnended for 
measurement of eNO (6). However, this manoeuvre is difficult to pelionn for 
many children (7), and requires the presence of an NO-analyser and equipment 
to measure flow with a visual feedback control. We have developed a simple 
oft~line single breath balloon sampling method to measure eNO. Blowing air in 
a balloon is feasible even for young children, and produces values similar to tho-
se of end-expiratOlY plateaus (7,8). Oft~line sampling has the advantage that 
children may be studied at home or school, and that it can be used for large epi-
demiological studies, independent from the direct presence of an NO-analyser. 
The aim of this study was to establish a reference range of eNO sampled in bal-
loons, of a large group of healthy school-aged children. Furthermore, we exa-
mined the influence of ambient NO, the eflect oflO sec of breath holding and of 
using a noseclip 011 measured values. 
PATIENTS AND METHODS 
All pupils of a primalY school (n= 129) participated. They were intelvie-
wed with validated questionaires on astlllna, allergy, eCZet11a and rhinitis transla-
ted ti-Ol11 the core questionnaires on wheezing, rhinitis and eczelna of the inter-
national study of asthma and allergies in childhood (ISAAC) (9), and were in 
addition asked for recent symptoms of cold (stuHy or running nose, sneezing, 
coughing, sore throat, with or without fever). Measurement of eNO was done 
on two occasions in the Sat11e children. On the first occasion, the alnbient NO 
was high (median 35 ppb, range 15-188 ppb). At that time, 91 children (mean 
age 10 yrs) had negative questionnaires on asthma, allergy and eczema (all ques-
tions answered negatively) and did not report symptoms of cold within the 3 
weeks before the l11easurements. On the second occasion 3.5 tnonths later, a111-
bient NO was low (median 7.0 ppb, range 1.5-9.0 ppb). At that time, 8 children 
were absent, 72 of those 91 who initially had negative ISAAC questionnaires 
reported no symptoms of cold, and 49 had either positive ISAAC questionnaires 
or reported a recent cold. Measurel11ents took place during several sessions at 
each occasion, always between 14.00 and 16.00 h pm. Ambient NO was drawn 
and stored for later analysis before and after each session, and the mean of these 
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two samples was taken as the atubient NO concentration at that session. All 
children were self-reported never stnokers, never had had any other chronic 
illness, and used no medication. The study was approved by the hospital ethical 
COllunittee. 
EXHALED AIR SAMPLING AND NO MEASUREMENTS 
The children were asked to take a deep oral breath and exhale via a piece 
of plastic tubing into a mylar balloon with a maximum content of 1750 mL. 
These balloons are impermeable to- and nonreactive with NO (10). The plastic 
tube (internal diameter 3.7 r11111 and length 5 cm) worked as a fixed flow restric-
tor, causing a positive lllouth pressure during the exhalation manoeuvre. Preli-
minary experiments showed that with a flow of250 mL/min, tllis pressure is 6 
C111 H20. At the school, exhalation flow and nlouth pressure were not nlonito-
red. Subjects filled the balloon within 3-5 s. The range of expiratory volumes 
which were collected was 250-1750 mL, the extrapolated expiratory flows thus 
ranged between 250-600 mL/s. 
All subjects performed expiratory manoeuvres into 4 balloons: I) immediate 
exhalation with a noseclip; 2) immediate exhalation without a noseclip; 3) exha-
lation after breath-holding for 10 seconds with a noseclip; 4) exhalation after 
breathholding for 10 seconds without a noseclip. All tneasurelnents were 
perfon11ed with the children seated. The NO concentration in balloons was 
measured within 4 h after collection. Air was drawn out of the balloons at 200 
mL/nlin by a chemilunlinescence analyser (Sievers 280, Boulder, CO, USA) 
with a response time of200 msec. The NO profile showed a rapid rise to a steady 
NO plateau, at wllich eNO was calculated. The analyser was regulary calibrated 
according to the 1nanufacturer's guidelines, with two difIerentcertified NO gases 
(100 ppb and 9 ppm) and a certified NO free air nlixture (HoekLoos, 
Barendrecht, The Netherlands). 
LUNG FUNCTION 
All subjects perfonned Inaxi1ual expiratolY flow-volume measurelnents 
immediatly after eNO was collected in the balloons on the first occasion. 
Flow-volmue curves were obtained in triplicate, using a calibrated single breath 
electronic screening spirometer (Vicatest P2A, Mijnhardt, Zeist, The Nether-
lands). Results of expiratory forced vital capacity (FVC) and forced expiratory 
volume in I second (FEV U were expressed as percentage predicted (11). 
STABILITY OF ENO IN BALLOONS 
Five subjects filled each I balloon with orally exhaled air and 1 with na-
sally exhaled air. These balloons were sealed and stored at room temperature. 
Nitric oxide [59 
During a period of 6 h, air ,vas satllpled for NO tlleasureluents with hourly in-
tervals. 
DATA ANALYSIS 
Data of NO tueasurements were fed into a cOlllputer at a salnpling rate of 
20 Hz. Mean values during 30 sec sampling of the plateau were calculated. Cor-
relation between eNO and other variables \vere analysed in a multiple regressi-
on model. In tins model, eNO was entered as the dependent variable and am-
bient NO, gender, age and FEV I were entered as independent variables. 
Difterences between healthy and "diseased" groups were evaluated with Stu-
dent's t-test for independent samples. Diflerences between eNO values at high 
and low ambient NO within groups were tested using a paired sample Hest. 
The relation between eNO and aillbient NO concentrations was tested with 
Spearman's rank test. Data are reported as means ± 1 standard error (SEM). In 
all statistical comparisons a two-tailed p value of <0.05 was considered signifi-
cant. 
RESULTS 
Characteristics of the study population are given in table 1. There were 
no difterences in age, 111ale/female ratio, anthropOlnetric data and lung function 
between healthy and "diseased" groups at both sampling moments. 
Referellce ,!allles. All children pe1formed the sampling procedures without diffi-
culty. Values obtained in 72 healthy children, not wearing noseclips, without 
breathhold, and while ambient NO was below 10 ppb are considered as reference 
values and show a nonnal, symmetric distribution, with a mean level of5.1 ± 0.2 
ppb (95% reference interval 1.7-8.5 ppb). Exhaled NO was sinnlar in boys and 
girls (means 5.1 ppb and 4.9 ppb respectively, p=0.15). There was no significant 
correlation between eNO and FVC or FEV I (p=0.56). We found a significant 
positive correlation between age and eNO; for evelY 10 months of increasing age 
eNO increased 0.3 ± 0.1 ppb (p=0.013). Individual data and 95% reference 
interval are given in figure 1. The children of the 'diseased' group (N=49) with 
positive questionnaires on asthma, rhinitis, and/or eczelna, and/ or SYlllptoms of 
cold within 3 ,veeks before eNO tneasurelnents, with atnbient NO<10 ppb, 
showed a significantly higher mean eNO than the corresponding healthy group 
(6.8 ± 0.3 ppb, p=O.OOl). The mean eNO values of the healthy and 'diseased' 
groups of children under the diflerent measnreillent conditions, with aillbient 
NO < 10 ppb, are given in table 2. 
Ifffect ,if ambiellt NO. High concentrations of ambient NO led to significantly 
higher eNO values in healthy children: 19.2 ± 1.6 ppb with ambient NO > 10 
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TABLE 1. Patient characteristics at two points in time, with high and (ow ambient NO. Data are 
presented as means and 1 standard error. 
Ambient NO < 10 ppb. Ambient NO > 10 ppb. 
healthy 'diseased'* healthy 'diseased'* 
N 72 49 91 38 
Sex M/F 31/41 28/21 46/45 19/19 
Age (months) 123.8. 1.8 123.3.2.2 125.1.6 120.2.2.5 
Heigth (em) 144.3.1.2 144.4.1.6 144.6.1.1 142.8.2.5 
Weight (kg) 37.8. 1.0 38.8.1.2 38.0.0.9 38.0.1.5 
FVC % pred. 98.1 99.1 98.1 100.2 
FEV 1% pred. 99.1 99.1 99.1 99.2 
*'Oiseased': a positive questionnaire for asthma and aUergy, and/or recent or current symptoms 
of cold. 
TABLE 2. NO values of schoolchildren with and without reported symptoms of asthma. allergy or 
colds (indicated as 'healthy' and 'diseased', respectively), with and without nosedip or breath-
holding, measured when ambient NO was < 10 ppb. Means, SEM and ranges are given for each condi-
tion. 
n noseclip - noseclip + nosedip + nosedip -
breathholding - breathholding - breath holding + breathholding + 
Healthy 72 5.1.0.2 4.5 ± 0.2** 6.2 ± 0.4** 6.4 ± 0.4*** 
(2.1 - 10.9) (1.1 - 9.5) (2.2 - 20.5) (2.7 - 21.6) 
'Diseased' 49 6.8.0.3' 5.9 ± 0.4* 8.9±1.1* 8.3 ± 0.9* 
(2.4 - 15.3) (1.8 - 14.3) (2.0 - 46.2) (2.3 - 32.1) 
* p = 0.001 compared to healthy children, same measurement conditions. ** p = 0.001 compared to 
healthy children without nosedip and breathhold. H* p < 0.0001 compared to healthy children 
without nosedip and breathhold. 
ppb, versus 5.1 ± 0.2 ppb with ambient NO < 10 ppb (p<O.OOOl). Exhaled NO 
values and ambient NO coucentrations were significantly related (Figure 2). 
With ambient NO levels >10 ppb this relation was stronger than with levels < 10 
ppb (r=0.86, p<O.OOOl versus r=0.34, p=0.004, respectively). Between 0 and 10 
ppb, eNO increases with 0.2±0.2 ppb per 1 ppb increase of ambient NO. 
Wearing a noseclip had no influence on the observed relation between eNO and 
ambient NO. 
liffeel <if lIoseclip. The noseclip significantly reduced eNO values when ambient 
NO was < 10 ppb. In 72 healthy children, the mean eNO value was 4.5 ± 0.2 
ppb, with- and 5.1 ± 0.2 ppb without noseclip (p=O.OOl). There was no signifi-
cant eftect of a noseclip on eNO values under all other lueasurenlent conditions: 
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FIGURE 1. Exhaled NO (in ppb, vertical axis) of 72 healthy school 
children versus age (in months, horizontal axis). Values are from 
children without reported asthma, allergy or recent cold, and were 
measured when ambient NO was <10 ppb. All measurements were 
done without breath hold or nosedip. There is a small but significant 
increase in NO with increasing age, corresponding to 0.3 ± 0.1 ppb 
per 10 months (r .. 0.3, p=O,013). lines indicate the 95% reference 
intelVal. 
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FIGURE 2. Exhaled NO (in ppb, vertical axis) versus ambient NO on 
days with ambient values> 10 ppb (horizontal axis) in 91 healthy 
children. Note that both axes are logarithmical. There is a significant 
correlation (Spearman rho = 0.86, p=O.OOOl). 
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FIGURE 3. NO concentrations in mylar-balloons, stored for 6 h 
at room temperature. Vertical axis depicts NO in ppb, the hori-
lontal axis shows time after baUoon fitling in h. The upper curve 
is the mean [NO] from 5 balloons containing nasal air, the lower 
curve the mean [NO] from 5 balloons with orally exhaled air. 
Concentrations were stable in time. 
high ambient NO levels with (p=0.2) or without breathholding (p=O. 9) and low 
ambient NO levels with breathholding (p=OA). 
E.Uecl <?/breatlliloldillg. In healthy children, 10 secs of breath holding resulted in an 
increase in eNO fiOin 5.1±0.2 ppb to 6.4±0.4 ppb (p<O.OOOl) with ambient 
NO< 10 ppb. In contrast, 10 secs of breath holding produced a significant reduc-
tion of eNO from 19.2±1.6 ppb to 9.6±0.8 ppb (p<O.OOOl) with ambient NO 
>10 ppb. 
StabilityifeNO ill balloolls.The mean NO concentration in 5 mylar-balloons with 
nasal air was 36.4±1.8 ppb and with oral air 7.5±0.9 ppb. Nasal and oral NO 
concentrations in the balloons were stable for at least 6 h (figure 3). 
DISCUSSION 
In this study, we define a reference range of eNO obtained off-line with 
balloon sampling in a large group of healthy school-aged children. The mean 
eNO concentration of healthy children in our study is in agreement with eNO 
concentrations of healthy children from a number of previous studies (12-16). 
Furthenllore, we show that a 1111lnber oflnethodological £1ctors influence eNO 
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collected off-line in balloons, including ambient NO, the use of a noseclip and 
breath holding. We detected significant diflerences between children with and 
without self-reported asthma, allergy and colds, suggesting that tills method is 
sufficiently sensitive to detect minor degrees of airway inflammation in groups 
otherwise healthy school-aged children. 
There are a number of factors that should be considered when comparing our 
simple ofl~linc sampling technique with more complicated on-line sampling 
teclullques where flow is controlled and the NO signal displayed during exhala-
tion. 
We previously showed that, despite lack of flow standardization, ofl~line 
sampling in balloons produces eNO values that are reproducible and similar to 
those of end-expiratOlY plateaus measured on-line with constant flow (7). We 
and others have shown that eNO is flow dependent, but mainly at flows ofS;150 
OlLis (17-19), whereas flow dependency is much less at higher flow rates. The 
children in our study blew relatively high flows of at least 250 mL/s. This could 
explain why eNO in balloons is reproducible despite a lack offlow standardiza-
tion (7). 
In a previous study we showed an excellent within~subject short-tenn repeat-
ability of eN 0 with an intraclass correlation coefficient (ri) ofO. 91, using the same 
technique without noseclip (7). Small alterations of tills original sampling tech-
nique, like the use of a noseclip or 10 sec breath holding, could potentially influ-
ence the repeatability. We and others previously showed that short-term 
repeatability in clinicallly stable allergic asthmatic children was also excellent 
when a noseclip was used (ri=O.96) (7,8,14,21). We did not specifically investi-
gate the influence ofl0 sees breathholding on the repeatability of eNO obtained 
with the ofi~line balloon method, and no such data are available in the literature. 
Contamination with nasal NO is another potential problem with off-line 
saillpling. An expiratory resistance is recollunended to isolate the lower airway 
gas fi'Olll gas with much lllgher NO concentrations produced in the nose and 
paranasal sinuses (6). In our study, balloons were filled via a plastic tube during a 
single oral exhalation. The tube worked as a fi.xed flow restrictor willch causes a 
positive lllouth pressure during the exhalation lllanoeuvre. It has been shown in 
adults that a mouth pressure of 4 cm H 20 is sufficient to keep the soft palate 
closed, thus preventing contanllnation with NO from upper airways (22). Studies 
on lllouth pressure and Veltllll closure were done in adults; it lllay well be that 
lower pressures close the Veltllll in children. The lowest estimated lllean exhala-
tion flow of250 mLlsec in this study produces a mouth pressure of6 cm H 20. 
This should be sufficient to close the velum, and we are therefore confident that 
contalnination with NO frOIll the upper airways, despite our simple setup 
without lnonitoring of flow or pressure during exhalation, did not occur to an 
itnportant degree. 
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The potential eflect of NO in the dead space air volume on eNO in the balloon is 
another point of concern. Children have a smaller dead space volume than adults 
which, in a similar balloon volume, ,vill cause a smaller efiCxt on NO values. We 
speculate that in children the effect of the dead space air on the eNO value will be 
minimal when ambient NO is < 10 ppb, and when subjects inhale orally before 
exhaling into the balloon, as was done in the present study. 
Previous studies on the effect of ambient NO on eNO vary remarkably. Some 
authors found no influence of ambient NO on eNO values (23-27), others found 
important effects (28-32). We found a strong positive relation between ambient 
NO concentrations and eNO in balloons. The variation of sampling techniques 
used in the different studies probably explains the diflerences. As an example, 
Corradi et al (32) found no relationship between ambient NO and eNO in 
balloons, with ambient NO < 35 ppb, but the expiration in their study in adults 
took at least 20 s compared to 3-5 sec in our study. This may explain the differ-
ence, as we found that breathhold significantly reduces the effect of high ambient 
NO on exhaled values. The positive relation between ambient and eNO was 
luore pronounced with high alubient NO levels, but there was also a positive 
correlation at ambient NO levels below 10 ppb. The magnitude of this eflect, a 
mean rise of eNO 0.2 ppb for each 1 ppb rise in ambient NO, is small compared to 
the differences in eNO between healthy and 'diseased' children. To minimize the 
eflect of ambient NO on eNO, we recommend that eNO should not be 
measured when ambient NO is above 10 ppb. Ambient NO should be recorded, 
or sampled in balloons and analyzed later. Alternatively, NO-free air may be 
inhaled before sampling, but tllls makes the method more complicated and 
formal cOlnparisons of these approaches have not been done. 
We found a significant correlation between increase in eNO concentrations and 
increasing age in healthy clll1dren. A possible explanation is the influence of the 
different dead space air volumes on eNO values in balloons. One could also spec-
ulate that tllls correlation is caused by increasing nasal contamination of the eNO 
with age, due to developtnent and pneumatization of the paranasal sinuses in 
clll1dhood. Indeed, nasal NO increases with age reaclllnglevels sinll1ar to those in 
adults at the age of approximately 10 years and tllls corresponds roughly with the 
period of sinus development (33). However, oral pressures were probably sufli-
ciellt to close the velum and prevent contamination by nasal NO (22). Further-
more, Franklin et al recently described a positive correlation between eNO and 
age, in a comparable group of healthy children. using an on-line single breath 
plateau teclullque at a mouth pressure of 15 cm H 20 (34). Other eNO studies in 
clll1dren have not been able to demonstrate a relationslllp of eNO with age 
(14,15,30). However, a number of methodological diflerences of the different 
studies Blakes it difficult to cOll1pare results. For instance, different ages, difier-
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ences in sampling methods with eNO values obtained in difierent ways and 
difierences in dealing with the ambient NO. 
It has been stated that using a noseclip enhances nasal contamination of eNO, 
although there are no data to support this (2,10,17). Several investigators 
routinely require subjects to wear noseclips during NO lneasurelnents (10,26, 
31,35), wlule others do not (17,21,36). Without a noseclip, diffusion of NO 
through the nares as well as into the posterior nasopharynx is possible; with a 
noseclip only diffusion towards the phal)'tL'( can occur, and tlus would increase 
contamination with high nasal NO levels. Using the present ofi:line single breath 
balloon sampling method with an expiratOLY resistance, we found that a noseclip 
in cOinbination with low ambient NO levels causes a sInall but significant 
decrease in exhaled NO values. A possible explanation is that a noseclip prevents a 
llunitnal nasal inspiration, thus preventing contanunation of eNO with nasal 
NO. Although a noseclip only minimally affected eNO, our data do not argue 
against the ERS task force recommendation not to use noseclip during NO 
measurement (6). 
Prior studies have shown that breathholding increases eNO in asthmatics and in 
healthy subjects in a time dependent way (10,17,37,38). However, others 
showed that when 40 ppm is inhaled, a breath hold of several seconds reduced NO 
in exhaled air to 1-3 ppm (25). This decrease may be caused by rapid uptake of 
NO by haemoglobin in the lung capillaries (17,25,39). We found that the effect 
of breathholding on eNO depends on ambient NO; with lugh levels, 
breathholding reduces NO, whereas with low levels it increases eNO. It is not 
likely that these results are influenced by nasal contamination during 
breath holding or in the oral expiration phase, as shown earlier with an inert tracer 
gas (22). 
IVe (ol/ell/de, that off-line measurement of NO sampled in balloons is a 
simple and feasible method of measuring eNO in children. Off-line sampling 
has the important advantage that it offers independence from the presence of an 
NO analyser. Ofi:line balloon sampling without use of a noseclip and without 
breathhold, and with ambient NO < 10 ppb, shows differences between heal-
thy children and those with self-reported asthma, allergy or cold, confirnung 
that eNO l11ay be llsed as a surrogate Inarker of airway inflammation. The siln-
plicity of tlus method makes it attractive for studies in larger populations, where 
difierences between groups can be detected. 
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ABSTRACT 
The aim of this study was to validate exhaled NO (eND) values obtained with an 
alternative off-line, single breath, low flow balloon sampling method against 
on·line sampling according to ERS guidelines, in children old enough to per-
form both methods. One hunderd and twenty seven children (median age 14.1 
yrs), all pupils of a secondary school, participated. They performed the 2 differ-
ent sampling techniques at three different flows of 50, 100, 150 mL/sec. Addi· 
tional measurements were done in a random subgroup of 76 children to 
determine the influence of the dead space air on eND values obtained off·line, 
by excluding the first 220 mL of exhaled air. All children completed a question· 
naire on respiratory and aUergic disorders, and underwent spirometry. 
Results: the off· line eND values were significantly higher than the on-line val-
ues at all flows. At 100 mL/sec, median off-line eND was 12.9 ppb (range 
6.4·104.4 ppb) and on-line eND was 9.6 ppb (3.2-128.8 ppb) (p<O.OOOl). How-
ever, when dead space air was discarded, off-line and on-line values were simi-
lar at all flows; at 100 mL/sec, off·line eND was 8.8 ppb (3.3-32.5 ppb) and 
on-line eND 8.7 ppb (3.2-35.0 ppb). There was a highly significant linear rela· 
tion between off-line values, especially without dead space air, and on-line 
eND (r=0.93, p<O.OOOl). Off-line eND at 100 mL/sec of 80 children with nega· 
tive questionnaires for asthma, rhinitis and eczema was 10.7 ppb (6.4-50.0 
ppb) versus 23.9 ppb (8.3-104.4 ppb) in the remaining 47 children with posi· 
tive questionnaires on asthma and allergy and/or recent symptoms of cold 
(p<O.OOOl). We conclude that, in children, off-line assessment of eND values 
using constant low flow sampling and excluding dead space air are similar to 
values obtained on-line with the same exhalation flow. Both sampling methods 
are sufficiently sensitive to differentiate between groups of otheJWise healthy 
school children with and without self-reported asthma, allergy and or colds. 
Nitric oxide 171 
INTRODUCTION 
Nitric oxide (NO) is produced by various cells in the respiratOlY tract, 
and has been implicated in the pathophysiology of airway diseases (1,2). NO can 
be detected in human exhaled air (3). Exhaled NO (eNO) has been proposed as 
a non-invasive marker of airway inflammation, especially in astillna (4). Re-
cently, attempts have been Inade to standardize eNO tneasurenlent procedures 
(5,6). An ERS task force recommended on-line single breath collection of eNO 
in adults and children £i·om the age of6 yrs (5). An alternative method is of1:line 
sampling, which has the advantage of independence from the presence of an 
analyser. Here, subjects perfonn a single deep expiration against a resistance into 
an NO inert and -impermeable balloon (7). The content of the balloon is analy-
sed for eNO later. Subjects may be studied outside the laboratOlY, so that this 
method is potentially useful for large epidemiological studies or home monito-
ring of astlunatic airway inflanunation. 
Measurements conditions, including expiratOlY flo,v rate and profile, atnbient 
NO, breath holding, previous forced expiratory manoeuvres and contanunation 
by nasal NO, have important effects on eNO values (5,6,8). NO in exhaled air is 
flow dependent, an effect that is most pronounced at low flows (9-11). Until 
now, most off-Hne tneasuretnent techniques for children did not take flow 
dependency into account. We previously showed in children that, despite lack of 
flow standardization, off-line sampling in balloons produces eNO values that are 
reproducible and similar to those measured on-line, with high flows (7). Further-
more, we showed that eNO separates better between difierent disease states, 
when measured on-line with low flows (11). Therefore, the aim of this study was 
to compare a modified of1:line single breath, low-flow method with on-line 
single breath Ineasnrelnents in children, and to establish a reference range of 
low-flow, off-line eNO in healthy schoolchildren. 
PATIENTS AND METHODS 
We recruited 127 non-smoking children (median age 14.1 yrs, range 
12.0-16.1 yrs) from a secondary school. They were interviewed with question-
naires on asthma, eczerna and rhinitis, translated and validated frOln the core 
questionnaires of the International Study of Asthma and Allergy in Childhood 
(ISAAC)(12), and were asked for recent symptoms of cold. Of these 127 chil-
dren, 80 had negative questionnaires and did not report symptoms of cold wit-
hin the 3 weeks before the study. Those 80 children were regarded as healthy. 
The remaining 47 children had positive questionnaires and/or recent colds, and 
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will be referred to as 'diseased'. The study was approved by the hospital ethics 
cOlnmittee and infonned consent was obtained. 
EXHALED AIR SAMPLING 
Exhaled air was sampled on-line and ofl:line. Both sampling methods 
were performed by all subjects with 3 different flows: 50 mL/sec, 100 mL/sec 
and 150 mLlsec in randOlll order. All meaStlrelnents were perfonned with the 
children seated and without a noseclip. Between the different luanocuvres, a 
resting period of 2 nun was maintained for equilibration of resting ventilatolY 
conditions. After the exhaled air sampling procedures all subjects underwent 
flow-volUlllc curve IneasurCluents, using a heated Lilly-type pncml1otacho-
graph Oaeger, Wiirzberg, Germany). Results offorced expiratory vital capacity 
(FVC) and forced expiratOlY volume in one second (FEV!) are expressed as per-
centage of predicted values (13). 
Oil-Hue measuremeot: the Ineasurement circuit consisted of a 1110uthpiece 
connected to a two-way nonrebreathing valve (Rudolph Inc., Kansas City, MO, 
USA) through which the subjects inhaled ambient air when the ambient NO 
concentration was below 10 ppb, and NO-free medical air when the ambient 
NO was higher. The subjects inhaled to total lung capacity (TLC) and immedi-
ately exhaled, with a constant flow, for as long as possible into a wide bore tube 
with an in-line flow resistance (20 cm H20/L/sec, Rudolph Inc.). A fine bore 
teflon tube continuously sampled the exhaled air fi'om a side-port directly after 
the Inouthpiece at 200 mL/nliI1 for IneasnrCInent of eNO. This manoeuvre was 
performed with three diflerent expiratory target flows of 50, 100 and 150 mL/sec. 
This produced mouth pressures of respectively 4, 7 and 10 cm H20. Airflow was 
measured by a heated Lilly-type pneumotachograph Oaeger, Wiirzberg, 
Germany) mounted after the resistance. A biofeedback display provided visual 
guidance to help the subject maintain their exhalation flow at the desired level. 
An end-expiratOlY flow-plateau of at least 3 s for the different flows was the 
end-point of the measureluent. A plateau was defined as a tracing where flow 
varies less than ± 10% around the target flow. All subjects peliortned this test in 
triplicate for each target flow. Both the NO signal and the flow signal were fed 
into a computer at a sampling rate of20 Hz. Values of NO and flow were obtained 
by calculating the mean value in defined time intervals of at least 3 seconds, using 
custom-made software. Individual means of exhaled NO for each target £low 
were calculated from at least 2 acceptable manoeuvres. 
QU:/ille measllremellt: The collecting device consisted of a mouthpiece connected 
to a rigid perspex tube with a fixed flo\v restrictor, \vhich contained an upstrean1 
pressure transducer (14). The signal from the transducer was used to feed a 
LED-display, mounted on the tube, to enable the subjects to maintain a constant 
flow (figure 1). Subjects were asked to take a deep breath and to perform one 
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FIGURE 1. Sampling unit used in the off~line coUection of eND. The mouthpiece (A) is connected to a 
rigid perspex tube (B) which has a side port (C) with low resistance by which a non-compliant 
balloon (D) first fills with dead space air. Next, air passes through a small box (E), containing the 
flow transducer with lED dispLay (F) and an in-line flow resistance through which a second balloon 
(G) fills while oral pressure is elevated. 
single exhalation with a constant flo,v into an NO inert and -itnpenneable tnylar 
balloon (maximum capacity 1750 mL). Children inspired ambient air, or NO-free 
medical air when the ambient NO was 10 ppb or higher. This manoeuvre was 
pe,{onned with three diflerent target flows of 50, 100 and 150 mL/sec, leading to 
mouth pressures of respectively 7 cm H 20, 20 cm H20 and 35 cm H 20, sufficient 
to close the velum and prevent contamination with nasal NO (15). The mean NO 
concentrations in the balloons was Ineasured during 30 s sampling within 3 h after 
collection, and were fed into a computer at a sampling rate of20 Hz. We fonnedy 
found that NO is stable for at least 6 hours in mylar balloons (16). 
To investigate the influence of the exhaled dead space volume on eNO in 
balloons ,ve perfonned additionaltneasuretuents in a randOln subgroup of chil-
dren (n=76) where we adapted the off-line collecting device with a 
low-resistance, noncompliant small NO impermeable balloon (capacity 220 mL) 
connected to the exhalation tube, upstream of the fixed flow restrictol'. The first 
220 mL of exhaled air was thus discarded in this small balloon, after which the 
large balloon was inflated with the remaining part of the exhaled volume. 
Short-tel1l1 reproducibility of the off-line sampling method was assessed in a 
randOln subgroup of 15 children who repeated the manoeuvre after a 5 nun 
interval. 
NO MEASUREMENT 
NO was tneasured with a Sievers 280 chemiluminescence analyser (Sie-
vers, Boulder, CO, USA) with a sensitivity of <0.1 ppb and a detection range of 
<0.1-500,000 ppb. The sampling flow was 200 mL/min, the response time 200 
ms and data were displayed with a lag time of approximately 2 sec. The analyser 
was calibrated regularly using certified NO gases (100 ppb and 9 ppm) and certi-
fied NO-free gas (HoekLoos, Barendrecht, The Netherlands). 
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DATA ANALYSIS 
Results of eNG concentrations arc expressed as median and range. Be-
cause eNO was log-normally distributed, comparison of individual eNO levels 
obtained on-line and off-line with the same target flow, and of eNO at different 
target flows within the satne sampling l11Cthod, was carded out on logtransfor-
med data by using Wilcoxon's matched-pairs signed rank test. Difierences be-
tween the healthy and 'diseased' groups were assessed by the Mann-Whitney 
test. Reference intervals of eNO for the difierent target flows in the healthy 
group are expressed as median and 95% reference intervals. The relation be-
tween age and FVC on the one hand and eNO on the other hand in healthy 
children was assessed by Spearman's rank correlation coefficient. To analyse the 
within-subjects short-term reproducibility, intraclass colTelation coefficients (r;) 
were calculated (17). A two tailed p-value of <0.05 was considered significant. 
RESULTS 
Characteristics of the two groups are shown in table I. Mean values of 
FVC and FEV 1 were normal for both groups. Both eNO sampling methods 
were well tolerated and performed by all children. No significant difierence was 
observed in eNO between girls and boys. In both groups, there was no signifi-
cant correlation between eNO and age or lung function data under all diflerent 
sampling conditions. The off-line sampling method was succesfully performed 
by all subjects. With on-line measurement, some children failed to blow an ac-
ceptable plateau (6-10 % of all children for various fiows). The median eNO 
concentrations at the on-line end-expiratory plateau are shown in figure 2. 
Exhaled NO fell significantly with increasing flows under all sampling conditi-
ons in both groups (all p<O.OOOI) (figure 2). 
TABLE 1. Subject characteristics (mean, SEM) 
sex m/I 
age (months) 
length (cm) 
weight (kg) 
FVC % pred 
FEV1 % pred 
healthy (n=80) 
44/36 
166 ± 1.15 
162.9 ± 1.24 
51.4 ± 1.26 
98.5 ± 133 
100.4 ± 1.37 
"diseased" (n=47)' 
23/24 
170.9 ± 1.91 
166.2 ± 1.25 
55.5 ± 1.62 
98.6 ± 1.81 
99.4 ± 1.75 
* "diseased" means self-reported asthma, eczema or hay fever and/or recent colds 
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TABLE 2. eNO values of 100 school-aged children measured at 3 different flow rates, on- and off-line 
(in ppb), values are medians; ranges of at least 2 successful attempts 
n ~ 100 on-line eNO (ppb)" off-line eNO (ppb)" 
50 ml/sec 12.7 (3.9 -160.3)" 15.6 (7.4 -152.8) 
100 ml/sec 9.6 (3.2 - 128.8)" 12.9 (6.4 - 104.4) 
150 ml/sec 8.3 (2.9 - 82.7)" 11.8 (6.1 - 98.4) 
** aU differences between-methods and between-flows are significant (p<O.OOl) 
COII/parisoll of oll-lille alld ~tFlille lIIethods: 100 children performed the two different 
samplings methods at the three expiratory flows successfully. Their on-line eNO 
was significantly lower than their off-line eNO at the same target flows (figure 3). 
The median (range) eNO values for on-line and off-line data at the three different 
target flows are given in table 2. 
bif/liellce of dead space air Oil ~O:lille eNO: 53 children pel{onned off-line measure-
ments with and without discarding the fil~t 220 mL of exhaled air, with an exhala-
tion flow of 50 mL/sec. The eNO in balloons including dead space air were 
significantly higher than eNO without dead space air: 16.4 (S.0-97.S) ppb and 
13.7 (6.S-63.9) ppb, respectively (p<O.OOOl). In another 23 subjects who exhaled 
at a controlled exhalation flow of 1 OOmLI sec, eNO in the balloons including the 
dead space was 10.5 (7.2-34.6) ppb, compared to 8.8 (3.3-32.5) ppb when the 
dead space was discarded (p=O.OOI). 
Of nine eNO without dead space air with an exhalation flow of 50 or 100 mL/sec 
was not significantly different from on-line measured eNO values obtained with 
the same target flows: 13.7 (6.8-63.9) ppb versus 14.7 (4.9-73.2) ppb at 50 
mL/sec (p=0.07, n=53) and S.S (3.3-32.5) ppb versus 8.7 (3.2-35.0) ppb at 
100mL/sec (p=0.6, n=23) (figure 4). 
Riferellce rallge <if eNO ill IIo/'IIIal childrell, obtailled oll-lille and ~O:lille: eNO values 
obtained with the different sampling methods and target flows in the healthy 
group can be used as reference values. The eNO concentrations sho\ved a 
log-normal distribution. Median and 95 % reference intervals are given in table 
3A. Under all different measurement conditions, the children of the diseased 
group (n=47) with positive questionnaires on astluna, eczenla and/or rhinitis, 
and/or symptOllls of cold \vithin 3 weeks before the eNO Ineasurelllents, showed 
a significantly higher eNO than the healthy group (p<O.OOOI). (table 3B) 
Reprodlicibility <if ~:lille eNO: The within-method short-term reproducibility of 
duplicate NO values obtained off-line with exhalation flow of 100 mL/sec was 
excellent (ri=0.94). The mean of all individual coefficients of variation of all eNO 
values was 6 %. Bland and Altman analysis showed that differences between 
repeated eNO llleasurements were slllall and independent of mean eNO within 
the measured range (figure 5). 
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FIGURE 2. Boxp(ots showing median and quartiles of eND values of 
the whole study population at flows of 50, 100 and 150 ml/sec 
obtained off~(ine and on-line. AU differences between on-line and 
off~line values at corresponding flows, and all within-method differw 
ences at different flows are significant. 
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FIGURE 3, Scatterplot showing individual eNO values obtained 
on-line (x-axis) and off-line (y-axis) at a target flow of 100 ml/sec 
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FIGURE 4. $catterplot showing individual eNO values obtained 
on-line (x-axis) and off-line excluding dead space at a target flow of 
50 ml/sec (n~53). 
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TABLE 3A. Reference values of eNO (ppb) obtained with the different sampling methods (median 
and 95% reference interval) 
Healthy Off-line "On".-.,li::.ne"-____ _ 
group with dead space without dead space 
median Ri 95(1/0 median Ri 95% median Ri 95% 
50 mL/sec 12.B B.4-33.B 11.0 7.1-52.4 9.9 4.7-24.2 
100 mL/sec 10.7 7.6-22.6 B.5 3.3-16.2 B.1 4.3-17.6 
150 mL/sec 9.9 7.1-17.6 6.6 4.1-13.1 
TABLE 38. eNO values of healthy and "diseased" children measured at 3 different flow rates, on- and 
off-line (in ppb, values are medians and ranges) 
healthy "diseased" 
median (range) n median (range) n 
on-line 
50 mL/sec 9.9 (3.6-69.1) 73 29.6 (B.4-160.3) 41 
100 mL/sec B.1 (3.2-59.4) 74 22.5 (5.9-12B.B) 45 
150 mL/sec 6.6 (2.9-42.4) 73 19.1 (4.7-B2.7) 41 
off-line (dead space air included) 
50 mL/sec 12.B (B.0-70.1) BO 30.9 (7.4-152.B) 47 
100 mL/sec 10.7 (6.4-50.0) BO 23.9 (B.3-104.4) 47 
150 mL/sec g.g (6.1-37.1) BO 21.3 (6.9-9B.4) 47 
DISCUSSION 
This study shows that on-Jine eNO was lower than off-line eNO, mea-
stu'cd with a controlled low-flow balloon sampling technique. However, when 
dead space air was discarded, agreclnent was excellent. Furthermore, we found 
significant differences of eNO between children with and without self-reported 
asthma, allergy and colds, suggesting that our off-line method is sufficiently sen-
sitive to detect minor degrees of airway illflauul1ation in groups of otherwise 
healthy school-age children. 
The concentration of NO in exhaled air depends critically on the flow of exhala-
tion, an effect that is most pronounced at low flow rates (11). Therefore, it is desir-
able to 11lCasttre eNO at a constant, low expirato1Y flow. Recol1unendations 
about the preferred flow rate are not uniform. Silkofl' et aJ. recommend to 
measure eNO at very low flow rates of 10 to 40 ml./sec (9). Hagman et aJ. 
propose a flow rate of150 to 300 ml./sec (10). The ERS task force report recom-
mends flow rates of167 to 250 ml./sec, independent of age (5). AnATS task force 
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reCOnll1lends for on-line IneaSUrelnents 50 InL/sec for adults as well as for chil-
dren. For off-line measurements in adults and children a target flow rate of350 
tnL/sec is recommended (6). Low flows may allow for a better detection of 
various disease states (9,11). Because of the non-unifonn flow recol111nendations, 
we used three different target flows (50, 100 and 150 mL/sec) to compare two 
sampling methods, and we found a significant flow dependency of eNO in chil-
dren with both methods. Ofr·line measurement studies of eNO in children 
previously did not take flow dependency into account (7,18-20). 
We found that on-line eNO values were lower than off-line values under all 
l11easureluent conditions. This seenlS in contrast with results fi-onl our previous 
eNO study in younger children, which showed similar eNO values on-line and 
off·line with a balloon sampling procedure (7). We can think of three explana-
tions for this discrepancy. First, the latter study employed high flows of at least 250 
mL/sec. There is much less flow dependency of eNO with high flows, and less 
time for contamination. Secondly, the children in the fonuer study were younger 
and had a smaller dead space volume than the school children in the present study. 
The influence of a smaller dead space volume will be less important in a large 
exhaled volume. Thirdly, the nasal contribution to the dead space air might be less 
important in young children. With the development and pneumatization of the 
paranasal sinuses in childhood. nasal NO increases with age. For instance, it was 
recently shown in a limited number of young children that mixed orallnasal eNO 
values collected ofl::=-line via a face mask in a balloon were sinlllar to eNO values 
obtained after tracheal intubation (21). 
The concentration of NO in the airway dead space represents a nlLxture of 
alubient NO and upper and lower airway NO which luay influence eNO values 
with off·line sampling (5). Therefore, it is desirable to exclude dead space air with 
ofi:'line sampling. In adults, Paredi et al. (22) compared on-line eNO with 
oU:'line, flow- and pressure controlled salupling excluding dead space air, and 
found good agreeluent. The present study extends these observations and shows 
that exclusion of dead space volume iluproves the agreeluent of on-line and 
ofT-line eNO lueasureluents in children, in the recollll11ended low flow range. 
The on-line eNO measurement technique proposed by the ERS (5) is rather 
difficult for young children (7,23). Canady et al. (23) showed that 24 % of children 
were unable to perfonu this luanoeuvre. In a previous study ,ve found that nearly 
30 % of children were not able to sustain a stable end expiratOlY flow plateau, 
employing relatively high flows (7). In the present study, only up to 10 % of 
school children had difficulty in obtaining a stable end-expiratory plateau at 
various flows. The expiratOlY flow of 100 mLlsec with a corresponding mouth 
pressure of7 cm H 20 had the lowest (,ilure rate in this study. A likely explanation 
of the higher success rate of on-line sampling in tills study compared to our 
previous study (7) is the difference in age of the study populations; median age and 
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range in this study 14.1 yrs and in the previous study 11.7 yrs. Especially for 
younger children the on-line sampling method remains difficult to perform and 
for those an alternative methodology should be developed. 
A source of error in the present study l11ay be nasal contamination, especially with 
the lowest mouth pressures, e.g. 4 cm H 20 during on-line sampling at 50 
mL/sec. One could argue that tlus pressure was not high enough to close the soft 
palate, potentially leading to nasal contaluination. However, a study in adults 
found no contamination of NO frolll the nasopharynx with a tllouth pressure of 
atleast 3 mmHg (= 4 em H 20) by using Argon as a tracer gas wluch was applied to 
the nose and not retrieved in the exhaled air (15). No sinular studies have been 
published for children. Baraldi et a!. obselved in children no correlation between 
nasal and exhaled NO values using a low expiratolY resistance providing a lllouth 
pressure of3-4 cm H 20 (20). Furthermore, in the present study eNO at flows of 
100 and 150 mL/sec obtained on- and off-line, and employing higher pressures, 
suggest no ilnportant contamination at lowest flows, selectively. This suggests 
that contamination with nasal air has not introduced a bias. 
Interestingly, we found sigtuficantly elevated eNO in children who reported 
atopic symptoms or recent colds. Tlus suggests that eNO difierentiates between 
healthy children and those who are likely to have minitnal airway inflanllnatioll 
but no actual symptoms and normal lung function. We speculate that subclilucal 
airway inflammation may already produce significant elevation of eNO. 
bl cOl/clusion, off-line l11easnrClllent of eNO is a sitnple and feasible tne-
thod of measuring eNO in school children. The ofi:line eNO values with con-
stant low flow, excluding dead spaee volmne, show good agreelnent with 
on-line values, and are feasible in school-aged children. Both sampling methods 
discrinunate between groups of children with and without self reported asthma, 
allergy and colds. Ofi:line sampling ofiers the possibility to study eNO inde-
pendently of the presence of a NO analyser, which could be useful for epidenu-
ologie studies and hOlne Inonitoring of asthma. 
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ABSTRACT 
An increased content of hydrogen peroxide (H,O,), a marker of inflammation, 
has been described in the condensate of exhaled air from adults and children 
with inflammatory lung disorders, including asthma. However, the normal 
range of [H,O,] in exhaled air condensate from healthy children has not been 
established. Therefore, the aim of this study was to determine the reference 
range of exhaled [H,O,] in healthy school-aged children. Ninety-three healthy 
nonsmoking children (48 female and 45 male, mean age 10 yrs, range 8-13 
yrs), with a negative history for allergy, eczema or respiratory disease and with 
a normal lung function, participated. Exhaled air condensate was examined 
fluorimetrically for the presence of H,O,. In addition, the reproducibility of 
[H,O,] within-subjects and between days and the stability of [H,O,] during 
storage at -20'C were assessed. The median [H,O,] in the exhaled air conden-
sate of all children was 0.13 ~M, with a 2.5-97.5% reference range of <0.01-
0.48 11M. No significant difference existed between males and females. There 
was no correlation between exhaled [H,O,] and age or lung function. Repeated 
[H,O,] measurements on two consecutive days showed satisfactory 
within-subject reproducibility and [H,O,] in stored samples remained stable 
for at least 1 month at -20'C. In conclusion, this study provides reference data 
for exhaled H,O, in a large group of healthy children. The observed levels were 
lower than those reported previously for healthy adults and were independent 
of age, sex and lung function. 
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INTRODUCTION 
A noninvasive method to assess the presence and activity of airway in-
flammation would be valuable in the early diagnosis and monitoring of inflam-
mat01Y airways diseases (1). Exhaled air condensate can be collected with mini-
mal risk and inconvenience and its content tnay reflect the cOlnposition of the 
lower airway fluids (2-3). Hydrogen peroxide (H20 2) in the exhaled air con-
densate is a potential marker of airway inflammation (4-10). The only two stu-
dies to suggest elevated levels of exhaled H20 2 in asthmatic children have used 
small numbers of healthy adults as controls (4,10). The aim of this study was, 
therefore, to establish reference values of [H20 2] in the exhaled air condensate 
of a large group of healthy school-aged children. 
PATIENTS AND METHODS 
One hunderd and twenty-nine school children, pupils of a prima,y 
school, were interviewed with questionnaires on astluna, rhinitis and eczema, 
translated and validated fronl the core questionnaires of the "International Stu-
dy of Asthma and Allergy in Childhood" (ISAAC). Of these children, 93 had 
negative questionnaires and were included. Their tnean age was 10 years (range 
8-13 y'~) and 45 were male (table 1). All were term born, Caucasian lifelong 
nonslnokers, within the nonnal range for height, and used no tnedication. 
None of the subjects reported sYlnptonls of acute respiratory infection within 
the previous 1110nth. Maximal expiratolY flow-vohulle measurements were 
pe,fonned in all children (Vicatest P2A, Mijnhardt, The Netherlands); forced 
vital capacity (FVC) and forced expirat01Y volume in one second (FEV 1) were 
expressed as percentage predicted (11). Condensate was collected while the 
children, wearing a nose-clip, breathed quietly through a mouthpiece and a 
two-way non-rebreathing valve (Rudolph, Kansas City, MO, USA), which 
also served as a saliva trap. At least 1.5 mL of condensate was obtained by passing 
expired air through a 50 em double jacketed glass tube cooled to O°C, and col-
lected on ice. The concentration ofH20 2 in the condensate was determined in 
duplicate with a fluorimetric assay based on the reaction ofH20 2 with horsera-
dish peroxidase to form a compound which oxidizes p-hydroxyphenylacetic 
acid to a fluorescent product, as described previously (4,12). As saliva is a source 
ofH20 2, the equipment was designed to avoid such contamination, as verified 
previously by measuring amylase in saliva and breath condensates. Amylase was 
present in saliva in high concentrations (20.000-300.000 UIL), and could never 
be demonstrated in condensate (invariably < 1 0 U IL, unpublished data); there-
fore, it could be stated with confidence that no contamination with saliva had 
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TABLE 1. Characteristics of the study population. Healthy children (n 0 93)' 
age yrs (mean, range) 10 (8-13) 
sex male/female 
fVC % pred (mean ± SD) 
fEV, % pred (mean ± SD) 
45/48 
98 ± 12 
100 ± 12 
1 AIL were lifelong nonsmokers, had no symptoms of asthma, eczema or rhinitis, used no medication, 
and had no symptoms of respiratory infection in the 4 weeks before the study. 
taken place. To examine the reproducibility of repeated H 20 2 measurements 
within subjects, condensate was collected from 10 healthy subjects on two con-
secutive days in the morning. To assess the stability of[H2021 in the fiozen con-
densate, 4 mL of condensate was collected from 5 subjects. These were devided 
into l111L aliqllots J in which H 20 2 concentrations were detennined inuuediatly 
after collection, after 48 hours, one week and one month of storage at -20°C. 
ANALYSIS Of DATA 
Results ofH20 2 Ineasnrements are expressed as tuedian and range becau-
se of an asynmlctrical distribution and because some values were below the de-
tection litnit. Least squares regression analysis was used to detenrune possible ef-
fects of age or lung function on ex11aled H 20 2. Differences between males and 
females were evaluated with the Mann-Whitney test. Reproducibility was as-
sessed by calculating the mean within-subject difference of two H 20 2 measure-
ments obtained on separate days from 10 subjects and the standard deviation 
(SD) of these dillerences. Stability of H 20 2 in frozen samples was estimated by 
comparing nlean concentrations using a two sided paired t-test, and by calcula-
ting mean dillerences and SD of the dillerences of immediately determined va-
lues and values after a given period of storage. Significance was assumed at 
p<O.OS. 
RESULTS 
All subjects had a normal lung function with a mean FVC of 98% (SD 
12%) and an FEV l of 100% (SD 12%). The H20 2 concentration in the exhaled 
air condensate ranged from below the detection limit of 0.01 J.lM to 0.50 J.lM, 
with a median value 0[0.13 J.lM. The 2.5 and 97.5 percentiles were <0.01 and 
0.48 J.lM, respectively. Median [H2021 from males and females were similar 
(0.13 J.lM and 0.14 J.lM, respectively, p=0.98). Individual data of all children are 
shown in figure 1. There was no effect of age on [H2021 (1'=-0.04, p=0.68). 
Likewise, no correlation ,vas found between absolute values of FEV 1 and 
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FIGURE 1. Concentration of ~02 in the exhaled air condensate in flMol 
(y-axis) of 93 healthy children. The results were independent of age 
(x-axis), The dotted line represents the 97.5 percentile upper reference 
limit (0.48 ~M); and the solid line represents the median (0.13 fIM). 
Each symbol represents one subject. Triangles indicate values below the 
detection limit (0.01 ~M). 
[H20 2] in the condensate (r=0.07, p=0.48). Repeated measurements on two 
consecutive days showed a mean within-subject dift"rence of 0.02 flM (SD 0.04 
flM). The stability of[H20 2] in frozen condensate was satisfactOlY, with no sig-
nificant dift"rence between the [H20 2] (mean, SD) immediately after collection 
(0.13, 0.03 flM) and after storage at -20°C for 48 hours (0.11, 0.02 flM; 
p=0.14), one week (0.12, 0.05 flM; p=0.S5) and one month (0.13, 0.02 flM; 
p=0.S9). 
DISCUSSION 
In this study the reference range ofH20 2 in exhaled air condensate obtai-
ned from a large group of healthy school-aged children has been defined. The 
methodology was noninvasive and well-tolerated and gave reproducible results. 
Samples could be stored for at least one month and analyzed later without 
changes in [H202]' 
Until now, published data on normal values ofH20 2 concentration in exhaled air 
were obtained from small numbers of adults (4-6,8-10). Peroxide concentrations 
were observed previously in healthy adults that were higher than the upper limit 
of the reference range in the present study (4). TIlls suggests either that healthy 
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children produce less peroxide than adults or that subclinical airway inflammation 
may be more common in asymptomatic adults than in healthy children. On the 
basis of these results it can be stated that earlier observations in asthmatic children 
indeed have shown H 20 2 concentrations in exhaled air that ,vere substantially 
higher than those found in healthy children (4,10). 
II/ (ol/c/llsial/, this study defined the reference range of HzOz, a putative 
marker of airway illt1anullation, in exhaled air condensates frOln a large group of 
healthy school-aged children. Longitudinal studies are needed to examine the 
potential value of this inflammatory marker in the management of childhood 
astluna. 
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ABSTRACT 
Exhaled air condensate provides a noninvasive means of obtaining samples 
from the lower respiratory tract. Hydrogen Peroxide (H,O,) in exhaled air has 
been proposed as a marker of airway inflammation. We hypothesized that in 
stable asthmatic children the H,O, concentration in exhaled air condensate 
may be elevated as a result of airway inflammation. In a cross-sectional study, 
66 allergic asthmatic children (of whom, 41 were treated with inhaled steroids) 
and 21 healthy controls exhaled through a cold trap. The resulting condensate 
was examined fluorimetrically for the presence of H,O,. All subjects were clini-
cally stable, non-smokers and without infection. The median H,O, level in the 
exhaled air condensate of the asthmatic patients was significantly higher than 
in healthy controls (0.60 and 0.15 IImol, respectively; p<0.05), largely because 
of high values in the stable asthmatic children who did not use anti-
inflammatory treatment (0.8 IImol; p<O.Ol compared to controls). We conclude 
that H,O, is elevated in exhaled air condensate of children with stable asthma, 
and may reflect airway inflammation. 
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INTRODUCTION 
Our present understanding of astlu11a as a disease of airway inflatl1mation 
has been greatly enbanced by studies using bronchoalveolar lavage (BAL) (1). In 
young children, BAL is generally not acceptable for diagnostic and monitoring 
purposes. A noninvasive l11ethod to assess airway inflammation is ilnportant for 
this group (2). Exhaled air condensate has been proposed as a noninvasive means 
of obtaining samples fimn the lower respiratmy tract, based on the hypothesis 
that aerosol particles excreted in breath may reflect the composition of the lo-
wer airway fluids (3). Several investigators have analysed exhaled air condensate 
for diflerent mediators of inflammation (3-5); however, data on children are 
scanty (5). Hydrogen peroxide (H20 2) is a putative marker of airway inflannna-
tion in exhaled air: Inflammatmy cells produce H 20 2 (6), which causes Inng in-
flammation and damage (7-9); stimulated alveolar macrophages from asthmatics 
generate lllore reactive oxygen species than alveolar macrophages frOl11 healthy 
subjects (10). Indeed, an increased content ofH20 2 has been described in vari-
ous inflammatory lung disorders: in exhaled air of cigarette smokers (1/); pa-
tients with adult respiratmy distress syndrome (ARDS) (12,13); and patients 
with acute hypoxemic respiratmy f.lilure (14). Dohlman et al. described an in-
creased H 20 2 concentration in exhaled air condensate in a slna11 group of 
asthmatic children, mainly in those with acute disease (5). As inflammation is 
also likely to be present in symptom-free asthmatics (15), we hypothesized that 
the hydrogen peroxide concentration l11ay also be elevated in exhaled air con-
densate of children with stable astluna, and 111ay serve as a n1arker of airway in-
£lamInation. 
PATIENTS AND METHODS 
STUDY POPULATION 
Sixty-six asthmatic children (23 females and 43 males) attending the 
out-patient clinic of Sophia Children's hospital were included in the study. 
Astll111a was diagnosed on clinical grounds following international guidelines 
(16). Appropriate therapy was prescribed by the patient's own physician, and 
had not been changed during the 3 months preceding the study. All 66 patients 
used an inhaled bronchodilator on demand, and 41 (15 females and 26 males) 
used an inhaled corticosteroid daily. The median age of those without steroids 
was 12.6 yrs, and of those receiving steroids 11.1 yrs. All were lifelong 
non-smokers, and were clinically stable. All had bronchial hyperresponsiveness 
(provocative dose of inhaled metacholine that produced a 20% fall in forced ex-
piratOlY volume in one second, PD20 of < 150 flg) documented in the past, and 
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had allergy as documented by radio allergosorbent test (RAST) class 2 or higher 
for at least one C0111111011 airborne allergen. Control subjects were healthy, non-
smoking young adult volunteers (median age 25 years), with no history of aller-
gy and respiratory disease, nor of any other chronic illness, and used no tnedica-
tion. None of the subjects had had symptoms of acute respiratolY infection 
within the month before the condensate was collected. The study was approved 
by the Hospital Ethical Committee. 
COLLECTION OF EXHALED AIR CONDENSATE 
Exhaled air condensate was obtained by passing expired air through a 50 
cm double jacketed glass tube cooled to a temperature of O°C by means of 
countercurrent circulating iced water. The subjects breathed through a 
mouthpiece and a two-way nonrebreathing valve (Rudolph, Kansas City, MO, 
USA), which also served as a saliva trap. They were asked to breath at a normal 
frequency and tidal volume, wearing a noseclip, for a period of 10-15 min. The 
condensate, at least 1 mt was collected on ice. 
LUNG FUNCTION 
All subjects uuderwent flow-volmne IneaSllrelnents iuunediatly after col-
lection of the condensate. Flow-voltune curves were obtained in triplicate, 
using a Lilly-type pneumotachograph (Masterlab Jaeger, Wiirzberg, Germany) 
before and after inhalation of 1 mg of terbutaline powder (Turbohaler®). Re-
sults were expressed as percentage predicted (17). 
HYDROGEN PEROXIDE 
The concentration of H20 2 in exhaled air condensate was determined 
with a fluorimetric assay based on the reaction of H 20 2 with horseradish pe-
roxidase to form a compound which oxidizes p-hydroxyphenylacetic acid to a 
fluorescent product (18). Briefly, 400 fll of condensate was mixed with 1.5 mM 
(10 fll) p-hydroAl'phenylacetic acid and 100 flg/ml (4 fll) horseradish peroxida-
se (both Sigma Chemical Co., St. Louis, MO, USA) immediately after collec-
tiOll, and fiozen at _20o e. The fluorescent product of the condensate and of 
standard solutions of H 20 2 were measured with a fluorimeter (model 3000; 
Perkin-Elmer, Norwalk, USA) at an excitation wavelength of295 11111 and an 
emission wavelength of 405 nm. The lower limit of H 20 2 detection was 0.1 
flM. Concentrations ofH20 2 in condensate were obtained by linear interpola-
tion of a standard curve. Preliminary observations in a limited number of young 
healthy adults indicated that, with tills method, the within-subject be-
tween-days variations were within 0.1 J1-11101. 
Hydrogen peroxide 197 
DATA ANALYSIS 
Results are expressed as l11edian and range because of a nonsynlluetrical 
distribution and because some values were below the detection limit. Since the 
anti-inflammatory action of inhaled steroids could be a confoundig £1ctor influ-
encing H 20 2 in exhaled air condensate as tnarker of airway inflanllnation, sub-
groups with and without steroids were analysed separately. COlnparisons be-
tween groups were made by the Mann-Whitney test for two unpaired 
independent samples. A two tailed p-value less than 0.05 was considered signifi-
cant. There were insufficient data to perf 01111 a forn1al power calculation, but 
we reasoned that with a group size of20 subjects we should be able to detect a 1 
SD difference (our own preliminary observations suggested this to be about 
20%) at a two-sided alpha of 0.05 with a power of90%. 
RESULTS 
All subjects completed the protocol without difficulty. The time to col-
lect at least lmL of condensate varied between 10 and IS minutes. 
Lung function tneasuretnent in astlllnatic children without steroids showed 
near-normal values mean forced vital capacity (FVC) 93% pred, forced expira-
tOlyvolume in one second (FEV [)I 00% pred, increase in FEV [after Imginhaled 
terbutaline 7%). Asthmatics with steroids were slightly better (FVC 100% pred, 
FEV[ 107% pred, increase in FEV[ after terbutaline 6%), but not significantly 
different from the children without steroids. Controls all had a normal lung func-
tion (mean FVC 108% pred, FEV [ III % pred, increase in FEV [ after terbutaline 
3%). 
The llledian H 20 Z concentration in condensates of all astlullatic children was 
significantly higher than in condensate from healthy control subjects (0.60 and 
0.15I1mol, respectively; p<0.05). The median HzOz concentration in the asth-
matics who used steroids (0.451111101) was higher than in healthy control subjects, 
but the difference was not significant. There was a highly significant difference in 
ll1edian H Z0 2 concentration between asthtnatics without anti-inflanllnatOlY 
treatment and healthy controls (0.8 I1mol and 0.15 I1mol, respectively; p<O.OI). 
Individual data arc shown in figure 1. There was no correlation between the 
concentration of exhaled HzOz and the change in FEV[ before and after 
bronchodilatation in control subjects or in asthmatic patients. Furthermore, no 
correlation was found between the daily dose of inhaled steroids and Hz0 2 
concentration in the condensate (data not shown). 
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FIGURE 1. Concentration of H2~ in exhaled air condensate of 
stable asthmatic chHdren and healthy control subjects. The asth-
matics are divided into a subgroup using inhaled corticosteroids 
(ICS+), and a group without anti-inflammatory treatment (ICS-). 
Each dot represents one patient. Median values are indicated by a 
horizontal line and the detection limit by a horizontal broken line. 
The differences between median values of healthy subjects and all 
asthmatic subjects was significant (0.15 and 0.60 ~Imol, respec-
tively; p<0.05), the difference between healthy subjects and the 
asthmatics without steroids is highly significant (0.15 ~lmol and 
0.80 IImol respectively; p<O.Ol). 
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DISCUSSION 
This study is the first to delnonstrate a significantly increased concentra-
tion ofH20 2 in exhaled air condensate from stable asthmatic children compared 
to healthy controls. That the H 20 2 concentrations are lower in astlu11atics who 
use anti-inflammatory medication supports the hypothesis that exhaled H20 2 
reflects the presence of airway inflanll11ation. 
The present results seem different from those of an earlier study by Dohlman et aI, 
describing increased H 20 2 concentration in exhaled air condensate in a sl11all 
group of asthmatic children, with acute respiratory disease, whereas exllaled 
H 20 2 from stable asthmatics was not different from control subjects (5). Both 
studies used similar control groups. We think that much larger groups in the 
present study, and the separation of asthmatics with and without anti-
inflanll11atory treatl11ent explain the different outcOllles. 
The present study shows that inhaled steroids are associated with lower exllaled 
H 20 2 concentrations in astlunatics. A study in ARDS patients treated with 
corticosteroids showed a tendency towards lower levels ofH20 2 in the exllaled 
air condensate as compared to ARDS patients not receiving corticosteroids (14). 
The present cross-sectional study cannot deillonstrate a causal relationship 
between steroid use and lower exhaled peroxide; prospective controlled inter-
vention studies are needed for that purpose. 
An increased content of H 20 2 has also been reported in other inflammatoty 
respiratory diseases (11-14). This means that exllaled H 20 2 is probably not a 
specific diagnostic test for asthma. Rather than a diagnostic test, exhaled peroxide 
may be used to guide anti-inflanll11atory treatment and estimate disease severity 
over tit11e within-subjects. 
It can be argued that the control subjects in the present study were not 
age-matched, and that age-dependent changes in exhaled peroxide might partly 
explain the results. This seems unlikely: there arc no data suggesting that healthy 
children produce nlore reactive oxygen species in their airways than healthy 
young adults. However, we do feel that, in the absence of such data, establishing 
normal values over a wide age range is an itnportant goal for the near future. 
III COlldllShm, tIllS cross-sectional study has shown that the concentration 
of H 20 2 in exhaled air condensate is increased in stable asthmatic children, and 
lower in patients receiving anti-in£lalllmatolY treattnent, suggesting that airway 
inflammation increases exhaled peroxide. Correlation of H Z0 2 in exhaled air 
condensate with invasive lueasures of airway inflanullation, such as bronchial 
biopsies, is needed to validate the hypothesis that exhaled peroxide reflects air-
way inflanll11ation. On the basis of the present findings, we believe that the con-
centration ofH20 2 in exllaled air is a potentially useful marker of airway intlam-
l11ation in asthmatic children, especially since the procedure is quick and easy to 
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perform. Further studies should explore its value as a noninvasive test, e.g. for 
lllonitoring effects of anti-inflanll11atolY therapy. 
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ABSTRACT 
Cystic fibrosis (CF) patients characteristically have severe chronic airway 
inflammation due to bacterial infection. A noninvasive marker of airway 
inflammation could be useful to guide treatment of CF lung disease. The aim of 
this study was to assess whether measurement of hydrogen peroxide (H,O,) 
and nitric oxide (NO) in exhaled air can serve to monitor the effect of treat-
ment with antibiotics in CF-chitdren with acute infective pu[mona!)' exacerba-
tions. Sixteen CF-patients (mean age 12.3 yrs) with exacerbation oftheir lung 
infection were treated with intravenous antibiotics. During treatment, H202 in 
exhaled air condensate was measured twice a week. In addition, serial NO 
measurements were performed in 9 patients. During antibiotic treatment the 
median H202 concentration in exhaled air condensate decreased significantly 
from 0.28 11M (range 0.07-1.20 11M) to 0.16 11M (range 0.05-0.24 11M) 
(p=0.002) and the mean FEV, significantly increased from 55 % of predicted 
value to 75 % (p=O.OOl). In individual subjects, changes of H,O, and FEV, 
between pairs of serial measurements correlated weakly (p=O.08). Data on 
exhaled NO were inconclusive; eNO did not change systematically during treat-
ment. We condude that CF-patients with an acute pu[mona!)' exacerbation 
have abnormally high concentrations of H,O" but not of NO, in exhaled air, 
which decrease during i.v. antibiotic treatment. Further studies should estab-
lish if exhaled H2021 may serve as a noninvasive parameter of airway inflamma-
tion to guide antibiotic treatment in CF lung disease. 
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INTRODUCTION 
Invasive procedures such as bronchoscopy, bronchoalveolar lavage 
(BAL) and bronchial biopsies have greatly enhanced the understanding of the 
role of airway inflanll11ation in various respiratory disorders like asthma and cys-
tic fibrosis. Lung disease in patients with cystic fibrosis (CF) is characterized by 
recurrent exacerbations of respirato1Y sYlnptoms due to chronic bacterial infec-
tion of the airways. Shortly after birth, patients with CF acquire respiratory in-
fection that incites an inflammatOlY response (1,2). The continuous presence of 
bacteria in the lung induces a strong inu11unological response resulting in the re-
lease of inflammatOlY cytokines and lnediators (3,4) which can be measured in 
bronchoalveolar lavage (BAL) fluid or sputum, even in young and stable 
CF-patients with clinically mild lung disease (1,5,6). In cystic fibrosis lung 
disease the inflammatory response leads to massive neutrophil recruitment (5,6). 
Activated neutrophils and lnacrophages are tnajor sources of oxygen free radi-
cals including hydrogen peroxide (H20zl. Indeed, lung infection in CF leads to 
increased oxygen free radical generation (7,8). Furthen11ore, sputmn of 
CF-patients has been shown to pri1ne neutrophils to\vards enhanced release of 
oxygen radicals (9). The airways in patients with CF are exposed to increased 
oxidative stress which appears to be a result oflower airway inflanllnation (10). 
The current available 111ethods to obtain luaterial frOln the lower respiratory 
tract are in general inappropriate for routine use in the assesstnent of lower air-
\vay inflammation in children because of the invasive nature of these procedu-
res. A sil11pIe, noninvasive test to 111Olutor airway inflanllnation would be im-
portant for the diagnosis of airway inflaulluation and to evaluate current and 
new therapeutic options. Exhaled air (condensate) has been proposed as a 
nOlunvasive t11eans of obtaining salnples fr0111 the lo\ver respiratolY tract (11). 
H 20 2, a reactive oxygen radical, is a putative tnarker of airway inflanunation in 
exhaled air condensate. An increased content ofH20 2 has been described in ex-
haled air of patients with various inflammatory lung disorders (12-15). Exhaled 
lutriC oxide (NO) has been put forward as another noninvasive marker of air-
way inflammation (16,17). However, in stable CF-patients orally exhaled NO 
levels are not elevated (18,19). Data in children on NO and H 20 2 during acute 
infectious respiratory tract exacerbation in CF are lacking. The aim of this study 
was to assess whether exhaled H 20 2 and NO can serve as noninvasive tnarkers 
of airway inflamtnation during treatment of cystic fibrosis patients with an acute 
infective puhnonalY exacerbation. 
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METHODS 
STUDY POPULATION 
Children with CF were recruited from the CF-centre of the Sophia 
Children's Hospital. CF had been diagnosed on the basis of typical symptoms, 
hvo mutations in the CF-gene, and an abnonnal sweat test (a sweat sodiu111 
concentration> 70 mmolll). SL'{teen CF-patients with an acute infective pul-
1110nary exacerbation, successively admitted for a course of in-patient intrave-
nous antibiotic treattnent, were included. Patients characteristics are shown in 
the table. Exclusion criteria were inability to pClfonn pulmonalY function tests, 
concOluitant diagnosis of astluna. current oral steroid therapy and a spntmll cul-
ture containing Burkholderia cepaeia. Disease severity of the subjects varied wi-
dely when they entered the study, with predicted forced expiratory volume in 
one second (FEV I) ranging from 42 to 75 percent (mean 55%) . Nine subjects 
used nebulized recombinant human dornase alpha (DNase). All subjects were 
infected with either Psel/dolllollas aef/lgil/osa (n= 10) and with Slaphyio«o(ClIS al/-
WIS (n=2) or a combination of the two organisms (n=4). All patients received a 
standard treatll1ent protocol, including intravenous antibiotics, based on bacte-
rial sensitivities, and chest physiotherapy. The duration of the intravenous anti-
biotic therapy ranged from 2 to 5 weeks (median 3 weeks). Informed consent 
for the study was obtained fimn the patients and parents on the day of admissi-
on. The study was approved by the medical ethical committee of the Erasmus 
University Medical Centre. 
COLLECTION OF EXHALED AIR CONDENSATE 
The subjects breathed through a mouthpiece and a two way 
non-rebreathing valve (Rudolph, Kansas City, MO, USA) which also served as 
as saliva trap. They were asked to breath at a normal frequency and tidal volume, 
wearing a nose clip. Exhaled air condensate was obtained by passing expired air 
through a 50 cm double jacketed glass tube cooled to a temperture of 0 0 C, by 
Ineans of counter-current circulating ice water. The resulting condensate was 
collected on ice and frozen immediately at - 200 C until analysis. The first col-
lection of exhaled air condensate took place before the beginning of the intrave-
nous antibiotics. Further salnples were obtained twice a ,veek at the satne tilne 
of day during the intravenous antibiotic treattnent period. 
HYDROGEN PEROXIDE MEASUREMENT 
The concentration of H20 2 in exhaled air condensate was Ineasured in 
duplicate with a fluoritnetric assay based on the reaction ofH20 2 with horsera-
dish peroxidase to form a compound which oxidizes p-hydrm.:yphenylacetic 
acid to a fluorescent product, as described in detail previously (12,20). The fluo-
TABLE 1. Patient characteristics before start of i.v. antibiotics 
(F-patients (n=16) 
Sex (male/female) 
Age (months, median, range) 
Height (em, mean, SEM) 
Weight (kg, mean, SEM) 
FV( (% pred, mean, SEM) 
FEV, (% pred, mean, SEM.) 
Inhaled steroids (n) 
4/12 
148.0 (83-226) 
145.3 ± 3.9 
33.7 ± 2.5 
68 ± 3 
55 ± 3 
6 
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rescent product of the condensate and of a standard solution of H 20 2 were 
quantified fluOlimetrically. Tlus assay showed a statisf.1ctOlY within subject re-
producibility of exhaled hydrogen peroxide values of healthy subjects obtained 
on 2 consecutive days and with 1 week interval (21, 22). Concentrations of 
H 20 2 in condensate were obtained by linear interpolation of a standard curve. 
The lower limit ofH20 2 detection was 0.01 IlM. The equipment was designed 
to avoid contamination of the condensate \vith saliva, as saliva is a source of 
H 20 2 • We excluded saliva contamination, as described previously (21), by me-
asuring alnylase in all breath condensates which is a sensitive marker to detect 
contamination of the condensate with saliva (22, 23). 
NITRIC OXIDE MEASUREMENT 
In 9 subjects NO was measured in exhaled air, following the exhaled air 
condensate collection. NO was Ineasured with two difierent sampling methods, 
each in duplicate. Firstly, ofT-line tneasnreillent via one single deep expiration 
into a NO-impemleable balloon: subjects were asked to exhale, without breath 
holding, via a plastic tube, which acts as a flow restlictor and causes elevation of 
oral pressure sufficient to avoid nasal contanunation, into an NO-inert Mylar 
balloon. This off-line sampling method, including the advantages and disadvan-
tages oftlus technique, was described earlier in detail (24). The NO concentra-
tion was 111easured from the balloons. Secondly, in children able to perfonn 
Inore c0111plicated Inanoeuvres, NO was tneasured on-line during a controlled 
slow exhalation from total lung capacity (TLC) through a mouthpiece and a 
two ,yay non-rebreathing valve against an in-line resistor (20 Cln H 20/L/sec, 
Rudolph Inc., Kansas City, MO, USA) with an individually standardized flow 
rate of20% of the subject's vital capacity (Ve) per second, as described previ-
ously in detail (24,25). A biofeedback display provided visual guidance for the 
subject to maintain the exhalation flow at the target level. The mean 
end-expirato,y NO level was measured during an end-expirato,y flow plateau 
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of at least 3 sec. Between the different expiratoty manoeuvres, all children were 
allowed 2 min rest, to restore resting conditions of ventilation. To exclude the 
efrect of high ambient NO levels on the exhaled NO values, children breathed 
NO-free air when the ambient NO was above 5 ppb. During NO measure-
ments, subjects did not wear a noseclip. NO was tneasured with a chcluilumi-
nescence analyser (Sievers 280, Boulder, CO, USA) with a sampling flow of 
200 mL/min and a response time of 200 msec. The analyser was regulalY cali-
brated according to the manufacturer's guidelines, employing certified NO ga-
ses (100 ppb and 9 ppm) and certified NO-fi'ee gas (Hoek-Loos, Barendrecht, 
The Netherlands). 
LUNG FUNCTION 
All subjects underwent flow-volume l11casnrelllents imlnediately after 
collection of the condensate and measurClnent of NO. Flow-voltune curves 
were obtained in triplicate (Masterlab Jaeger, Wiirzberg, Germany). Results of 
forced expiratOlY volume in 1 second (FEV Il and forced vital capacity (FVC) 
were expressed as percentage predicted (26). 
DATA ANALYSIS 
Results of H20 2 and NO l11casnrClllcnts are expressed as luedian and 
ranges because of a nonnonnal distribution. Lung function data are presented as 
mean ± SEM. Compalison of exhaled H 20 2> NO and spirometric values before 
and after antibiotic therapy was done with the Wilcoxon signed ranks test for 
paired samples. A two tailed p-value ofless than 0.05 was considered significant. 
Spearman correlation tests were perfonlled to detect a correlation of changes of 
FEV! on the one hand, and changes of NO or H 20 2 on the other hand between 
the first and last measurelnents in each child. Correlation between changes of 
H20 2 and changes of FEV I for the individual subjects between all subsequent 
pairs of IneaSUrelnents was investigated with regression analysis (27). 
RESULTS 
DUling i.v. antibiotic treatment, FEV! improved fi'om55 ± 3 % to 75 ± 4 
% (p=O.OO 1). Figure 1 shows the individual FEV I data at the start and at the end 
ofi.v. treatment. All subjects completed the condensate collections without dif-
ficulty. Of82 collected condensate samples, 3 were discarded because of conta-
llunation with saliva, as shown by detectable alnylase. In 2 condensate samples, 
the H202 concentration was below the detection limit. Serial exhaled H 20 2 
111eaSurenlents during i. v. antibiotics showed a decreasing trend with titne. The 
median H 20 2 concentration in exhaled air condensate just before the start of 
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FIGURE 1. Changes in FEV 1 (expressed as percentage of 
predicted normal value) before and after i.v. antibiotic treat-
ment of respiratory tract infectious exacerbations in 16 
CF-patients. Closed dots indicate values of individual patients, 
open dots are mean values and SEM. The increase is statistically 
significant (p=O.OOl). 
i.v. antibiotics was significantly higher than the concentration at the end of the 
treatment period: 0.28 J.lM (range 0.07-1.20 J.lM) and 0.16 ~lM (range 
0.05-0.24 J.lM) respectively (p=0.002). The individual data are shown in figure 
2. During treatment, 9 subjects showed decreases in exhaled H 20 2 together 
with an itnprovelnent in lung ft1llction, 3 subjects showed decreases in exhaled 
peroxide with no consistent improvelnent in lung function and 4 subjects exhi~ 
bited no consistent change in peroxide concentrations with (n=2) or without 
(n=2) improvement in lung function. Figure 3 shows, for the individual sub-
jects, the negative correlation between changes ofH20 2 and changes of FE VI 
of all diflerent pairs of measurelnellts during the treatlnent period. The overall 
correlation, corrected for the l1lunber of Ineasurelnents per child, is ofborderli~ 
ne significance (p=0.08). At the onset of each treatment, exllaled peroxide le-
vels did not correlate with exhaled NO levels nor with baseline FEV lor FVC 
(p>O.1 for each). There was no significant difference in level of exhaled H 20 2 
between CF-patients on inhaled steroids (n=6) and those not on inhaled ste-
roids. 
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FIGURE 2. Changes in exhaled H,O, in 16 CF'patients before and after 
i.v. antibiotic treatment of respiratory tract infectious exacerbations. 
Closed symbols are data from individual chitdren, open dots are median 
values. The change is statistically significant (p=0.002). 
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FIGURE 3. Scatterplot of changes in exhaled H20,? versus changes in FEV 1 
in paired observations made during antibiotic treatment of 16 children 
with (f treated with antibiotics for respiratory exacerbations. Regres-
sion analysis, correcting for the numbers of observations per patient 
showed a weak correlation of borderline clinical significance (p=O.08). 
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O/l:line eNO measurements by means of balloons were obtained without diffi-
culty in all 9 children. In contrast, 3 out of9 children were not able to sustain a 
stable end~expiratolY flow plateau of at least 3 sec for on-line Ineasurelnents of 
NO with constant flow. Serial exhaled NO tueasureluents during Lv. antibiotics 
showed no consistent trend with time. For both sampling methods, the mean NO 
levels in exhaled air before treatment were not significantly different from those 
after treatment. Initial values of NO obtained with the balloon method and with 
slow controlled exhalation were 3.5 ppb (2.3-6.5 ppb) and 4.2 ppb (3.1-6.1 ppb) , 
respectively. At the end of treatment exhaled NO was 3.4 ppb (2.2-6.8 ppb) 
(p=0.6) and 4.0 ppb (2.4-5.6 ppb) (p=O.4) for balloon- and on-line sampling, 
respectively. The correlation between FEV 1 and NO was not significant. No 
conclusion can be drawn about the efiect of inhaled steroids on eNO, because 
only 2 of the 9 CF-children, in which we measured eNO, used inhaled steroids. 
DISCUSSION 
In this study we found that exhaled H 20 2 was elevated and decreased sig-
nificantly in CF-children with acute infective puhnonary exacerbations who 
were treated with i.v. antibiotics. Their lung function (FEV 1) improved signifi-
cantly. Data on exhaled NO were inconclusive and showed no trend. 
Careful monitoring of CF lung disease is important, especially in early stages of 
the disease where infection and the associated inflammatOlY response and oxida-
tive stress are frequently insidious and aSYlllptOlnatic (28). However, conven-
tionaltuethods to assess airway inflanllllation are cOlnplicated (bronchoscopy, 
broncho-alveolar lavage), and sputum may be difficult to obtain in young chil-
dren. Hence, luarkers of inflanllnation like peroxide and NO that can be 
obtained easily and repeatedly are potentially important for monitoring CF lung 
disease. Exhaled H 20 2 levels in adult CF-patients were investigated earlier and 
appeared not significantly different from those of healthy controls (22,29). In our 
study in CF-children ,vith acute infective puhnonary exacerbations we found 
higher levels than in healthy children (21), and a significant decrease of serial 
exhaled H 20 2 levels in the course of treatment with antibiotics. The observed 
H 20 2 concentrations at the end of the treahnent period are similar to those vie 
found previously in healthy children (21), and are in agreement with the results of 
stable CF-adults (22,29). Thus, exhaled H 20 2 may not be a suitable marker of 
airway in£lallllnation ill stable CF-patients, but is of potential value to nlonitor the 
efiect of anti~inflanlll1atory treattnent for exacerbations. 
That exhaled H 20 2 is not elevated in stable CF-patients is possibly due to an 
increase of scavenging by for example glutathione or catalase which may balance 
the increased oxidative stress (29). In that case, our results suggest that infective 
112 
puhllona1Y exacerbations may disturb such a balance, and this could be due to 
various l11cchanisll1s. For eXJluple, increased oxidative stress; bacterial infection 
could contribute to oxidative stress by recrllitlllcnt and activation of phagocytic 
cells in the lung (30), and by inactivating o"ygen radical scavenging molecules. 
McGrath et a1. recently showed that senllll in£lanllnatOlY markers during acute 
respiratolY exacerbations in CF-patient were significantly elevated and showed 
iluproVCluent with antibiotic treatlnent (8). Furthermore, alveolar luacrophages 
obtained by BAL fluid from subjects with a recent lower respirat01Y tract infec-
tion released more H 20 2 (31). On the other hand a decreased antioxidant status; 
Range et al. recently demonstrated in 17 CF-subjects with infective exacerba-
tions that treatment with intravenous antibiotics resulted in increased plasma 
levels of antioxidants (32). 
There was no significant difference in tuedian level of exhaled H 20 2 between 
CF-patients on inhaled steroids and those not on inhaled steroids. TIllS observa-
tion contrasts with results in stable astlunatic children where inhaled 
corticosteroids were associated with lower exhaled H 20 2 (12). On the other 
hand, earlier studies in CF and bronchiectasis also showed no significant influence 
of inhaled steroids on exhaled H 20 2 (13,22). A possible explanation is that 
corticosteroids do not alter the neutrophilic inflammation in CF as efiixtively as 
they aficct eosinophilic inflammation in asthma (13); alternative, the relatively 
low levels in CF leave less room for change than the Illgher levels in untreated 
asthmatics. 
Exhaled NO in CF-children was measured with two diflerent sampling methods: 
on-line single slow flow controlled exhalation Inethod and off .. line via a single 
exhalation into a balloon. In contrast to the ofi~line sampling method the on-line 
NO sampling method recommended by the ERS (17) is rather difficult to 
pe1form in children. In tllls study the on-line constant flow method had a L1ilure 
rate of33%. In a previous study in a larger study population of 101 stable allergic 
asthmatic children we found a silllllar L1ilure rate of 30% (24). Canadey et al. 
showed that 24% of their studied children (n~33) were unable to perform the 
on-line measurement at constant flow (33). Both NO sampling methods were 
used in tIlls study; exhaled NO levels showed no consistent trend with titne in 
both sampling methods. This result is in agreement with an earlier study by Ho et 
al. who found no change in exhaled NO levels during 7 days of treatment in 8 
adults with infectious exacerbation ofCF (34). This suggests that eNO may not be 
a suitable marker to 11l0lutor airway inflammation and to evaluate anti-inflaln-
InatOlY treatlnent in CF-patients with an infective puhnonary exacerbation. 
However, for a def11utive conclusion on tIlls subject £luther studies with larger 
study populations are needed. The initial NO value obtained with the balloon 
method in the present study was slightly lower than values obtained previously in 
healthy children with the same sampling method (35). Other studies also reported 
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exhaled NO levels in CF-subjects that were not higher than in control subjects 
(18,19,34). Whether tlris finding reflects reduced diililSion and metabolism of 
NO within the viscous airway secretions or a genuine reduction in airway 
111ucosal NO synthesis is not clear. However, nitrite levels in exhaled air conden-
sate were found lrigher in CF-patients than in normal subjects (36). This suggests 
that exhaled NO may not reflect the total NO production in the airways. 
The relationship between initial values of exhaled H 20 2 or NO and lung func-
tion was not significant. Probably, 111easurel11ent oflung function and of exhaled 
NO and H 20 2 give different information about the infiammatOlY process of the 
airways. Ail-way inflanuuation is only one of the luany determinants of airflow 
limitation. Nevertheless, figure 3 shows a weak negative correlation between 
changes ofH20 2 and changes ofFEVj between the different serial measurements 
in individual subjects, and this does suggest that generation of peroxide is related 
to the inflauuuatory process which illlpairs lung fi.lnction in CF. 
ill cOllclllSioll, our study shows that the levels of exhaled H20 2 are elevated 
in CF-children with an infective pultnonary exacerbation. Furthcl1nore, in 
contrast to exhaled NO, exhaled H 20 2 siglrificantly decreases during serialmeas-
tU"Cluents in CF-patients during i. v. antibiotic treatment. This suggests that exha-
led H20 2 l11ay be a helpfl.ll marker to nlOnitor oxidative stress due to airway in-
flammation in CF-sllbjects with an acute infective puhnonary exacerbation. 
REFERENCES 
1. Annstrong DS, Grimwood K, CarlinJB, Carzino R, GutierrezJP, HullJ, Olinsky A, 
Phelan EM, Robeltson CF, Phelan PD. Lower airway inflammation in inf.1uts and 
young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 
1197-1204. 
2. Davis PB, Drumm M, Konstan M\V. State of the art: cystic fibrosis. AmJ Respir Crit 
Care Med 1996; 154: 1229-1256. 
3. Bonfield TL, Pauuska]R, KonstanM\V, Hilliard KA, Hilliard]D, Ghnaim H, Berger 
M. Inflammatory cytokines in cystic fibrosis-lungs Am] Respir Crit Care Med 1995; 
152: 2111-2118. 
4. Dean TP, DaiY, ShuteJK, ChurchMK, WarnerJO. Interleukin-8 concentrations are 
elevated in bronchoalveolar lavage, sputum and sera of children with cystic fibrosis. 
Pcdiatr Res 1993; 34: 159-161. 
5. KOllStan M\V, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings 
in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infec-
tion and inflammation. Am] Respir Crit Care Med 1994; 150: 448-454. 
oo 
~ 
:;: 
"' ~ u 
114 
6. Khan TZ, WagenerJS, BostT, Martinez], AClirso Fj. Riches DWH. Early pulmonary 
inflammation in infants with cystic fibrosis. Am] Respir Crit Care Med 1995; 151: 
1075-1082. 
7. \Vinklhofer-Roob. O}""l'gen free radicals and antioxidants in cystic fibrosis: the 
concept of an oxidant-antioxidant imbalance. Acta PaediatrSuppl1994; 83: 49-57. 
8. McGrath LT, Mallon P, Dowey L, Silkc D, McClean E, McDonnell M, Devine A. 
Copeland S, Elbron S. Oxidative stress during acute respiratory exacerbations in cystic 
fibrosis. Thorax 1999; 54: 518-523. 
9. Kharazmi A. Rcchnitzer C, Schiotz PO,jcnscn T, Back L, Hoihy N. Priming of 
neutrophils for enhanced oxidative burst by sputum from cystic fibrosis patients with 
Pseudomonas aerl.1ginosa infection. Eur J Clin Invest 1987; 17: 256-261. 
10. Hull], Vervaart P, Grimwood K, Phelan P. Pulmonary oxidative stress response in 
young children with cystic fibrosis. Thorax 1997; 52: 557-560. 
11. Scheideler L, Manke HG, Schwulera U, Inacker 0, Hammerle H. Detection of 
nonvolatile macromolecules in breath: apossible diagnostic tool? Am Rev Respir Dis 
1993; 148: 778-784. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
]obsis Q, Raatgeep HC, Hermans P\VM, de ]ongste ]C. Hydrogen peroxide in 
exhaled airis increased in stable asthmatic children. Eur Respir] 1997; 10 :5l9-521. 
Loukides S, Horvath I, Wodehouse T, Cole P], Bames PJ. Elevated levels of expired 
breath hydrogen peroxide in bronchiectasis. Am] Respir Crit Care Med 1998; 158: 
991-994. 
Dekhuijzen PNR, Aben KKH, Dekker I, Aarts LPH], Wielders PLML, Van 
Herwaarden CLA, Bast A. Increased exhalation of hydrogen peroxide in patients with 
stable and unstable chronic obstructive pulmonalY disease. Am] Respir Cdt Care Med 
1996; 154813-816. 
Kietzmann D, Kalil R, MUller M, Burchardi H, Kettler D. Hydrogen peroxide in 
expired breath condensate of patients with acute respiratory failure and with ARDS. 
Intensive Care Med 1993; 19: 78-8!. 
Lundberg]ON, Weitzberg E, Lundberg]M, Alving K. Niuic oxide in exhaled air. 
Eur RespirJ 1996; 9: 2671-2680. 
Khadtonov SA, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: 
recommendations. Eur Respir] 1997; 10: 1683-1693. 
Lundberg]ON, Nordvall SL, \Veitzberg E, Kollberg H, Alving K. Exhaled nitric 
oxide in paediatric asthma and cystic fibrosis. Arch Dis Childhood 1996; 75: 323-326. 
Dotsh], Demirak~a S, Terbrack HG, Hiils G, Rascher W, KiiW PG. Airway nitric oxide 
in asthmatic children and patients with cystic fibrosis. Eur Respir] 1996; 9: 2537-2540. 
Hyslop PA, Sklar LA. A quantitative fluorimetric assay for the detennination of 
oxidant production bypolymOlphonuclcar leukocytes: its use in the simultaneous 
fluodmetric assay of cellular activation processes. Anal Biochcm1984; 141: 280-286. 
21. Jobsis Q, Raatgeep HC, Schellekens SL, Hop WCj, Hermans PWM, deJongsteJC. 
Hydrogen peroxide in exhaled air of healthy children: reference values. Eur Respir J 
1998; 12: 483-485. 
Hydrogen peroxide 1115 
22. Ho LP, FaccendaJ, InnesJA, Greening AP. Expired hydrogen peroxide in breath 
condensate of cystic fibrosis patients. Eur Respir J 1999; 13: 103-106. 
23 Dauletbaev N, Diegel H, BerkefeldM, Orcmek G, Loitsch SM, \VagnerTO, Dargon 
J. Monitoring the salivaty contamination of breath condensate by measuring 
alpha-amylasc and urea.Eur Respir) 1999; 14: 166, (p 1187). 
24. )6bsis Q, ScheJlekcns SL, Kroesbergen A, Hop WCj, de )ongste)c. Sampling of 
exhaled nitric oxide in children: end-expiratory plateall, balloon and tidal breathing 
methods compared. Eur Respir J 1999; 13: 1406-1410. 
25 Kroesbergen A,)obsis Q, Bel EHD, Hop WCj, de)ongste)c. Flow-dependency of 
exhaled nitric oxide in children with asthma and cystic fibrosis. Eur RespirJ 1999; 14: 
871-875. 
26. Zapletal A, Samanek M, Paul T. In: Lung function in children and adolescents: 
Methods, refcrence values. Dasel; Karger Verlag, 1987; 191-197. 
27. HMDP Statistical Software Manual. Unbalanced repeated measures models with 
structured covariance matrices. University of California Press, Berkeley, 1992: 
1330-1335. 
28. \Vood AJJ. Management of pulmonary disease in patients with cystic fibrosis (review). 
N Engl) Med 1996; 335: 179-188. 
29. Worlitzsch D, Herbeth G, Ulrich M, Doring G. Catalase, myeloperoxidase and 
hydrogen peroxide in cystic fibrosis. Eur Respir J 1998; 11: 337-383. 
30. Henson PM, Johnston RB. Tissue injury in inflammation. J Clin Invest 1987; 79: 
669-674. 
31. Greening AP, Lowrie DB.Extracellular release of hydrogen peroxide by human alve-
olar macrophages: the relationship to cigarette smoking and lower respiratory tract 
infections. Clin Sci 1983; 65: 661-664. 
32. Range SP, Dunster C, Knox AJ, Kelly FJ. Treatment ofpulmonalY exacerbations of 
cystic fibrosis leads to improved antioxidant status. Eur Respir J 1999; 13:560-564. 
33 Canady RG, Platt-Mills T, Murphy A,Johannesen R, GastonB,. Vital capacity reser-
voir and online measurement of childhood nitrosopnea are linearly related: clinical 
implications. AmJ Respir Crit Care Med 1999; 159: 311-314. 
34. Ho LP, InncsJA, Greening AP. Exhaled nittic oxide is not elevatcd in the inflanuna-
tOly airways diseases of cystic fibrosis and bronchiectasis. Em Respir J 1998; 12: 
1290-1294. 
35. J6bsis Q, Kroesbergen A, Schellekens SL, de Jongste Je. Nitlic oxide in exhaled air of 
healthy children, sampled with the balloon method. Am] RespirCrit Care Med 1998; 
157: A469. 
36. Ho LP, InnesJA, Greening AP. Nitrite levels in breath condensate of patients with 
cystic fibrosis is elevated in contrast to exhaled nitric oxide. Thor,lX 1998; 53: 680-684. 

CHAPTER 9 
Elevated hydrogen peroxide in exhaled air 
during upper respiratory tract infection 
Q. Jobsis"', S.L. Schellekens', A. Kroesbergen', H.C. Raatgeep' and J.C. de Jongste' 
, Dept. of Paediatrics, div. of Paediatric Respiratory Medicine, Erasmus University 
and University Hospital/Sophia Children's Hospital, Rotterdam and' Dept. of 
Paediatrics, University Hospital Maastricht, The Netherlands 
Submitted 
1117 
118 
ABSTRACT 
Hydrogen peroxide (H,O,) is a potential marker of airway inflammation in ex-
haled air condensate, which is elevated in various inflammatory disorders of 
the lower respiratOlY tract. We hypothesized that upper respiratory tract infec-
tions may increase H,O, in exhaled air condensate of healthy subjects. There-
fore, we examined exhaled H20Z in 20 normal subjects after symptomatic upper 
respiratory tract infection and during recovery 2 weeks later, and similarly, in 
10 healthy controls without recent or current symptoms of infection. Exhaled 
air condensate was obtained by mouth breathing through a cooled glass tube. 
The concentration of H20Z in condensate was measured with a fluorimetric as· 
say. At the time of infection, the median (range) H,O,level in condensate was 
0.20 11M (0.03-1.2 11M), and this decreased to 0.09 J.IM «0.01·0.40 J.IM) after 
recovery (p=0.006). There was no significant difference in FVC and FEV, during 
and after infection. In the healthy control subjects, exhaled H,O, values were 
reproducible over a 2 week period: 0.10 J.IM (0.01·0.30 J.I M) initially, compared 
to 0.08 J.IM «0.01-0.25 J.IM) after 2 weeks (NS). We conclude that the H,O, 
concentration in exhaled air condensate is significantly elevated during a 
symptomatic upper respiratory tract infection, and returns to normal within 2 
weeks of recovery in healthy subjects. This implies that, when using exhaled 
H20Z as a marker of chronic inflammatory airway disease such as asthma, mea· 
surements should not take place within 2 weeks of symptomatic upper respira-
tory tract infection. 
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INTRODUCTION 
Exhaled air condensate can be collected with minimal risk and inconve-
nience and provides a t11eans for obtaining samples frOl11 the lower respiratory 
tract (1,2). Hydrogen peroxide (H20 2) in exhaled air condensate is a potential 
marker of airway inflammation (1,3). An increased content ofH 20 2 has been 
described in exhaled air of patients with various inflanullatory lung disorders 
(1,4-7). Therefore, H 20 2 in breath condensate may be a simple and non.invasive 
marker to diagnose and t11onitor chronic airway inflan1111ation in the lower respi-
ratory tract. However, H 20 2 in exhaled air condensate could be potentially con-
founded by intercu1Tent acute infection, especially C01l11110n cold. \vhich causes 
transient inflanu11ation of the upper respiratoty tract. It is. therefore, important to 
know the effect of upper airway infection on exhaled H 20 2, and such data is lac-
king. The aim of tIus study was to assess to what extent upper respiratory tract in-
fections afrect orally exhaled H 20 2 in otherwise healthy subjects. 
METHODS 
STUDY POPULATION 
We recruited by advertisement 20 normal subjects with acute (less than 
48 hours) sytnptOl11s of upper respiratOlY tract infection: stufl)r or running nose, 
sneezing, sore throat. \vith or without fever. Similarly, we recnlited 10 healthy 
age-t11atched control subjects without symptoms of upper respiratolY tract in-
fections. All subjects of both groups were lifelong nonsmokers, had no histOlY 
of allergy. sinusitis and respiratoty or cardiovasculair disease, and had no synlp-
toms of asthma or eczema and used no medication. Healthy control subjects had 
no Syt11ptOluS of respiratolY tract infection in the 4 weeks before, or during, the 
measurements. Characteristics of the study population are shown in table 1. The 
study was approved by the medical ethical committee of the Erasmus Un.iversity 
Medical Centre. 
COLLECTION OF EXHALED AIR CONDENSATE 
Condensate was collected twice in all subjects: at inclusion and 2 weeks la-
ter, when symptoms had dissapeared. The subjects breathed through a mouth-
piece and a two way non-rebreathing valve (Rudolph, Kansas City, MO, USA) 
which also served as as saliva trap. They were asked to breath at a normal frequen-
cy and tidal volume, wearing a noseclip. Exhaled air condensate was obtained by 
passing expired air through a 50 cm double jacketed glass tube cooled to a tem-
perture of 00 C, by tueans of counter-current circulating ice water. The resulting 
condensate was collected on ice and frozen inlluediately at - 20 0 C until analysis. 
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TABLE 1. Patient characteristics, lung function and H202 values of all subjects 
N 
Sex (male/female) 
Age (years; median, range) 
FVe (% pred, mean ± sEM) 
FEV 1 (% pred, mean ±SEM) 
H ,0, (median,ftM) 
(range, ftM) 
Upper Respiratory Tract Infection 
20 
7/13 
25.6 (19.8-51.2) 
toO wks t=2 wks 
(acute infection) (recovered) 
108 ± 1.8 109 ± 1.8 
106 ± 1.9 107 ± 1.9 
0.20 0.09 
(0.03-1.20) «0,01-0.40) 
HYDROGEN PEROXIDE MEASUREMENT 
Controls 
10 
5/5 
26.0 (20.1-48.4) 
toO wks t=2 wks 
101 ± 2.8 98 ± 3.1 
101 ± 3.3 100 ± 3.1 
0.10 0.08 
(0,01-0.30) «0.01-0.25) 
The concentration of H 20 2 in exhaled air condensate was Ineasured in 
duplicate with a iluOllll1etric assay based on the reaction ofH202 with ho"eradish 
peroxidase to fonn a compound which oxidizes p-hydroxyphenylacetic acid to a 
fluorescent product, as desClibed in derail previously (1,8). The fluorescent product 
of the condensate and of standard solutions ofH20 2 were quantified fluorimetdcal-
Iy. Concentrations ofH20 2 in condensate were obtained by linear intelpolation of 
a standard cmve. The lower limit ofH202 detection was 0.01 11M. 
The equiplnent "'as designed to avoid contamination of the condensate with 
saliva, a source ofH20 2 . We excluded saliva contamination, as described previ-
ously (9), by measuring amylase in all breath condensates. 
LUNG FUNCTION 
All subjects perfonned flow-volume Ineasurelnents inuuediately after 
collection of the condensate. Flow-volmue curves were obtained in triplicate, 
using a Lilly-type pneumotachograph (Masterlab Jaeger, Wiirzberg, Germany). 
Results offorced vital capacity (FVe) and forced expiratOlY volume in 1 second 
(FEV,) were expressed as percentage predicted. 
DATA ANALYSIS 
Results ofH20 2 are expressed as Inedian and range because of a nonSYlU-
Inetrical distribution and because some values were below the detection linlit. 
Lung function data are expressed as luean±SEM. The difierence, over a 2 week 
interval, in H 202levels and lung filllction paralneters within each group waS as-
sessed after nonualization by logtransfonnation with Student's paired t-tests, 
whereas difierences between groups were tested with unpaired t-tests. A two 
tailed p-value of less than 0.05 was considered significant. 
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RESULTS 
All subjects performed the condensate collections without difHculty. In 
none of the 60 collected condensate samples amylase was detected, excluding 
contamination with saliva. In subjects with upper respiratOlY tract infection 
H 20 2 levels were 0.20 11M (0.03-1.20 11M). After recovery, H 20 2 was signifi-
cantly lower: 0.09 11M «0.01-0040 11M) (p=0.006). Decreases in exhaled per-
oxide were seen in 17 out of20 subjects. In the control group the exhaled H20 2 
levels were stable and reproducible over a 2 week period: 0.10 11M (0.01-0.30 
11M) and 0.08 11M «0.01-0.25 flM) (NS). The individual H 20 2 data are shown 
in figure 1 and 2. 
There was no significant change in FVC and FEV 1 during and after upper respira-
tmy tract infection: FVC 108 ± 8 %, FEV 1 106 ± 9 % compared to FVC 109 ± 
8%, FEV,107 ± 9 % after 2 weeks (fig. 3). Likewise, lung function was stable in all 
controls. There was no corre1ation between exhaled H 20 2 leve1s and lung func-
tion in both groups. 
respiratory infection group 
1.2 f p=0.006 l 
0.9 
:E 0.8 2; 
N 0.7 0 
N 
:J: 0.6 
'0 
" 0.5 iii
.c 0.4 x 
" 0.3 
0.2 0 
0.1 0 
0 
Infection recovery 
1=0 t=2wks 
FIGURE 1. Individual values of exhaled H,O, in 10 normal 
subjects during a symptomatic upper respiratory tract infection 
and 2 weeks afterwards when asymptomatic. Open dots are 
median values. 
122 
Control group 
0.3 ~ 0.25 
~ p=O.4 
..:; 0.20 
N 
0 
N 
:z: 0.15 
'0 
., 
'iii 
.<= 
x 0.10 ., 0 
0 
0.05 
0 
1=0 t=2wks 
FIGURE 2. Individual values of exhaled H20, in 10 healthy 
subjects, without symptoms of a upper respiratory tract infec· 
tion, with a 2 week interval. Open dots are median values. 
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*' if 110 
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symptomallc upper respiratory 
tract infection group 
Infection 
1=0 
p=0.2 
recovery 
t=2wks 
FIGURE 3, Changes in fEV1 during and after respiratory tract 
infection (N.S.) Closed dots indicate values of individual 
patients, open dots are mean values and SEM. 
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DISCUSSION 
The results of this study show that upper respiratOlY tract infections are 
associated with transiently elevated levels of exhaled H 20 2 in nonsmoking nor-
mal subjects. After recovery, 2 weeks later, exhaled H20 2 had decreased to va-
lues similar to those of an age-matched healthy control group. Lung function 
data in subjects with upper respiratOlY tract infection showed no significant 
change. These.findings suggest that symptomatic upper respiratory tract infecti-
on increases production of peroxide in the respiratory tract, and may thus act as 
confounder in studies using exhaled H 20 2 as a marker of chronic lower airway 
inflammation, especially in astillna. 
Our present understanding of astillna as a disease of chronic lower airway inflanl-
mation has been greatly enhanced by studies using bronchoalveolar lavage (BAL) 
and bronchial mucosal biopsies (10-12). The invasive nature of those diagnostic 
procedures linuted their use in the assesselnent of airway inflanllnation in chil-
dren. Current treatlnent guidelines for astlllna relies on symptoms and lung func-
tion for monitoring disease severity. Based on these guidelines, sufficient 
suppression of airway inflanllnation l11ay not be aclueved. potentially leading to 
irreversible changes in airway function (13,14). To trace patients with ongoing 
airway inflanll11ation and to tnonitor the effects of therapy. assesslnent of lower 
airway inflanllnation in a l110re direct way would be valuable. H 20 2 is a potential 
marker of airway inflammation, released by inflammatOlY cells such as 
eosinophils, neutrophils and macrophages. H 20 2 damages DNA, proteins and 
lipids, resulting in airway epithelium damage (15,16), and mediates the release of 
inflammatory mediators (17). An increased content ofH20 2 has been described 
in exhaled air condensate of patients with various noninfectious inflanllnatory 
disorders of the lower respiratory tract, including asthma (1,4), adult respiratory 
distress syndrome (ARDS) (5), chronic obstructive pulmonary disease (COPD) 
(6), bronchiectasis (7) and is elevated in exhaled air of cigarette smokers (18). 
We based the diagnosis of upper respiratory tract infection on typical clinical 
sYlnptol11s. We did not attelnpt to identif)r respiratolY vir-uses by means of culture, 
serology or other tests. However, the nature and titne course of upper airway 
symptoms and the season of the year in which this study took place (autumn) 
tnakes it likely that respiratory viruses were involved. We have no indication that 
the lower ainvays were involved in the infectious process, as there was no signifi-
cant change in FVC and FEV 1 or flow voltune curve configuration during and 
after upper respiratory tract infection. Furthermore, none of the subjects of the 
infected group mentioned lower respiratory symptoms like bringing up sputum 
or dyspnea. Chest auscultation was always normal. 
The elevated exhaled H 20 2 1evels (median 0.20 /.1M) during upper respiratory 
tract infection in this study were below levels reported previously by different 
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groups in stable steroid-naive asthmatic children and adults (1,3) and were in the 
same range as those in stable COPD patients (6). Our baseline values are in the 
same range as those reported in previous studies in normals (9, 19). 
One could argue that increased H 20 2 during COllltll0n cold COBles frot11 the 
upper rather than the lower airways. We excluded saliva contamination and air 
was collected by mouth breathing with use of a noseclip which should prevent or 
limit contamination with nasal air. 
Therefore it is likely that increased HzOz was due to oral, phalyngeal or lower 
airway inflammation. Indeed, subclinical lower airway inflallll11ation has been 
documented in viral upper respiratory tract infections and may go without signif-
icant changes in lung filllction (20-22). 
What are the clinical implications of our findings? When using exhaled HzOz as a 
marker of chronic airway inflauullation in inflanunatory lower airway disorders, 
an intercurrent sytllptOlnatic upper respiratory tract infection will likely 
contribute to exhaled peroxide levels and thereby act as a confounder. To avoid 
this, exhaled H 202 Il1eaSUrements for l11Olutoring lower airway inflanllnation 
should not take place during a sytllptomatic upper respiratolY tract infection. An 
interval of2 weeks appears sufficient for return to baseline, at least in normals. 
111 conclusiol1, we found that H 20 2 concentration in exhaled air condensa-
te is significantly elevated during symptomatic upper respiratory tract infections, 
and returns to nonnal witlun 2 weeks. Thus, when evaluating exhaled 1-:120 2 as 
a lnarker of chrOluc lower airway inflammation in asthma, tneasurements during 
or soon after symptomatic upper respiratoty tract infection should be avoided. 
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GENERAL DISCUSSION AND SUMMARY 
On-line measurement of exhaled NO as recommended by 
the ERS and ATS: single breath with a constant low flow 
against a resistance (anno 2000). 
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CHAPTER 10 
General discussion 
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A noninvasive test for the detection of airway inflamll1ation prOlruses to be far 
more practical in the clinical setting than currently available methods, such as 
bronchoscopy and BAL, and analysis of induced sputum. Potentially, these 
noninvasive tests will alio,,, early and appropriate anti-in£lanllnatory treatment, 
which hopefully will at least partly prevent later development of chronic respira-
tOly diseases, and will help to avoid such treatment on patients whose symptoms 
are not related to airway in£lanunatiol1, and who are unlikely to benefit. 
10.1 NITRIC OXIDE IN EXHALED AIR 
Since the beginning of eNO measurements, different methods of air sam-
pling have been used, making it difficult to compare data. Thusfar, the differen-
ces in salnpling techniques have limited the value of eND Ineasnrelnents in the 
assessment of airway inflammation. Major methodological concerns, related to 
all sampling teclmiques, are the possible contamination with NO from the up-
per airways and from ambient air and the flow dependency of eNO. We and ot-
hers have shown that eNO is flow dependent (1-3). Exhaled NO decreases with 
increasing flow, but mainly at flows of $150 mL/s, whereas flow dependency is 
much less at higher flows. NO is formed in the upper and lower respiratory tract 
and diffuses from the walls of the airways into the lumen by gaseous difitlsion 
down a concentration gradient, thus conditioning exhaled air with NO (4). 
Since NO is continuously released into the airway IU1l1en, high concentrations 
will result when exhalation is slow. and low concentrations when exhalation is 
f.1st. So, low flow rates amplity the NO signal. We also showed that differences 
in eNO between asthmatics, CF and healthy children are greatest at low flows 
(1). This means that to be able to compare eNO results of different studies and 
to maximize the sensitivity of eNO in discriminating between healthy subjects 
and those with airway inflanunatioll, a standardized low exhalation flow rate 
must be agreed upon. Although several international guidelines for the measu-
rement of NO in exhaled air have been published there is still no uniformity in 
the recommended expiratory flow rate (1-3,5,6). Not only the absolute eNO 
concentration at a constant low flow rate, but also the slope of the NO/flo,v re-
lationship discriminates between asthmatics and healthy subjects or CF patients 
(1). For diagnostic purposes, eNO measurements at different flow rates may pro-
ve an additional new tool for the difierential diagnosis of airway diseases. 
Methods to control nasal NO contamination are ilnportant for standardization of 
the exhaled air sampling procedures. Exclusion of nasal NO is important in view 
of the high nasal NO values compared to the NO values of the lower airways. So, 
with nasal contamination the orally exhaled air may not adequately reflect the 
NO production in the lower airways. Exhalation against a resistance will create 
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positive Illouth pressure. A positive 1110uth pressure of at least 4 Cl11 H20 is suffi-
cient to close the soft palate and avoids nasal contamination, as validated by nasal 
Argon insufllation (7). The single breath profile shows in the initial part of the 
exhalation a peak in eNO, which corresponds with al11bient NO accumulated in 
the dead space air volume, followed by a NO plateau. The eflect of elevated 
ambient NO on on-line single breath end-expiratOlY plateau NO values is prob-
ably minor. However, high ambient NO values will prolong the exhalation time 
necessary to reach a plateau, which requires a l11anoeuvre that is difficult to 
perform, especially for children. If exhaled air is collected in a reservoir, during 
tidal breathing or single exhalation, the dead space air volume including ambient 
NO is also collected which l11a), influence the tneasured eNO values. Indeed, we 
found a strong positive relation between atllbient NO concentrations and eNO 
values in balloons, especially with ambient NO> 10 ppb (8). Therefore, during 
eNO measurements the ambient NO should be recorded, eNO should not be 
measured if ambient NO is above 10 ppb or alternatively, NO-free air may be 
inhaled before sampling. Compalison of these approaches has not yet been done. 
There is a need for standardization of eNO tneasuretnent procedure in both 
adults and children if eNO measurements are to be applied in daily clinical prac-
tice and when cOlllparing results fimn different research groups. In an attempt to 
standardize NO l11easurelllent in exhaled air, a European Respiratmy Society 
(ERS) task force report was published (5). The on-line single breath method, 
exhalation frmn TLC with a constant flow against a resistance, was reconmlended 
for adults and children from the age of 6 years. However, we and others showed 
that children had problems in maintaining a constant exhalation flow, resulting in 
f.1ilure rates of up to 30% of the on-line single breath method in children (9-11). 
In contrast to the high failure rate of the on-line single breath method, the off-line 
single breath balloon method was performed without any difl1culty by children 
(9,10). The ofl~line method is attractive when subjects are studied outside the 
hospital, where exhaled air s,nnples can be obtained without the direct presence 
of a NO-analyser, which could be useful for epidemiologic studies and home 
tnonitoring of asthma. Balloons can be transported to the analyser and 111easured 
later. We found that NO remained stable in NO-inert Mylar-balloons for at least 
6 hours (8). The flow during exhalation into the balloon can be standardized, by 
including a InanOllleter and fixed resistor in the exhalation channel, or by a 
progressive resistance, or can be uncontrolled (9,12,13). We previously showed 
that ofl~line single breath sampling with uncontrolled high flows produces repro-
ducible eNO values that are similar to those measured on-line single breath with 
constant flow (8). In the off-line balloon method, sufficient resistance should be 
present in the exhalation channel to create a positive tnouth pressure of at least 4 
cm H 20 to assure closing of the soft palate to avoid nasal contamination. By 
discarding the first part of the exhaled air volume in a separate balloon, it is 
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possible to exclude contamination with dead space air which consists of a lULxture 
of ambient NO and upper and lower airway NO. In children we showed that the 
off-line eNO values with constant low flow, excluding dead space air volume, 
show excellent agreclnent with on-line values obtained with the same constant 
low exhalation flow (13). The off-line single breath balloon method with uncon-
trolled flow is a simple and hence attractive method for exhaled NO measure-
ments with children older than 4 years. It difterentiates between groups with and 
without self reported asthma, allergy and colds but is less suited for diagnostic use 
on individuals (8,13,14). In contrast, the controlled low flow off-line technique 
as described in chapter 5 is a more sensitive tool which should be able to detect 
meaningfill within-subject changes of eNO. 
There are only preliminalY studies with small numbers regarding eNO measure-
ments in inf.1nts and young children who have no ability to co-operate (15-18). 
However, especially in infants there is a need for developing noninvasive 
tnethods for the asseSSlnent of airway inflammation and to evaluate the effect of 
anti-inflauunatory treatlncnt. Wheezing in in£1nts is a velY COll11110n sYlnptml1. 
affecting 30 to 40% of all infants. However, wheezing in£1uts are a heterogeneous 
group and different patterns of wheezing disorders exist (19). If eNO is validated 
as a reliable marker of airway inflammation in infancy, it might help to distinguish 
children with early-onset asthma fion1 recurrent transient wheezing disorders 
without inflammation, and may be helpfill to identif), risk groups for airway 
inflammation in wheezing infants for approptiate early intervention ,vith 
anti-inflanunatory treatment. I;:xhaled air sampling in young unco-operative 
children and infants has been tried by using forced expiration and by collecting 
mixed exhaled air during quiet tidal breathing. With both sampling methods it 
was possible to measure NO in exhaled air. In recurrently wheezing infants, 
elevated eNO values, which decrease after corticosteroid therapy, were detected 
(15,16). It was recently shown, in a limited number ofin£onts, that mL'Ced expired 
eNO values collected off-line via a £lce Inask in a reservoir were similar to eNO 
values obtained in the same children after tracheal intubation suggesting that 
contamination from the nose may not be as important as in older subjects (16). 
However, nlore data on reproducibility, normal ranges, nasal NO production 
and contamination are necessalY to validate reliable sampling Inethods which can 
be used for the assessment oflo,ver airway inflammation in infants who are unable 
to co-operate. 
In children, we found that stable, treated asthmatics had significantly higher eNO 
values than healthy subjects, but only at low exhalation flows (1). Asthmatics 
using inhaled steroids tended to have lower eNO values than those without 
steroids. We found no significant difference in eNO values, obtained off-line 
with high flows, between stable asthmatic children using inhaled steroids and 
healthy children (8,9). These results are in agreement with eNO studies on adults, 
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where an increase in eND in astlunatics has been reported in several studies and 
eNO has not increased in stable asthmatics treated with inhaled steroids. 
Ho,vever, there is an increase in eNO values during astluna exacerbations and 
when the maintenance dose of inhaled steroids is reduced in well controlled asth-
lnatic patients; eNO increased before an increase in symptOIns or a fall in FEV1 
was seen (20-22). In conclusion, exhaled NO reflects airway inflammation, espe-
cially in astluna, and Inay therefore be useful as a noninvasive diagnostic Inethod 
of asthmatic inflanunation in the respiratolY tract, but eND lnay also be used as an 
early predictor of relapse after reducing anti-inflamInatolY treattnent or as a 
111easure of compliance with inhaled steroid treatl11ent. 
As stated in the general introduction of tlus thesis the ideal marker of airway 
inflammation should fulfil certain criteria. To what extent does exhaled NO meet 
the criteria of an ideallnarker? Increased eNO values are not disease specific. 
There is persuasive evidence that eND values are increased in association with 
(eosinophilic) airway inflammation and are decreased by anti-inflammatOlY 
treatlnents. Furthermore, there is now prelinrinary evidence that an increase in 
eND may precede the increase in symptOlns and the deterioration in lung func-
tion in astlllnatics and thus may be one of the earliest signs of disease activity. 
However, validation against nlore direct (invasive) lneasurelnents ofinflamma-
tion is needed. Despite the ongoing technical debate on how to measure NO in 
exhaled air, it is obviolls that eNO Ineasurelnent is an acceptable, siluple, quick, 
reproducible, and a completely nOlunvasive method. Without any discomfort it 
can be performed repeatedly on children and adults, where more invasive tech-
niques are impractical. Chemiluminescence NO-analysers are still expensive, but 
when using eNO in mass screening the costs are relatively lo,v. In astlllnatics, 
eNO is a sensitive and rapid marker of the anti-inflammatOlY effect of (inhaled) 
steroids and nlay so be useful in monitoring cOlupliance with treatment. 
10.1.2 DIRECTIONS FOR FUTURE RESEARCH 
A rapidly growing body of literature supports the use of NO as an inflam-
matory marker in variolls respiratolY disorders but especially in astlllua. It may 
be useful in the assessment of airway inflanullation and lnonitoring (cOlnplian-
ce) anti-inflamInatory treatment. Surprisingly the lnechanisms underlying in-
creased NO output fi'om inflammed airways have not been studied in detail. 
Studies linking increased NO output to increased expression of iN OS in human 
airways are lacking. Therefore, it is important to validate the concept of increa-
sed iNOS expression in iuflanlluation or to consider alternative explanatiolls for 
increased ND output during airway inflammation. Also the clinical relevance of 
eNO remains to be validated. There is a need to further standardize the sam-
pling tecluuque, if eNO measurements are to be applied ill the clinical setting, 
and for comparison of results from different laboratories. At the moment eNO 
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IneasurClllcnts are still a research tool. One can speculate that in the future 
hand-held portable NO-analysers may be available for home use as an easy, fast, 
and noninvasive way of daily llloilltoring airway i11£1an11nation; possibly leading 
to better individual adjusttnent of anti-inflauuuatory treatment dosage. But, be-
fore eNO measurements can be routinely applied in daily clinical practice the 
following issues have to be addressed: 
• Standardization of on-line and oll~line sampling techniques in adults and 
children, regarding 1110uth pressure, exhalation flow and dealing with 
ambient NO. 
• 
• 
• 
• 
• 
• 
• 
Collection of normal reference values of eNO with the (different) stan-
dardized sampling techniques in dillerent age groups. 
Examination of the influence of circardian rhytnl on eNO is needed. 
Further development and standardization of sampling techniques in 
young uueo-operative children and infants. Developlnent of dynamic 
£low restrictor, and elitnination of nasal NO contamination. 
Validation of eNO against more direct l11casnrClllcnts of in £lam mati on in 
the airways, such as obtained by bronchoalveolar lavage, bronchial biop-
sies, induced sputum, in different patient groups and healthy subjects is 
needed. 
Do markers of airway inflanllllation improve the manageillent of various 
respiratory inflauullatolY diseases? What is the benefit of l11onitoring 
eND as a response to treatment on top of clinical SYlllptOlllS, lung func-
tion and hyperresponsiveness in tenns of prevention of exacerbations and 
long-term reduction in chronicity of disease? These questions require 
long-tern1 prospective studies with repeated 111easurelllents in individual 
subjects and correlation with clinical paralneters. 
Predictive value of eND with respect to benefits fi-om anti-inflallullatolY 
treatlnent, InonitOling cOlnpliance with treatments, and relapse of in-
flanunation after reduction or termination of anti-inflall11natolY treat-
luent. 
The sensitivity and specificity of eNO in the detection of different 
inflanunatory diseases, including non-respiratolY disorders. 
10.2 HYDROGEN PEROXIDE IN EXHALED AIR CONDENSATE 
The collection of exhaled air condensate is simple and noninvasive to 
perform. There is a variety of methods to collect exhaled ail' condemate, 
although they are fundamentally similar, based on condensation of exhaled air 
on a cold surface. A lilllitation is that the aillount of condensate necessalY for 
duplicate determination requires at least 10 minutes of quiet tidal breathing 
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through a mouthpiece, which is not feasible for most children younger than 
about 4 years. A point of concern is the potential possibility of contamination of 
the condensate by saliva, a rich source of proteins and inflanunatOlY mediators 
snch as reactive o:A)'gen species and cytokines. As we showed, saliva contamina-
tion of the condensate sample can be verified by detennining aUlylase concen-
tration in the condensate (23). Amylase is present in saliva in high concentrati-
ons, whereas no traces could be detected in condensate sarnples and high 
amylase values in deliberately spiked condensate samples (23,24). 
Hydrogen peroxide is a marker of oxidative stress in exhaled air condensate. We 
found elevated H 20 2 values in exhaled air condensate of children with stable 
asthma, in CF-children with an acute infective pulmonalY exacerbation, and in 
adults with symptomatic upper respiratOlY tract infections (25-27). In healthy 
children we found statisfactOlY within-subject reproducibility of repeated H20 2 
Ineasurelnents on 2 consecutive days (23). Furthennore, increased alllounts of 
H 20 2 have been described in various other respiratory disorders such as unstable 
asthma, COPD, bronchiectasis, and cigarette smokers (28-31). This means that 
elevated exhaled H 20 2 values are not disease specific. Rather than a diagnostic 
test, exhaled H 20 2 may be used to guide anti-inflallllnatolY treatillent and esti-
mate inflammation severity over a period oftitne within subjects. Exhaled H20 2 
values of asthmatic patients were correlated with induced sputmn eosinophils and 
airway hyperresponsiveness (28). We found that in CF, exhaled H 20 2 falls during 
antibiotic treatment, and that in asthmatics inhaled corticosteroids were associ-
ated with lower exhaled peroxide values (25,27). So, exhaled H20 2 may poten-
tially serve as a noninvasive paratneter of inflanllnation to guide anti-inflam-
matory treattnent in inflanllnatOlY respiratolY diseases. Different methods of 
IneaSuretnent of peroxide in exhaled air condensate have been used by various 
research groups. Methods ofH20 2 Ineasurelnent are based on its ability to react 
with suitable reagents leading to colour, or fluorescence (32). Diflerent reagents 
such as homovanillic acid (HVA), p-hydroxy phenylacetic acid (pHPAA) and 
tetramethylbenzidine (TMB), have been used. The measured H20 2 values are 
often at the lower limit of detection of the employed method in the diflerent 
studies. Each method has a diflerent lower limit of detection, by using diflerent 
substrates, which Blakes direct cOlnparison of results obtained with difierent 
methods difHcult (33). The storage of condensate samples is also a point of 
concern. H 20 2 ,vill rapidly degrade at rOOIn temperature. Condensate saIuples 
should be collected on ice and after collection immediately fi-ozen below -20°C 
until analysis. We found that the H 20 2 concentration in ii-ozen condensate 
samples remained stable for at least 1 month (28). The importance of collecting 
and storing the condensate sample in the dark to avoid break-down ofH20 2 and 
the influence of the collectingsurf.1ce of the sampling device on H 20 2 concentra-
tion has not been evaluated. Another point which has not yet been evaluated, and 
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was not standardized in the difrerent peroxide studies, is exhalation flow. This 
could critically influence the exhaled HzOz concentration as it does in eNO 
Ineasurement, and some prelilninalY evidence suggest that this indeed might be 
the case (R.A. JOlTes, personal conul1unication). 
In contrast to NO, exhaled HzOz is a far less studied marker of airway inflamma-
tion. Therefore, for H 20 2 111casurClnent in exhaled air condensate SOlne criteria 
of the ideal marker of airway inflammation, tnentioned in the introduction of this 
thesis, have not yet been evaluated. Collection of exhaled air condensate is a 
simple, feasible, and completely noninvasive method which can be performed 
repeatedly with minimal discomfort, by adults as well as co-operative children. 
The determination of peroxide in condensate is reproducible and can be done at 
relatively low costs. Compared to eNO techniques, the collection of condensate 
as well as the measurement ofH20 Z in condensate takes considerably IHcre tilne. 
An increased content ofH 20 2 in condensate has been reported in various respira-
tOlY disorders, which tneallS that H 20 2 is not a disease specific diagnostic test. 
Rather than a disease specific diagnostic test, H 20 2 can be used in the noninvasive 
assessment of airway inflamluation ,vithin subjects, and to lnonitor the efiect of 
anti-inflalnmatOlY treattnent. Whether exhaled peroxide values are sensitive 
enough to detect early stages and small changes of airway inflammation is unclear. 
Anyhow, validation of this luarker against luore direct (invasive) lneasurenlents 
of inflammation is necessaly. 
10.2.2 DIRECTIONS FOR FUTURE RESEARCH 
Inflanlll1atory luarkers in exhaled air condensate, such as H20 2• for the 
noninvasive asseSSluent oflower airway inflanlluation may bec01ne usefill when 
the following issues are addressed: 
• Standardization of the collecting method of condensate, with exclusion 
• 
• 
• 
• 
• 
• 
of saliva contamination. 
Influence of the breathing pattern and exhalation flow on the concentra-
tion of the various potentiallnarkers of airway inflaulluation. 
Influence of the upper airways on the concentrations of the exhaled 
markers. 
Influence of the collecting surface (glass, teflon, plastic,metal) of the 
sampling device on 111arker detectability and concentration. 
Development of sampling technique of exhaled air condensate that is 
suitable for young children and inf.1nts. 
Standardization of the Il1eaSUrelnent procedures ofinfla1111uatolY luarkers 
in condensate. 
Correlation of t11arkers against direct lueasurements of airway in£la111111a-
tion (biopsies) in groups with various inflammatOlY respiratOlY disorders 
and in healthy subjects. 
• 
• 
• 
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Reproducibility, normal variation (interday and intraday) and reference 
ranges (age dependent) of the inflammatory marker. 
Evaluation of the sensitivity and specificity of the various tnarkers in 
difierentiating inflammatory airway disorders. 
Predictive value of the various exhaled inflanllnatory tnarkers in conden-
sate as a response to anti-in£lanllnatory treatment, relapse oflower airway 
inflanunation after reducing or stopping anti-inflanllnatolY treatment, 
and nlOtlltoring compliance with treattnent. 
Existance of specific pattetTIs of difierent tnarkers concentrations in the 
detection of different respiratory disorders. 
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Summary 
Airway inflanullation plays a central role in various respiratoL)r disorders. In daily 
clinical practice, assessment of airway inflanuuation is based on clinical sylnptOllls 
and lung fill1ction IneasnrClnents. Especially in young children, these indices of 
airway int1auunation are less reliable and feasible than in adults. Anyhow, these 
indirect Inethods do not specifically measure degree of inflammation which may 
potentially lead to insufficient or unnecessalY treatlnent. Bronchial biopsy, BAL, 
and induced sputum can be llsed to assess the presence of airway intlanunation. 
These Incthods are invasive, making their routine use ilupractical. Thus, there is a 
need for noninvasive lueaSUrCll1ent of airway inflanlluation which will allow 
early and appropriate anti-inflanllnatory treatlnent in order to reduce 1110rbidity 
and prevent or linuted the development of chronic respiratory diseases. Exhaled 
air and breath condensate contain substances \vhich can potentially be used in the 
asseSSlnent of airway inflammation. The llse of exhaled air (condensate) for the 
asseSSlnent of airway inflammation has the great advantage of being noninvasive 
and thus feasible and suitable for repeated measures in adults and children. It offers 
the prospect of relating airway intlanunation to clilucal features, abnonnalities of 
lung function, and treatlnent response in various respiratolY disorders. 
This thesis contains a lnunber of studies exploring the relevance of exhaled air and 
breath condensate as vehicles ofinflanllnatolY markers, and addresses a nmnber of 
lnethodological issues of their use. 
Chapter 1 contains a general introduction to the thesis, with particular reference 
to the exhaled infiammatOLY markers NO and H 20 2 , and the aims of the studies 
and outlines this thesis. 
In chapter 2 we compared three different NO measurement methods in 10 1 
stable allergic asthmatic children. The on-line single breath constant flow method 
recommended by a ERS task force was used as the gold standard and compared 
against an off-line uncontrolled high flow single breath balloon method and a 
tidal breathing method without expiratOlY resistance. Almost 30% of the study 
population was not able to perfonn the recol111nended on-line single breath 
method. All children performed the off-line single breath balloon method and 
tidal breathing method without any difficulty. StatishlctOLY agreement and no 
significant diflerences were found between the eNO values obtained with the 
on-line single breath method and the off·line single breath balloon method. In 
contrast, a poor agreelnent was found between the eNO values obtained with the 
on-line single breath method and the tidal breathing method, which was prob-
142 
ably due to nasal NO contamination in the tidal breathing method. The 
within-method short term reproducibility of duplicate NO measurements 
obtained with the three different sampling methods was good. The of}:·line 
uncontrolled high flow single breath method is a simple and feasible method of 
measuring eNO in children, which has the important advantage that it ofrers 
independence from the presence of an NO-analyser. 
The study in chapter 3 tries to quanti£), the efrect of varying the flow rate on the 
NO concentration in exhaled air in children and to establish the efrect of diflerent 
disease states on the NO/flow relationship. The eND values were obtained with 
an on-line single breath constant flow method at four different flows in children 
with stable asthma (n=19), CF (n=10), and in healthy children (n=20). Exhaled 
NO decreased with increasing flow in all children. Children with asthma had 
significantly higher eNO concentrations than healthy children, but only at the 
lowest flows. Asthmatics using inhaled steroids tended to have lower eNO values 
than those without steroids. CF-patients had a significantly lower NO concentra-
tion over the cntire studied flow range, cOlnpared to asthmatics and control 
subjects, with similar NO/flow slope as healthy subjects. The slope of NO/flow 
plots was significantly steeper in asthmatics than in healthy controls. The clinical 
implication of these results is that eNO measurement clearly distinguished 
between the difierent disease states at lo,v £low rates, and that not only NO 
concentration at a fi.."ed flow rate, but also the slope of the NO/flow relationship 
discriminates between asthmatics and healthy subjects or CF patients. 
In chapter 4 we studied methodological aspects of an off-line balloon method 
which could potentially influence eND IncasureUlcnt. Wearing a nosec1ip or 
holding one's breath affect measured eNO values and should therefore be stan-
dardized or, preferably, avoided. We found a significant positive correlation 
between 3tnbient NO concentrations and eNO values in balloons, especially 
with ambient NO > 10 ppb. Tlus suggests that ofl:line balloon eNO sampling 
should not be done when ambient NO is above 10 ppb, or NO-free air may be 
inhaled before sampling. The stability of NO in Mylar-balloons was assessed and 
NO showed to rClnain stable for at least 6 hours. Furthennore, we defined a refer-
ence range of eNO obtained ofi:line with this balloon sampling method in a large 
group of healthy school-aged children (n=72). We detected significant difler-
ences between children with and without self-reported asthma, allergy and colds, 
suggesting that this sampling l11ethod of eNO l11easurel11ent is sufficiently sensi-
tive to detect minor degrees of airway inflanunation in groups of otherwise 
healthy school-aged children. 
We previously showed (chapter 2) that off-line sampling in balloons with lugh 
uncontrolled flows produces eNO values that are similar to those Ineasured 
on-line with high flows. However, we also found (chapter 3) that low exhalation 
flow rates amplify the measured NO concentrations and allow a better separation 
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between asthmatics, CF-patients and healthy children. Therefore, we validated 
in chapter 5 an alternative off-line single breath controlled low-flow balloon 
sampling method against on-line single breath controlled low flow sampling 
according to ERS guidelines. The oft~line eNO values with constant low flow, 
and without dead space air, show excellent agreement to values obtained on-line 
with the same low exhalation flow, and are feasible in school-aged children. Both 
sampling methods discriminate between groups of children with and without self 
reported asthma, allergy and colds. 
In chapter 6 we defined the reference range ofH20 2 in exhaled air condensate 
obtained from a large group of healthy school-aged children. The observed H20 2 
levels were independent of age, sex and lung function. Furthenuore, sonle 
111ethodological aspects ,vere examined: the fluorill1etric assay gave reproducible 
H 20 2 results, the H20 2 concentration in frozen condensate salnples relnained 
stable for at least 1 month, and the determination of amylase in breath condensate 
is a sensitive Inarker to detect contam.illation of the condensate with saliva. 
In chapter 7 a cross-sectional study of66 allergic asthmatic children (of whom41 
were treated with inhaled steroids) and 21 healthy controls showed that the 
concentration ofH20 2 in exhaled air condensate is significantly increased in the 
asthmatic children, and the exhaled H 20 2 values are lower in asthmatics who 
used inhaled steroids. These resuits support the hypothesis that exhaled peroxide 
reflects airway inflalunlation. 
In the study described in chapter 8 we monitored the exhaled inflammatory 
markers NO and H 20 2 in CF-children (n=16) with an acute infective pulmo-
nary exacerbation during intravenous (Lv.) antibiotic treatlnent. We found that 
the levels of exhaled H 20 2are moderately elevated in CF-children with an exac-
erbation of their lung infection and decrease significantly during i.v. treatlnent. 
The lung function of those CF-children improved significanly during antibiotic 
treattuent. In individual subjects, there was a weak negative correlation between 
changes ofH20 2 and FEV!. Exhaled NO did not change systematically during 
antibiotic treatment. So, exhaled H 20 2 may be a helpful marker to morutor 
oxidative stress due to airway inflanlluatioll and luay serve as a noninvasive 
paratneter of inflammation during antibiotic treattllent in CF lung disease. 
The study of chapter 9 showed that symptomatic upper respiratOlY tract infec-
tions are associated with elevated levels of exhaled peroxide in otherwise healthy 
subjects. After recovery, exhaled H 20 2 had decreased to values similar to those of 
an age-tnatched control group. There was no significant change in lung function 
data during and after upper respiratory tract infection. Thus, upper respiratory 
tract infections increases production ofH20 2 in the respiratOlY tract, and Illay be 
m.isleading in studies using exhaled peroxide as a marker oflo,ver airway inflaIu-
Illation e.g. in astluna. Two weeks was sufficient for peroxide levels to £111 to 
nonnal values after upper respiratolY tract infection. 
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The tneasurement of exhaled NO and H 20 Z Inay provide a simple, noninvasive 
lneans of 111casuring inflammation and oxidative stress in the respiratol), tract. 
These markers l11ay be useful in the assessment of airway inflammation and Inoni~ 
toring of anti-inflallunat01Y treatment. Indeed increased exhaled NO and H 20 2 
values are associated with variolls respiratolY disorders, and reduced by 
anti-inflammatory treatment. However, levels of these exhaled inflanllnatory 
tuarkers varied widely in similar patient groups and even in healthy subjects, 
probably due to diflerences in methodology used by the different research groups. 
So there is a need for standardization of the IneaSUrCll1ent procedures of NO and 
H 20 2, to enable accurate cOJllparison of results (rOl11 different research groups, 
and if these markel~ are going to be applied in daily clinical practice. Furthermore, 
the clinical relevance of both exhaled markers needs to be established in longitu-
dinal studies in various respiratory disorders, with repeated 11lCaSUrClllcnts in indi~ 
vidual patients. Correlation with clinical paranlcters and IHcre direct, invasive, 
l11casnrements of airway inflauunation is needed. 
Samenvatting 
Luchtwegenontsteking wordt aangetroften bij verschillende respiratoire aandoe-
ningen en kan lei den tot diverse klachten en symptomen. In de dagelijkse praktijk 
\vordt een ontstekingsproces in de luchtwegen vennaed op grand van ananll1cse, 
symptomen, enlongfunktie onderzoek. Bij kinderen die te jong zijn voor long-
funktie-onderzoek is de (waarschijnlijklleids)diagnose derhalve aileen te stellen 
aan de hand van sytnptOlnen en (hetero)anamnese. Alvorens cen langdurige 
ontstekingsrenunende therapie, bijvoorbeeld met inhalatie-sterolden, bij Gonge) 
kinderen gestart wordt Zou de aanwezigheid van luchtwegontsteking 1110eten 
worden geobjectiveerd. Hiertoe ZOU het ontstekingsproces in de luchtwegwand 
direkt moeten worden aangetoond, hetgeen in de praktijk problema tisch is daar 
dit bronchoscopie en biopsie van de mucosa ofbronchoalveolairc lavage vereist. 
Met l1atllC door de invasiviteit zijn deze onderzoek-methodieken dusdanig belas-
tend dat ze niet routinematig in de dagelijkse praktijk toepasbaar zijn. Er is 
derhalve behoefte aan cen eenvoudige en niet invasief te bepalen maat vaar 
luchtwegantsteking, enerzijds als diagnasticmn vaar een ontstekingsproces, en 
anderzijds 0111 de behalldelillg Inet antstekillgsrellunende Inedicatie te sturen. 
Hiennee kan tijdig cell gerichte ontstekingsrenunellde therapie gestart ,vorden, 
met de veranderstelling dat zodaende nl0rbiditeit en ontwikkeling van chra-
nisch respiratoire aandoeningen afnemen, en dat onnodige ontstekingsreln-
lllende behandeling voarkOluen wordt. Een nieuwe benadering voar het 
aantonen van luchtwegontsteking is onderzoek van uitgeadelnde lucht, waarin 
kleine hoeveelhcden voorkOlnen van staficn die vrijkOlnen bij ontsteking en 
dcrhalve potentieel zouden kunnen fungeren als indicatoren van luchtwegont-
steking. Voor Gonge) kinderen lijkt uitademingslucht een bijzonder geschikt 
luedimn te zijn vaar het bcstuderen van luchtwegantsteking, claar het zander 
bijzandere caoperatie op niet invasieve wijze te verkrijgen is en verder niet 
afhankelijk is van de techniek van longfi.mctieonderzoek. 
Het anderzoek in dit praefSchrift is verricht 1l1ct het oogll1erk een niet-invasieve 
methode te ontwikkelen, die potentieel bij jonge kinderen toepasbaar is, 
waannee de aanwezigheid van een ontstekingsproces in de branchiaalbaOln kan 
worden aangctoond. Twee benaderingen zijn bestudeerd: 
1. Meting van stikstofinonoxide (NO) in uitademingslucht. 
2. Bepaling van waterstofperoxide (H202) in uitademingsluchtcondensaat. 
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Hoofd.tllk 1 plaatst het ondenverp van het proefschrift in perspectief, enlicht 
zich Inet Baine op de potentiele rol van NO en H 20 2 in uitademingslucht als 
indicatoren vanillchtwegontseking op de kinderleeftijd. Verder worden in dit 
hoofdstuk de doelstellingen en een overzicht van de verschillende onderzoeken, 
zoals beschreven in de daarop volgende hoofdstukken, venueld. 
In de studie beschreven in hoofd.tllk 2 werden bij 101 kinderen met stabiel 
allergisch astlna, 3 verschillende llitademingslucht-opvangtechnieken, die ge-
bruikt worden on1 NO in uitademingslucht te 1ueten, vergeleken. De door een 
ERS werkgroep aanhevolen directe opvangtechniek, een uitademing Illet een 
constante llitademingssnelheid (flow) direct in het NO-meetapparaat, werd 
vergeleken met de ballon methode, waarbij de Illcht van een llitademing 
opgevangen wordt in een ballon waarna in een later stadium analyse van de NO 
concentratie in de hallaH plaats vindt, en lllet de fustadcmhaling Inethode. 
waarbij de gemiddelde NO concentratie inllitademingsillcht opgevangen in een 
Olnschreven tijdsinterval gClneten wordt. Bijna 30% van de kinderen van de 
studiepoplliatie was niet in staat de door de ERS aanbevolen techniek op een 
juiste wijze nit tc voeren terwiji de andere 2 opvangtechnieken in de uitvoering 
geen problelllen opleverden. De NO waarden in uitademingslucht gelneten 
middels de door de ERS aanbevolen directe methode vertoonden een goede 
overeenkOlllst. zonder significante verschilletl. n1et de NO waarden verkregen 
via de ballon methode met een hoge ongecontroleerde flow. Een slechte 
overeenkolllst. met significante verschillen. werd gevonden tussen de NO 
waarden van de directe (ERS) methode en die van de rustademhaling methode, 
waarbij de NO waarden van de rustademhaling methode konsekwent hoger 
waren. Dit berust naar aile waarschijnlijkheid op bijmenging vannasale lucht, die 
een evidente hogere NO concentratie heeft. aan de orale uitademingslucht 
hetgeen tijdens nlStademhaling, door wisselende monddruk, makkelijk plaats 
vind. De korte termijn reproduceerbaarheid van herhaalde NO metingen van de 
drie afzonderlijke opvangmethodieken was goed. De ballon methode is eell 
eenvoudige en makke1ijk uitvoerbare techniek 0111 NO in uitademingslucht van 
kinderen te meten, en heeft als bijkomend voordeel dat de meting niet gebonden 
is aan de plaats van de NO meetapparatllur. 
In hoofd.tllk 3 wordt, met de door de ERS aanbevolen directe methode met 
vier verschillende flows, de invloed van de flow op de uitgeademde NO concen-
tratie bestudeerd bij kinderen met astma (n=19), cystic fibrosis (CF) (n=lO) en bij 
gezonde kinderen (n=20). Bij aile onderzochte kinderen blijkt de uitgeademde 
NO concentratie flow afhankelijk te zijn; Inet toenelllende flo,v neelnt de uitgea-
demde NO concentratie af. Verder werd gevonden dat, bij lage flows, de 
kinderen met astma significant hogere uitgeademde NO waarden hadden dan de 
gezonde kinderen. Binnen de groep kinderen lllet asttna was er een trend zicht-
baar waarbij de kinderen met inhalatiesteroldenlagere NO waarden hadden dan 
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degene zonder inhalatiesteroiden. De kinderen met CF hadden over het hele 
bestudeerde flow traject significant lagere NO waarden in vergelijking met de 
gezonde groep, echter de NO/flow hellingvan beide groepen was vergelijkbaar. 
De NO/flow helling van de astma groep liep significant steiler dan van de 
gezonde groep. De klinische relevantie van de resultaten van deze studie is dat bij 
!age flows het onderscheidend vermogen van uitgeadelnde NO, tussen verschil-
lende aandoeningen, het grootste is en dat niet alleen absoluut uitgeademde NO 
waarden maar ook de NO/flow helling een onderscheid kan luaken tussen 
kinderen 111et astlna enerzijds en gezonde of kinder en lnet CF anderzijds. 
Hoofdstuk 4 is gewijd aan NO-metingen middels de kindvriendelijke ballon 
methode. Met deze methode werd in een grote groep gezonde schoolkinderen 
(n=72) nonnaalwaarden bepaald. Verder werden een aantal methodologische 
aspecten van deze specifieke methode bestudeerd. We vonden significante 
verschillen in uitgeadenlde NO waarden tussen gezonde schoolkinderen en 
schoolkinderen met zelf gerapporteerd astma, allergie en of verkoudheids 
ve"chijnselen, hetgeen aangeeft dat deze methode gevoelig genoeg is om onder-
scheid te Ina ken tussen geringe verschillen in inflammatie binnen een verder 
gezonde groep kinderen. Het gebnlik van een neusklenl alslnede het inhouden 
van de ademhaling beinvloedt de uitgeademde NO waarden en dient derhalve 
vermeden te worden of anders ten minste gestandaardiseerd te worden. Er bestaat 
een significant positieve corre1atie tussen de uitgeademde NO concentraties en 
de NO concentratie van de ingeademde Olngevingslucht, Inet name bij Olnge-
vingslucht met NO concentraties boven de 10 ppb. Dit impliceert dat NO 
metingen via de ballon methode in principe niet goed bruikbaar zijn tijdens peri-
oden met NO concentraties boven de 10 ppb in de buitenlucht. Een mogelijk-
heid Olll dit probleeln te omzeilen zou het inadernen van lucht Inet een Jage NO 
concentratie kunnen zijn alvorens de NO concentratie in uitademingslucht te 
bepalen. De NO concentratie was gedurende ten minste 6 uur stabie! in de door 
ons gebruikte Mylar-ballonnen. 
Een eerdere studie (hoofdstuk 2) toonde dat de ballon methode met hoge 
ongecontro]eerde flow geen significant verschillende NO waarden geeft ten 
opzichte van de directe (ERS) methode. Echter, uit een andere studie (hoofdstuk 
3) bleek dat met name bij lage flows het onderscheidend vennogen van uitgea-
delnde NO, tussen verschillende aandoeningen, het grootste is. Derhalve ,verd in 
hoofdstuk 5 een altematieve ballon methode met drie verschillende gestandaar-
diseerde laag gecontrolecrde flows, in- en exclusief dode nlilnte lucht, verge-
leken met de directe (ERS) methode. De ballon methode met lage 
gecontroleerde flow zonder dode ntilnte is een techniek \Vaal' de onderzochte 
kinderen geen moeite mee hadden en leverde gelijkwaardige NO waarden in 
uitademingslucht op in vergelijking met de directe (ERS) methode bij gelijke 
flow. De NO waarden van beide vergeleken technieken maakte een goed signifi-
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cant onderscheid tussen enerzijds gezonde kinderCll en anderzijds killderen met 
zelf gerapporteerd astma, allergie en ofverkol1dheid tijdens de meting. 
In hoofdstuk 6 wordt een methode beschreven om H20 2 in uitademingslucht-
condensaat tc l11cten. Verscheidende l11cthodologische aspecten van deze Juetho-
dick werden verder onderzocht. Gevonden werd dat de korte termijn 
reproduceerbaarheid van de H 20 2 bepaling goed is, dat contaminatie van 
condensaat met speeksel eenvoudig aan tc tonen is middels het bepalen van 
alnylasc in het cOlldensaat en dat in diepgevroren condensaattnonsters de H 202 
concentratie gedurende ten HUllste 1 IllJJlld stabiel blijft. Verder werd met deze 
Inethode in een grate groep gezonde schoolkinderen nOl1naalwaarden bepaald. 
De H 20 2 waarden waren in deze groep onafhankelijk van Ieeftijd, geslacht en 
Iongfl1nktie. 
In het cross-section eel onderzoek van hoofdstuk 7 werd bij 66 kinderen met 
allergisch astma, waarvan 41 inhalatie-stcro'iden gebruikten, en bij 21 gezonde 
controles de H 20 2 conccntratie in de uitademillgslucht gemetcn. Dc H 20 2 
concentratie was bij de kindercn met astma significant verhoogd in vergelijking 
met de gezonde controle groep. Dit verschil was het tlleest uitgesproken bij de 
kinderen Inet astma die geen inhalatie-steroi·den gebruikten. Deze resultaten 
steunen de veronderstelling dat H 20 2 in uitademingslucht gebruikt zou kunnen 
worden OBI op een niet invasieve wijze ontsteking in de lllchtwegen aan te tonen. 
Naast het aantonen van een ontstekingsproces in de luchtwegen zouden zowel 
H202 als NO in uitademingslucht ook een ral kunnen spelen bij het in de tijd 
vervolgen van het efrect van behandeling op een antstekingsproces. In hoofd-
stuk 8 vervolgden we het beloop van uitgeadelude NO en H20 2 concentraties 
bij 16 kinderen tnet CF, die waren opgellOlncn vallwege een pulmonale exacer-
batie op basis van een bacteriele infectie voor een intraveneuze bchandeling Inet 
antibiotica. De H 20 2 concentratie in uitademingsluchtcondensaat daalde signifi-
cant gedurende de intravencuze behandeling tnet antibiotica terwiji de long-
fimctie significant verbcterde. Binnen personen bestond er een zwak negatieve 
correlatie tussen veranderingen in H 20 2 en FEVt. In tegenstelling tot H 20 2 
toonde de uitgeadetnde NO concentraties geen systematische veranderingen 
gedurende de behandeling met antibiotica. Derhalve heeft NO geen plaats bij het 
op een niet invasieve wijze vervolgen van het effect van alltibiotica op het ontste-
kingsproces bij CF patienten. 
In hoafdstuk 9 toanden we aan dat tijdens een symptomatische bovenste Iucht-
weginfectie bij normaal gesproken gezollden, dc H 20 2 concentratic in uitade-
nlingsluchtcondensaat sigllificant verhoogd is in vergelijking met cen gczonde 
controle groep. Twee weken na herstel \varen de H 20 2 waarden weer gedaald tot 
het zelfde niveau als van de gezonde controle groep, terwijl in de gezonde 
controle groep geen significante verandering optrad in uitgeadetnde H 20 2 
waarden over eell periode van twce wcken. De longfunktiewaarden warcn in 
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beide graepen vergelijkbaar en zander significante verandering over de twee 
weken. Een bovenste luchtweginfectic beinvloedt dus de H20 2 concentratie in 
uitademingslucht en derhalve dient hiermee rekening te worden gehouden bij 
het gebruik van H 20 2 als indicator van ontsteking in de onderste luchtwegen. 
Zowel bij kinderen als bij volwassenen is het meten van NO en H 20 2 in uitade-
mingslucht een in potentie eenvoudige en niet invasicve luethode onlluchtwcg-
ontsteking vast te stellen. Naast het diagnosticeren van ontsteking zouden deze 
merkstofien ook een reI kunllell hebbell bij het vervolgell ell beoordelell vall het 
efiect van ontstekingsremmellde medicatie. Het blijkt inderdaad dat bij ve"chil-
lende respiratoire aandaeningen de NO en H 20 2 concentraties in uitadeuuugs-
lucht verhoogd zijll en dat ontstekingsremmende medicatie de uitgeademde 
waarden significant laat dalen. Eehter resultaten van versehillende onderzoeks-
groepen laten zowel voor uitgeadelnde NO ais voor H 20 2, waarden ziell die zelfs 
bij gezonden uiteenlopell. Dit berust waarschijnlijk op methodologische 
versehillen, zoals onder andere verschillen in opvangtechniek van uitadenungs-
lucht. Onl uitkolnsten van verschillende studies met elkaar te kunncn vergelijkell 
dient standaardisatie van de opvang- en lueetteehniek plaats te vinden. V oordat 
deze niet invasieve methode in de dagelijkse praktijk gebruikt bn worden zal 
verdere validering van deze luarkers plaats luoeten vinden door eorrelatie luet 
symptoluen en longfunktiewaarden maar Inet nanle met uitkOlllsten van inva-
sieve metingen van luehtwegontsteking zoals mucosa biopsie. De exacte klini-
sehe waarde van de bepaling van beide markers in uitademingslucht op lange 
tennijn is nog onvoldoende duidelijk, hetgeen ill longitudinale studies met 
herhaalde tuetingen binnen personen Inet versehil1ende luchtwegaandoeningen 
verder zalilloeten worden vastgesteld. 
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